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Abstract 
Hepatocellular carcinoma (HCC) is a devastating malignancy originating from 
hepatocytes. There is an urgent need for novel therapeutic approaches. Currently 
explored gene therapy systems have not yet achieved significant survival benefits. The 
aim of this thesis was the development and evaluation of novel genetic approaches to 
this malignancy. 
The results of this thesis show that the only non-conjugated gene delivery system 
achieving significant intratumoral transgene expression is direct injection. Systemic 
gene delivery systems based upon Tf-shielded, polyethylenimine (PEl) based 
polyplexes and stabilized plasmid lipid particles (SPLP) do achieve efficient 
intratumoral transgene expression levels comparable to direct intratumoral injection, but 
their use is limited by their low intratumoral biodistribution. Further, this study shows 
that the use of non-viral replicon vectors based on the autonomously replicating 
parvoviruses minute virus of mice (pMVM) is feasible. In contrast to its viral 
equivalent, it allows expansion of its genome size to > I 06% and avoids 
immunogenicity. It maintains its tumorselectivity, but loses its cytotoxicity. The results 
of this thesis show that the Edmonston strain of measles virus (MV-Edm) efficiently 
infects human HCC cell lines resulting in syncytia formation followed by apoptotic cell 
death. The use of recombinant MV-Edm expressing marker genes allows non-invasive 
tracking of MV-Edm infection and kinetics. Treatment of mice bearing subcutaneous 
human HeC xenografts with recombinant MV-Edm resulted in significant survival 
benefits and tumor regression in up to one third of animals. 
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Introduction 
I. Introduction 
1. Hepatocellular Carcinoma 
1.1. Introduction 
Hepatocellular carcinoma (HCC) is a malignancy originating from hepatocytes. It is the 
most common primary hepatic malignancy constituting 84% of primary liver cancers. 
Globally, it is one of the leading causes of cancer mortality and its incidence is 
increasing, especially in Western countries. Its prognosis is fatal with a median survival 
of less than one year after onset of symptoms. There are a variety of different 
therapeutic approaches including surgical, local ablative and systemic treatments. 
Unfortunately, the majority of patients present with advanced stage disease, at which 
curative therapies are not feasible. Hence, surveillance of patients at risk is essential 1. 
New therapeutic approaches are being explored and novel targeted therapies have been 
developed. Most recently, the kinase inhibitor Sorafenib has been shown to achieve 
significant prolongation of survival in intermediate stage HCC patients and is now 
commonly used in this patient subgroup. However, surgery continues to remain the only 
potentially curative treatment. Therefore, there is an urgent need for new curative 
approaches for HCC. The aim of this study was the development and evaluation of 
novel genetic therapies for HCC. 
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1.2. Epidemiology 
HCC is the fifth most common cancer in the world and the third most common cause of 
cancer mortality worldwide 2. The annual incidence for HCC has been estimated as high 
as 564,000 cases worldwide and its mortality as 548,554 cases in 2000. The di tribution 
ofHCC is heterogenous (Fig. 1) 3. 
MEN (398,364) J WOMEN (165 ,972 ) 
North America 
~el1 t ra l & South America 
(i t: ~:267 I VY : 7,182) 
AAIRs: 0 < 3.3 D < 5.6 
Europe 
Africa 
(M: 27. . I W: 14.421) 
o < 9.0 
Asia 
) 
~ < 15.0 • < 98.9 
Figure 1 HCC incidence. World map depicting estimated age-adjusted incidence rates of HCC 
cases among men in 2000. The corresponding age-adjusted incidence rates for women follows 
a similar pattern 4 . 
The highest incidence rates are being reported in Eastern Asia and Middle Africa with 
age-adjusted incidence rates (AAIR) of up to 98.9/100,000. In Australia, New Zealand, 
Europe and the American continents, the incidence of HCC is consistently below 
\011 00,000 4. However, incidence rates of HCC in USA and Europe have increased 
more than two-fold in the last three decades from 1.3/100,000 in 1976- 1980 to 
3.011 00,000 in 1991-1998 5, 6. Age-adjusted mortality rates (AAMR) of HCC follow a 
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geographic pattern consistent with the incidence rates. Mortality rates of HCC in the 
USA have also increased significantly in the last three decades and were estimated to be 
3.7/100,000 in 2001 5,6. The average age at diagnosis in Western countries is 65; HCC 
in patients younger than 40 years of age is rare. Starting at age 40 the risk increases 
progressively and peaks at age 70-75. In high-risk areas such as South East Asia and the 
West Coast of Africa, HCC is frequently diagnosed between age 20 and 35. HCC 
incidence rates in these countries increase from age 20 and peak at age 50. 72% of HCC 
patients are male. Causes of the gender difference have not been established. 
1.3. Etiology 
Several risk factors for HCC have been identified (Tab. 1). In 80% of cases, HCC 
develops in cirrhosis which is considered the most predisposing factors for HCC '. 
Frequently, HCC is the long-term result of chronic Hepatitis B (HBV) or C virus (HCV) 
infection. Hepatitis B virus (HBV) is the main risk factor in Asia and Africa with an 
annual incidence rate of 2-6% in chronic HBV patients with cirrhosis. Non-cirrhotic 
chronic hepatitis B patients have an annual HCC incidence rate of 0.4%. In developed 
countries, HCC predominantly develops in the setting of cirrhosis secondary to chronic 
alcohol abuse or chronic HCV infection. Up to one third of cirrhotic, chronic HCV 
infected patients develop HCC; the annual incidence rate of HCC in this setting is 3-
5%. The carcinogen aflatoxin B 1 increases the neoplastic risk three-fold and has been 
linked to mutations in the tumor suppressor gene p53. Other risk factors include a-l-
antitrypsin deficiency, hemochromatosis and non-alcoholic fatty liver disease. 
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- Cirrhosis 
- Chronic hepatitis B, C, 0 
- Toxins (e.g. alcohol,aflatoxins) 
- Hemochromatosis 
- a-1-antitrypsin deficiency 
- Non-alcoholic fatty liver disease 
- Autoimmune hepatitis 
Table 1 Risk factors for HCC. Shown are conditions considered to be significant risk factors 
for the development of HCC 8. 
Current surveillance and prevention recommendations are based upon the above-
described etiologic factors. Nationwide vaccination of infants for HBV in Taiwan 
between 1984-1986 decreased the prevalence of HBV carriers in childhood from 15% 
to 1%, and simultaneously decreased HCC in vaccinated children by 60% compared to 
non-vaccinated children 9, 10. Current screening recommendations by the American 
Association of the Study of Liver Disease (AASLD) are summarized in Table 2. Goal 
of regular screening of patients at risk is the early detection of HCC at a stage where the 
cancer is amenable to curative therapy. The recommended screening intervals are 6-12 
months based upon tumor doubling times 11. Most centers use a 6-months interval, 
although survival has not shown to be improved through 6- versus 12-months intervals 
12. The most commonly used screening tests are serum alphafetoprotein (AFP) and 
ultrasound of the liver. However, both tests have limitations as screening tests. AFP has 
a sensitivity of only 60% at a cut-off level of 20 ng/ml and a positive predictive value of 
41.5% in a population with a prevalence of 5% as usually seen in specialized centers. 
Ultrasound of the liver has a sensitivity of 65-80% and a specificity of >90% as a 
screening test for HCC. False-positive rates increase with combined use of these tests to 
7.5% and costs to $3,000 per detected tumor 11. 
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- Hepatitis B carriers: 
- Asian males ~40 years 
- Asian females ~50 years 
- All cirrhotic hepatitis B carriers 
- Family history of HCC 
- Africans >20 years 
- Non-hepatitis B cirrhosis: 
- Hepatitis C 
- Alcoholic cirrhosis 
- Genetic hemochromatosis 
- Primary biliary cirrhosis 
Table 2 AASLD HCC screening recommendations. These are level III recommendations 
issued by the AASLD in 2005. Conditions such as a-1-antitrypsin deficiency, non-alcoholic 
steatohepatitis and autoimmune hepatitis are not included in these recommendations due to the 
lack of data regarding the benefit of surveillance. 
1.4. Prognosis and staging 
The majority of HCC patients are diagnosed at an advanced stage due to the clinically 
silent character of this tumor. Tumor growth rates display a great variety with a median 
doubling time of 117 days. Its subclinical development lasts a median time period of 3.2 
years 13, 14. There are only few reports on the natural course and prognosis of HCC in 
patients receiving only symptomatic treatment. Earlier studies reported 1.6 to 4 months 
survival from onset of symptoms in symptomatically treated HCC patients 15,16. More 
recent studies described median survival of 17 month with an overall probability of 
survival at 1, 2 and 3 years of up to 54%, 40% and up to 28% in cirrhotic patients with 
. . I " 17 18 H h " "d" HCC receIvIng on y symptomatIc treatment ' . owever, t e Increase In me Ian 
survival over time has been attributed to lead-time bias as patients at risk are more 
aggressively screened, and diagnostic techniques are more advanced 19. As for most 
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cancers, prognosis ofHCC is related to its tumor stage 20. Very early stage HCC has 5-
year survival rates between 7l-89% after therapy and 3-year recurrence rate of 8%. 5-
year survival rates in early HCC range between 50-70% with treatment 21. 1-, 2- and 3 
year survival of intermediate stage HCC is 80%, 65% and 50%, and 29%, 16% and 8% 
for advanced stage HCC. Different staging systems have been implemented in order to 
TNM Variable 
T1 Solitary tumor wlo vascular invasion 
T2 Solitary tumor with vascular invasion OR mu Itiple tumors, none >5 cm 
T3 Multiple tumors >5 cm OR tumor involving major branch of portal or hepatic veins 
T4 Tumor(s) w. direct invasion of adjacent organs other than gallbladder OR 
w. perforation of visceral peritoneum 
NO No regional lymph node metastases 
N1 Regional lymph node metastases 
MO No distant metastases 
M1 Distant metastases 
Stage 
I T1 NO MO 
II T2 NO MO 
IliA T3 NO MO 
IIIB T4 NOMO 
IIIC AnyT N1 MO 
IV AnyT AnyN M1 
Table 3 TNM staging classification for HCC. HCC staging classification according to 
International Union Against Cancer (UICC) and the American Joint Committee on Cancer 
(AJCC). The system is based on tumor extent (T), extent of lymph node involvement (N) and 
presence of metastases. 
establish an optimal predictor of prognosis; these include the Okuda staging ystem, the 
CLIP-score, the TNM-staging system and the BCLC staging system. In contrast to most 
other tumor-types prognosis of HCC is highly complex and depends on different 
factors , including tumor stage, liver function, patient 's general condition and treatment 
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efficacy 19. At present, there is no consensus on one gold standard staging system for 
HCC 11,22. Classical cancer staging systems, such as the TNM- classification (Table 3), 
have been shown to be inaccurate in predicting survival or guiding management. In 
order to combine the two variables of liver function and tumor extent, the Okuda system 
was developed 16. This system grouped patients in three groups defined by tumor 
volume, ascites, jaundice and serum albumin concentration. The Okuda system was 
commonly used for two decades. In the 1990's, improvement in imaging technology 
allowed identification of hepatic lesions at earlier stages. With these techniques, the 
Okuda system was not sufficient anymore as it missed early and intermediate stage 
HCC. As a consequence a great variety of different scoring system was developed such 
as a modified TNM systems, the Cancer of the Liver Italian Program (CLIP) score and 
the Barcelona Clinic Liver Cancer (BCLC) staging system (Table 6) 23.25. Comparison 
of the Okuda and CLIP systems with the TNM system showed that neither one was 
superior to the TNM system in regard to their prognostic value in patients undergoing 
surgical resection 26. The BCLC staging system is based upon results of several 
independent studies and includes variables such as tumor stage, hepatic functional 
status, physical status and cancer related symptoms. It links staging with treatment 
modalities, and thereby provides survival estimates based upon published data on 
response rates to different treatments (Figure 2). Currently, there is no global consent on 
a preferred staging system for HCC. However, the BCLC system is the only staging 
system that includes information on the impact of treatment on life expectancy, and is 
therefore recommended by the AASLD practice guidelines II. 
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Stage PST Tumor Hepatic status 
Stage A (early HCC) 
A1 0 Single tumor No portal hypertension, Normal bilirubin 
A2 0 Single tumor 
Portal hypertension, 
Normal bilirubin 
A3 0 Single tumor Portal hypertension, Abnormal bilirubin 
A4 0 3 tumors, all <3 em Child-Pugh A-B 
Stage B (intermediate HCC) 
B 0 Large multinodular Child-Pugh A-B 
Stage C (advanced stage) 
C 1-2 Vascular invasion OR Extrahepatic spread Child-Pugh A-B 
Stage D (end-stage HCC) 
D 3-4 Any Child-Pugh C 
Table 4 The Barcelona Clinic Liver Cancer (BCLC) staging classifi cat ion. 
[ HCC ~ 
t'S I u" 1;-1I1rJ -'I .,. 
t 
Ve,," U<lrl \. ~ I - ,Ie E,,-I'( -(" (10 Inlc rrn llo l - ,II;U All .,...HICO -~ <I <;U - e lrn - '1 
..>w91.,.,. la-I "19"'0' 2 ,-:d~ 5 ~ _-T ;)~ 0 r l l-~lrO::J I ,~- G l) on,) Ir ... ·510' r~" 1.1 ' S 12 .,lLlrl O 
" 
. 1:1 
i PEI.lRF I Cherr oembo iza io n I NewAge nt5 
CUf.Jt lve eo tm e"lts l 
~------------~~--------~----~ 
Figure 2 Staging and treatment assignment for HCC patients according to t he BCLC 
11 
system . 
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1.5. Therapy 
A variety of therapeutic options are available for HCC including surgery, 
chemotherapy, local ablative therapies and hormone therapy. Surgery is considered to 
be the only potentially curative treatment. Most of the other treatment modalities are 
palliative or used as adjuvant or neoadjuvant treatment. More than 80% of HCC patients 
are diagnosed at an advanced stage at which they are not eligible for potentially curative 
treatments such as transplantation, surgical resection or liver-directed therapies 3. 
1. 5 .1. Surgery 
Partial hepatic resection and transplantation are the only potentially curative treatments. 
Unfortunately, only a minority of patients is eligible for these procedures. Initially, 
outcomes were poor in terms of recurrence and survival. Advances in pre-operative 
assessment and stricter selection criteria in regard of tumor burden improved survival 
rates and decreased rates of recurrence. There are no randomized controlled trials 
comparing partial hepatectomy versus liver transplantation. Transplantation has the 
advantage to treat not only the tumor but also the cirrhosis. At the same time, 
transplantation has disadvantages such as risk of graft failure and infection, risks of 
lifelong immunosuppression, high costs, shortage of donor organs and thus potentially 
long waiting times. In general, transplantation is offered to patients with poor hepatic 
function and small tumor nodules, while patients with sufficient hepatic reserve and 
larger tumors are preferentially treated with resection. 
1.5.1.1. Resection 
Resection is the initial treatment of choice. Especially patients with a small, unifocal 
tumor qualify for this treatment. Liver reserve and regenerative capacity are major 
Blechacz, B (2009). PhD thesis Page 9 
Introduction 
determinants of post-operative liver failure. As a majority of HCC patients have 
compromised hepatic function, the choice of candidates is restricted. The operative risk 
is especially in the setting of cirrhosis increased due to complications such as 
hemorrhage, infections, wound-related complications and respiratory compromise. It 
has been shown that cirrhosis is a factor associated with poor outcome 27. The ideal 
candidate is considered one with Child-Pugh class A cirrhosis, age <65 years, a single 
tumor nodule with a diameter of <5cm and no portal vein invasion. Contraindications 
for resection are advanced cirrhosis, multilocular HCC and extrahepatic metastases. 
Resectability of the tumor is dependent on its anatomic location and the absence of 
major vascular invasion. Non-cirrhotic patients recover well from partial hepatectomy 
preserving at least two segments of functional liver tissue. In well-compensated 
cirrhosis, resection of up to two functional segments is well tolerated. The operative 
mortality is reported to be up to 10% and 5-year survival ranges between 20-60%. 
Recurrence is the main reason for late post-operative mortality. 5-year recurrence rates 
are reported to be 50-100%; in the majority of the cases tumor recurrence is diagnosed 
within the first 3 years following resection. Early recurrence (12 months to 3 years) is 
thought to represent residual tumor spread, and is considered to be a poor prognostic 
factor. Late recurrence is thought to result from new tumor formation within the 
cirrhotic liver. In general, the following parameters are thought to correlate with 
surgical failure: vascular invasion, presence of satellite nodules, large tumor SIze, 
advanced pTNM stage, hepatitis activity in the non-cancerous hepatic tissue and 
peri operative transfusion. 
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1.5.1.2. Transplantation 
Initially, outcome of liver transplantation for HCC were poor, recurrence rates high and 
5-year survival only 18-40% 2H. 29. Limitation of candidates based upon established 
selection criteria has resulted in improved results. Most liver transplantation centers as 
well as the United Network for Organ Sharing (UNOS) apply the Milan selection 
criteria 30. According to these criteria, patients are eligible for liver transplantation, if 
they have a solitary tumor nodule with a diameter ~ 5 cm or fewer than 3 tumor 
nodules, no more than 3 cm each; vascular invasion and extrahepatic manifestations are 
considered contraindications. Restriction of patients fulfilling these criteria resulted in 
5-year survival rates of 70%. Attempts to expand Milan criteria resulted in worse 
outcomes with 5-year survival of 44% 31. A study comparing the Milan criteria with the 
expanded UCSF-criteria - defined as single tumor nodule ~ 6.5 cm or up to 3 lesions 
with the largest not exceeding 4.5 cm and the sum of tumor diameters not exceeding 8 
cm -showed no significant difference in survival, but significantly higher recurrence 
rates in the UCSF-criteria group 29.32. However, donor organ shortage results in long 
waiting times and as a consequence drop out rates are high with up to 25% drop out rate 
at 12 months 33. Living donor liver transplantation is an alternative approach achieving 
similar 5-year survival outcomes as deceased donor transplantation 28. However, it is 
also correlated with morbidity and mortality rates of 14-21 % and 0.25-1 % 28, 
1.5.1.3. Neoadjuvant and adjuvant therapy 
The aim of neoadjuvant therapy is to downstage tumors in order to facilitate resection or 
transplantation, or to prevent tumor progression prior to liver transplantation. However, 
systemic therapies for neoadjuvant treatment do not provide survival benefits in HCC 
20, Local ablative methods are frequently used as a neoadjuvant treatment for bridging 
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time to liver transplantation 34. However, also these approaches have not been proven to 
provide significant survival benefits 35. Adjuvant chemotherapy has been evaluated in a 
variety of trials due to the high recurrence rate of HCC. However, adjuvant treatments 
do not improve overall survival or disease-free survival 36,37. 
1.5.2. Local ablative methods 
Local ablative treatments are beneficial in patients who do not qualify for resection or 
transplantation. There are a variety of different techniques used for this approach 
including percutaneous ethanol injection (PEl), radio frequency ablation and 
transarterial chemoembolization (T ACE). 
1.5.2.1. Percutaneous ethanol injection 
PEl is a widely accepted and commonly used therapeutic method for small, localized 
HCC. 95% ethanol is intratumorally injected under ultrasound guidance. As a general 
rule, the total number of injections in order to ablate the tumor equals twice the tumor-
diameter measured in centimeters 38. This technique is indicated for HCC-patients with 
a tumor-nodule of S2 cm in diameter who are not being suitable candidates for liver-
transplantation or hepatic resection 39, 40. Treatment of tumors larger in size resulted in 
incomplete ablation, high rates of relapse and decreased survival; therefore, they are not 
considered suitable for PEl-therapy. Also, superficially located tumor-nodules are not 
suitable due to increased extravasation of ethanol and suboptimal treatment of tumor 
margins 39. Complication rate of PEl-treatment is 1.7% and mortality 0.1 % 39. Overall 
1- and 3-year survival rates in patients with HCC-nodules S 3 cm treated with PEl is 
90% and 63% but recurrence rates are high with up to 66% per year 41.43. 
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1.5.2.2. Radiofrequency ablation 
Thermal ablation is based on the principle of irreversible tissue damage caused by 
exposure to high temperatures. Temperatures between 60° C and 100° C cause cellular 
protein coagulation with irreversible damage to cellular enzymes and nucleic acid-
histone complexes. Several techniques have been used for induction of thermal injury 
such as radiofrequency ablation, microwave, laser and high-intensity focused ultrasound 
44. Radiofrequency ablation is the most established of these methods 45. A grounding 
pad is placed on the patients back and a partially insulated electrode is placed within the 
tumor tissue. High-frequency alternating current is applied to tumor tissue resulting in 
heat energy of >60° C in the area of the electode 46. This technique achieves similar 
response rates as PEl in tumors <2 cm but better outcomes in larger tumors. However, a 
significant long-term survival benefit has not been shown 8,20. 
1.5.2.3. Chemoembolization 
HCC is a highly vascularized tumor deriving its main blood supply through the hepatic 
artery. In contrast, hepatic parenchyma derives its main blood supply from the portal 
vein. Selective intra-arterial embolization of the tumor-supplying artery (T AE) was 
shown to have therapeutic efficacy 47, 48. However, it does not have any beneficial 
effects on overall survival and is therefore not recommended as routine treatment for 
HCC 49-52. 
Transcatheter arterial chemoembolization (T ACE) is defined as local delivery of 
chemotherapeutic agents conjugated to an embolic agent to the tumor. Embolization 
results in prolonged exposure of tumor tissue to the chemoterapeutic agent and reduced 
systemic side effects in comparison to systemic chemotherapy. Chemotherapeutic 
agents used for T ACE include doxorubicin, farmorubicin, adriamycin, eporubicin and 
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cisplatin 53-57. Embolizing agents include lipiodol, gelatin sponge particles, starch, 
collagen or blood clots 53. T ACE can be repeated after 6 to 12 weeks 38. Response rates 
to TACE are are reported as 33-55% 51,53. Initial analyses showed mixed results in 
regard of its effect on survival 48,49,51, 58-60. Modification of protocols and analysis of 
patient characteristics showed that therapeutic benefit of T ACE depends on hepatic 
function and tumor stage 61-63. Restriction of patient selection to Child-Pugh class A and 
Okuda stage I and II resulted in 1-, 2- and 3-year survival rates of 57%, 31 % and 26% 
after TACE compared to 32%, 11% and 3% with symptomatic treatment only 50,52. In 
patients with Child C cirrhosis, the rate of complication is significantly higher with 
mortality rates up to 30% 64. Therefore, cirrhosis Child-Pugh class C cirrhosis as well as 
portal vein thrombosis and presence of a portosystemic shunt are considered 
contraindications for TACE reducing the number of eligible candidates to 12% 50,53.65. 
1.5.3. Systemic therapies 
Systemic therapies for HCC are considered non-curative. The spectrum of this 
therapeutic mode includes chemotherapy, hormonal therapy and biologic therapies. A 
great variety of clinical trials have been conducted in patients with unresectable HCC. 
Chemotherapeutics were used either as single agents or as combination chemotherapy. 
The most common chemotherapeutic agents used were doxorubicin and its less 
hepatotoxic derivative epirubicin, 5-FU, cisplatin and gemcitabine 66. 
However, systemic chemotherapy for HCC shows only low response rates between 0-
30%, no survival benefit, and is correlated with significant adverse effects and 
I" " 3 20 67-81 F h h' h Ib . I I b'I' b' I I comp lcatlOns " . actors suc as Ig a umm, ow tota 1 lru m eve s, low 
transaminase levels, absence of ascites, non-elevated serum-AFP, absence of vascular 
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involvement and small tumor size have been associated with better response to 
chemotherapy 82-84. These factors reflect liver function and it has been hypothesized that 
better hepatic function allows better cytotoxic delivery 84. At the present time, there are 
no chemotherapeutic drug regimens considered standard of care for HCC 85. 
Based upon demonstration of over-expression of hormonal receptors - e.g. estrogen-
and androgen receptors - in HCC, it was hypothesized that inhibition of these receptors 
might elicit therapeutic effects 86. Initial results in small, uncontrolled trials using the 
estrogen receptor inhibitor tamoxifen for HCC were promising, reporting significant 
" I b fi 49 87-90 HI" f "fi' I d" d survlva ene ItS' . owever, re-eva uatton 0 tamoXl en In arge, ran omlze 
trials failed to show a significant therapeutic effect 91-97. Also, studies with the 
somatostatin analogue octreotide, initially reported to be beneficial in HCC, showed no 
therapeutic efficacy in more recent, large randomized controlled clinical trials. In 
conclusion, hormonal therapy is not considered to be of significant benefit in HCC 85,96. 
Results from trials evaluating biologic and biochemical agents such as interferon and 
thalidomide are inconclusive and can therefore not be recommended for HCC 85. 
1.5.4. Radiation therapy 
External beam radiation is not feasible for HCC as at least 50 Gy are required for tumor 
ablation but radiation hepatitis is induced by doses >30 Gy 98. Conformational 
radiotherapy did not show significant survival benefits despite tumor response. Newer 
techniques involve micropsheres such as Yttrium-90 TheraSpheres, which are currently 
under evaluation. 
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1.5.5. Novel therapies 
The growing understanding of the molecular pathogenesis of HCC has identified new 
therapeutic targets. A great variety of new agents have been developed and are being 
evaluated for their potential as novel treatment options. These include small-molecule 
inhibitors, monoclonal antibodies and others 99. The majority of these agents target 
tyrosine kinases such as epidermal growth factor receptor (EGFR), vascular endothelial 
growth factor receptor (VEGFR), MAPK kinases or Raf kinase. Other targets include 
mTOR or members of the Bcl-2 family. Recent evaluation of the multi kinase inhibitor 
Sorafenib in the clinical SHARP (Sorafenib HCC Assessment Randomized Protocol) 
demonstrated significant prolongation of survival by 3 months and longer time to 
progression in patients with advanced HCC resulting in its approval for HCC by the 
FDA 100. 
1.5.5. Summary 
In summary, despite intense research efforts, surgery continues to be the only curative 
therapeutic option for HCC. However, only a minority of patients qualifies for an 
invasive approach and the dropout rates for patients awaiting transplantation are 
relatively high. Novel therapies have resulted only in modest prolongation of survival. 
Therefore, there is an urgent need for new therapeutic approaches. Genetic approaches 
to the therapy of HCC might be a potent tool in its treatment. 
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2. Genetic approaches to the therapy of cancer 
2.1. Introduction 
Gene therapy is one of the most promising approaches to treat cancer as it has the 
potential to provide tumour cell selectivity and/or protection of untransformed cells of 
the body. There are four main strategies in cancer gene therapy: (1) immunogene 
therapy to produce an anti tumour vaccine effect or to enhance T-cell anti tumour 
capability; (2) anti-angiogenic gene therapy; (3) cytoreductive gene therapy; and (4) 
transduction of haematopoetic stem cells (HSCs) with drug-resistance genes to enhance 
their resistance to cytotoxic drugs. In order to transduce the gene of interest, either 
nonviral vectors or viral vectors are used. Nonviral vector strategies include naked 
plasmid DNA, liposome-DNA complexes, peptide-bound DNA and electroporation 101-
103, 104. The most widely used viral vectors are retroviruses, adenoviruses, adeno-
associated viruses (AAVs; members of the parvoviridae family and discussed further 
below) and herpesviruses, and there is a great diversity of new vector systems being 
d 1 d 105, 106, 107, 108 eve ope . 
Depending on the desired gene therapy approach, there are different requirements the 
vector must fulfill, including safety and efficiency of the vector, specific targeting of 
gene transduction, expression level of the transduced gene and ease of manufacture 109, 
The specific requirements for vectors in the various gene therapy strategies are 
discussed in the following sections and are summarised in Table 5. 
Two viral vector systems fulfilling the majority of these requirements are autonomously 
replicating parvoviruses and measles virus. In the following sections, cancer gene 
therapy strategies will be discussed, followed by overviews over both viral systems and 
their use in cancer gene therapy. 
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Tumour Tumour VECs T cells or T cells or 
cells cells HSCs HSCs 
ex vivo in vivo ex vivo in vivo 
Transfer to - - - + + 
progeny 
Expression in + + + - + 
nondividing cells 
In vivo - + + - + 
stability 
Transcriptional - + + - + 
targeting 
Targeted - + + - + 
attachment 
Table 5 Requirements of a gene delivery system with respect to different target cells. The 
table shows the requirements vector systems have to fulfil in the different cancer gene therapy 
strategies. Further details and explanations are described in the text of the corresponding 
sections. (Abbreviations: + = required, - = not required; VEC = vascular endothelial cell; HSC = 
haemopoietic stem cell) 
2.2. Immunogene therapy 
In oncologic diseases, neoplastic cells have escaped the immune surveillance that 
normally prevents tumour formation. Mechanisms by which tumors escap an immune 
response include development of tolerance towards tumour-associated antigens (T AAs), 
development in an immunoprivileged site, and suppression of cytotoxic T lymphocytes 
(CTLs) by immunosuppressive factors expressed on the tumour cell surface (e.g. 
apoptotic ligands) or secreted by the tumour cells (e.g. interleukin 10 (lL-IO), 
transforming growth factor ~ (TGF-~)) 110. The rationale underlying immunogene 
therapy is to enhance either tumour immunogenicity or the anti tumour effector 
capability ofT cells to overcome the tolerance of the immune system. 
The first approach can be achieved by transduction of tumour cells or antigen-
presenting cells (APCs) such as dendritic cells with cytokine genes costimulatory 
molecules, strong immunogenic tumor rejection antigens or foreign MHC molecule . 
This can be accomplished either by ex vivo transduction of explanted tumor cells for use 
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as cell-based cancer vaccines, or by in vivo transduction of tumour cells or APCs to 
achieve a vaccine effect. In the second approach, immune effector cells can be 
retargeted by transduction ofT cells with chimaeric antigen receptors (CARs) or human 
leukocyte antigen (HLA)-restricted a~ heterodimeric T-ceII receptors (TCRs). Both 
strategies aim at immune-mediated destruction of the tumour 110, \II, 112, 113, 114. 
2.3. Anti-angiogenic cancer gene therapy 
Tumor growth is dependent on angiogenesis as it supplies the tumor tissue with oxygen 
and other factors required for its survival and growth. The degree of vascularisation of a 
tumor has been associated with its aggressiveness 115, 116, 117. Tumour angiogenesis is 
driven by the proliferation and migration of vascular endothelial cells (VECs), which 
are therefore important targets in cancer therapy. VECs are stimulated by pro-
angiogenic proteins such as vascular endothelial growth factor (VEGF), basic fibroblast 
growth factor (bFGF) and platelet-derived endothelial growth factor-~ (PDGF-~). These 
proteins are synthesised by tumor cells, endothelial cells or both. VEGF in particular is 
highly expressed in many different tumor cells and has been correlated with tumor 
h · . d . 118 \19 growt ,InVaSiOn an metastasIs ' . 
In cancer therapy, there are three different strategies to disrupt tumour vessel growth. In 
the first, direct, strategy, endothelial cells are directly targeted to block proliferation or 
migration or to induce apoptosis. The second strategy is to attack tumor-associated 
endothelial cells indirectly by blocking the expression or activity of tumor proteins that 
stimulate angiogenesis. This can be achieved by neutralising pro-angiogenic proteins in 
the microcirculation, by preventing their binding to their cognate receptors or by 
blocking signal transduction by targeting the intracellular domains of receptor tyrosine 
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kinases. For example, the inhibition of epidermal growth factor receptor (EGFR) blocks 
the synthesis of VEGF, bFGF and TGF-a. A third strategy is the inhibition of multiple 
signal transduction pathways on both the tumor-associated endothelial cells and the 
tumor cells. These various anti-angiogenic approaches can be used in combination 120. 
The requirements vectors must fulfill for anti-angiogenic gene therapy approaches are 
demanding. Since the route of administration has to be systemic, vectors have to be 
stable in vivo. Also, they have to provide stable transgene expression since tumors can 
reoccur as soon as inhibition of tumor angiogenesis is stopped. Although no toxic side 
effects have been observed up to now, there are still concerns about the effect of 
angiogenesis inhibition on physiologic angiogenesis. 
2.4. Cytoreductive cancer gene therapy 
Cytoreductive cancer gene therapy is used to reduce the number of tumor cells by 
transducing them with a therapeutic gene encoding a cytotoxic protein or a prodrug-
sensitizing protein 109. In order to succeed with this approach, vectors require in vivo 
stability, high transduction efficiency and their trangene expression needs to be targeted 
in order to protect non-malignant tissue, either through transcriptional control using a 
tumour-specific promoter or transductional targeting 121.122, 
2.S. HSC transduction with drug-resistance genes 
One of the limiting factors in chemotherapy of malignancy is myelosuppression 123, 
Autologous stem cell transplantation is therefore a widely used method to facilitate 
high-dose chemotherapies. However, as the transplant is harvested before the therapy, 
the possibility of contamination of the transplant with tumor cells remains. As an 
alternative to this procedure, transduction of HSCs with a drug-resistance gene makes 
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these stem cells, as well as their offspring, more resistant to the cytotoxic effect of the 
chemotherapeutic agent, allowing the administration of higher doses of chemotherapy, 
which in tum increases the likelihood of a curative therapy of the malignancy 109, The 
most widely used multidrug-resistance gene is the gene encoding MDRl. Other 
examples of genes having a protective potential against chemotherapeutic drugs are 
those encoding dihydrofolate reductase (DHFR), 0 6 -methylguanine-DNA 
methyltransferase (MGMT), aldehyde dehydrogenase (ALDH), glutathione-S-
transferase (GST), cytidine deaminase (CDD) and dihydropyrimidine dehydrogenase 
(DPD) 124, The major requirement for the transduction of drug-resistance genes is the 
restriction of their expression to HSCs, because transduction of even a small number of 
tumor cells with drug-resistance genes would render them resistant to chemotherapy, 
HSCs can be collected from bone marrow, peripheral blood or umbilical cord blood, 
and selective transduction can be achieved ex vivo by transduction of the HSCs after 
CD34 selection and stimulation with growth factors 109, 125, 126, For direct in vivo gene 
transfer, the vectors would have to be targeted against proteins such as CD34 and c-kit, 
both of which are human haematopoetic progenitor cell-surface markers 127, 128, 128, 
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3. Parvoviridae 
3.1. Introduction 
The family parvoviridae IS subdivided into the subfamily parvovmnae (which use 
vertebrate hosts) and the subfamily densovirinae (using arthropod hosts). The subfamily 
parvovirinae includes three genera: parvovirus, erythrovirus and dependovirus (Table 
6). Members of the genus parvovirus are characterised by their oncotropism and 
oncosuppression, and their ability to mediate long-term gene expression. Together with 
their human apathogenicity, these characteristics make parvoviruses highly interesting 
vector systems for cancer gene therapy. The fo llowing section will focus on the 
autonomously replicating parvoviruses (ARP). 
Genus VirusU 
Parvovirus H1 
(PV) Lulll 
MVM (minute virus of mice) 
CPV (canine parvovirus) 
FPV (feline parvovirus) 
Erythrovirus 819 
Dependovirus AAV (Adeno-associated virus) 
serotypes 1- 8 
Table 6. The parvovirinae subfamily. Viruses of the parvovirinae subfamily that are commonly 
used for gene therapy are shown in bold. 
3.2. Parvoviridae biology 
3.2.1. Structure 
Parvo iridae are are among the smallest known VIruses. They are icosahedral, 
nonenveloped viruses with a diameter of 18- 26 nrn and a molecular mass of 5.5- 6.2 x 
106 Da 129 . Virions consist to 50% of protein and 50% DNA 130. The capsid is formed 
Blechacz, B (2009). PhD thesis Page 22 
Introduction 
by three capsid proteins VPl, VP2 and VP3 - 90% of the capsid is fonned by VP3, 5% 
by VPl and 5% by VP2 - and encapsidates a single-stranded DNA molecule. 
3.2.2. Genome 
The ARP genome has a size of approximately 5.1 kb. It consists of single-stranded, 
linear DNA of negative polarity. At both tennini, it has palindromic sequences that 
serve as self-priming origins of replication (Fig. 3) 131. 132. For the genus parvovirus, 
these inverted repeats at the left and right end are unique and fonn V-shaped and T-
shaped hairpin loops, respectively. In the MVM genome, the 3' -palindrome is 
approximately 115 nucleotides and the 5' -palindrome 207 nucleotides in length. These 
tennini contain the cis-acting elements required for replication \33. Additional sequences 
essential for efficient MVM replication include two regions inboard of the right 
palindrome called element A and B. Within the genome there are two overlapping open 
reading frames (ORFs) coding for the nonstructural and structural viral proteins. 
Expression of these proteins is regulated by two parvoviral promoters: the P4 promoter 
134 135 136 137 138· • 
and the P38 promoter. . . . . , ExpreSSIon of the non structural protems (NS 1 
and 2) is under the control of the P4 promoter. This promoter is induced at the G l-S-
phase transition and stimulated by oncoproteins 139, The P38 promoter is trans-activated 
by the NS 1 protein and regulates transcription of the capsid-coding genes (VP 1 and 
VP2) 140. 141. 142. 143. VPl and VP2 are derived from alternatively spliced mRNA 
transcripts. VP3 is synthesized by proteolytic cleavage of approximately 25 N-tenninal 
amino acids of VP2, a process only observed in DNA-containing virions 144. Unique 
regions in VP 1 contain phospholipase A activity and nuclear localization signals 130. 
NS 1 is an 83 kDa phosphoprotein that has helicase, ATPase, DNA-nicking and 
sequence-specific DNA-binding activities. It is therefore a multifunctional protein 
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Figure 3 Genome organisation of autonomously replicating parvovirus (ARP). The 5.1 kb 
single-stranded linear DNA genome has inverted repeat (IR) sequences at the termini that serve 
as self-priming origins of replication. There are two open-reading frames, coding for the 
structural (VP1 and VP2) and nonstructural (NS1 and NS2) proteins. Transcription is regulated 
by the promoters P4 and P38. The transcripts R1-3 and their corresponding parvoviral proteins 
are indicated below the schematic figure of the genome. 
essential for viral replication and promoter transactivation 145, 146, 147, 148, 149, 150, 15 1, 152, 
153 . It is also considered the major mediator of cytotoxicity 154 . NS2 is a 22 kDa protein 
that is essential for replication, virus production, nuclear egress of progeny virions and 
host-specific infection 155-1 60. In addition, NS2 enhances NS I-mediated cytotoxicity 161, 
162 
3.2.3. Life cycle 
The life cycle of the parvoviridae starts with receptor-mediated binding of the virus to 
the cell surface. Although not yet completely characterised, the receptor for binding of 
MYM (minute viru of mice) and HI is known to contain N-acetylneuraminic acid 
(sialyl)-containing glycoproteins 132. For the erythrovirus B 19, erythrocyte P antigen has 
been identified as a binding receptor and a5~1 integrin as a cellular coreceptor 163-165. 
Recently, the differential use of the transferrin receptor (TfR) as a binding receptor for 
canine parvoviru (CPY) and feline parvovirus (FPV) has been shown 166-169. Following 
cellular receptor binding viral particle are internalized via receptor- mediated 
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endocytosis. Endosomal trafficking and escape, uncoating and nuclear entry 
mechanisms of ARPs are not completely understood 170. It has been shown that 
endosomal transit is required for efficient infection and that the overall efficiency is low 
resulting in high particle-to-infectivity ratios 171, 172. After endosomal release and 
cytosolic transport, virus particles are actively transported into the nucleus \30 
Parvoviral DNA is replicated in specific nuclear structures termed autonomos 
. . d l' . b d' 173 174 ARP . d . h h parvovlrus-assoclate rep lCatton 0 les '. are not mtegrate mto t e ost 
genome 175. Parvoviral replication follows the "rolling hairpin model" and strictly 
depends on S-phase specific cellular factors 174, 176. Parvoviral DNA replication starts 
with synthesis of a complementary strand converting its single-stranded genome into a 
double-stranded monomer replicative form (mRF) 132. This initial conversion is 
independent from viral proteins, but requires cellular cyclin A that is induced at the 
G liS-transition, Cyclin A induction results in polymerase-b mediated complementary 
DNA synthesis starting from the self-primed, palindromic parvoviral 3' -terminus 173, 174. 
The right hand hairpin is nicked by NS 1 at a nicking site 18 bp downstream of the 
originalS 'terminus followed by new formation of two hairpins. The newly formed 3'-
terminus serves as primer for repair DNA synthesis extending through both strands of 
the mRF resulting in formation of di- and multimeric, double-stranded replicative forms 
(dRF). Both termini of this replication intermediate consist of the original 5'-terminus 
while the original left terminus is located in the middle forming the so called dimer 
bridge. The dimer bridge is asymmetrically resolved through single-strand nicking 
reactions followed by displacement syntheses and religations resulting in the formation 
of new replication intermediates which serve as templates for further replication, gene 
. d" 1 d DNA 129 130 132 C I" h' d °d . expressIon an smg e-stran ". ytoso IC synt eSIze caps1 protems are 
transported into the nucleus where they undergo assembly followed by NS I-dependent 
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incorporation of single-stranded parvoviral DNA. Using VP2 as a nuclear export signal, 
virions are transported from the nucleus into the cytosol followed by cellular release, a 
process frequently leading to cell death 130. 
3.3. Infectivity, pathogenicity and oncosuppression 
Viruses of the parvovirinae subfamily have the ability to infect a variety of different 
vertebrates. Although the natural hosts of parvovirus HI, MVM and LulU are rodents, 
they also have the ability to infect human cells 129. However, ARPs are not pathogenic 
in humans. Although viraemia after human exposure to HI has been described, B 19 (of 
the erythrovirus genus) is the only virus of the parvovirinae subfamily known to cause 
human diseases, which include erythema infectiosum, hydrops fetalis, transient aplastic 
anaemia, myocarditis, hepatitis, arthritis, vasculitis and neurological disorders 177. 
In the context of cancer, ARPs have special characteristics. They were first isolated 
from human tumour tissue and for that reason were believed to be oncogenic 178. It was 
then observed that ARPs possess an oncosuppressive potential, inhibiting the formation 
of spontaneous and chemically or virally induced tumours in vivo and in vitro 179, 180, 178, 
181, 182, 183, 184, 185, 186, 185, 187. Oncogenic transformation of several human and rodent 
cells resulted in an enhanced capacity for parvoviral DNA amplification and gene 
expression, and correlated with significantly increased susceptibility towards the 
. I .. 188 189 190 I h b h h . C • f parvovlra cytOtoxICIty , , . t as een sown t at oncogemc translormatlOn 0 
cells resulted in P4 promoter activation 139, 191, 192. A precondition for parvoviral 
cytotoxicity is cell proliferation. Parvovirus P4 promoter activation and replication is S-
phase dependent 174, 193, 176. Several oncoproteins have been shown to contribute to the 
activation of the P4 promoter during its stimulation at the G liS-phase transition 
Blechacz, B (2009). PhD thesis Page 26 
Introduction 
1 . . NSI d . h' h h' .. . 1 l' . 139 174 176 191-193 resu tmg In -pro uctIOn Ig enoug to mltIate vlra rep !CatIOn ' " . 
The exact mechanism of parvoviral tumour suppression is not completely understood 
but is thought to involve several factors, with the NS 1 protein as the major mediator of 
parvoviral cytotoxicity 194, 195, 196, 197, Depending on the cell line, the mechanism of 
parvovirus-mediated cytotoxicity is either apoptosis or necrosis 198, 199,200. 
3.4. Tissue targeting with parvovirinae vectors 
In order to prevent damage to non-malignant tissue, the specificity of a therapeutic 
agent for tumor cells is of high importance, particularly when the vector is to be used 
systemically. Unfortunately, the therapeutic index of most existing vectors is low 201, 
and the undesired transduction of non-malignant tissue can result in damage and cell 
death. Specificity of a gene therapy vector can be achieved by transductional or 
., 1 . 201 202 T d . 1 . d 'b h l' k transcnptlona targetmg , . rans ucttona targetmg escn es t e se ecttve upta e 
of the vector into the cells of interest, where the trans gene is transcribed. Depending on 
the gene therapy strategy, this can be tumor cells, endothelial cells of tumor vasculature 
or other target cells. Selective uptake can be achieved by various strategies, such as 
modification of the viral capsid or pseudotyping of viruses. In transcriptional targeting, 
the vector might be taken up by many different cell types but is only transcribed in the 
target cells. In this approach, selective expression of the trans gene is achieved by 
replacement of the natural promoter or by modification of the transcription factor 
binding sites within a promoter. There are promoters based on aberrant tumour biology 
(e.g. promoter induction by telomerase), tissue-specific expression (e.g. promoter 
induction by tyrosinase for cell type-specific expression in melanomas) and externally 
inducible promoters (e.g. heat shock protein 70). Transductional re-targeting of ARPs 
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has been reported for feline parvovirus (FPV), a parvovirus that normally infects feline 
cells, with the aim of modifying it to target human tumor cells for cancer gene therapy. 
Although modification of the FPV capsid to bind av integrins enabled transduction of a 
human rhabdomyosarcoma cell line, other human tumor cell lines expressing av 
integrins were not transduced 203. Thus, other factors are likely to be required. 
Transcriptional targeting of ARPs has the advantage that the vectors are already 
oncoselective, as explained above. Transcriptional targeting of ARPs has been used to 
achieve cell-type specific trans gene expression of the parvovirus LulU: recombinant 
LuIIl vectors expressing the luciferase marker gene under the control of a chimaeric 
promoter containing a liver-specific enhancer directed the preferential expression of the 
luciferase marker in transduced human hepatoma cells 121, 204. In another approach, 
targeted hybrid H-lIMVM parvovirus vectors were used. Transcription factor binding 
sites for the heterodimeric p-cateninlTcf transcription factor were inserted in the P4 
promoter. Activation of the wnt signaling pathway results in activation of promoters 
containing Tcf binding sites. The wnt signaling pathway is constitutively activated in 
colon carcinoma so that this system was used to target specifically colon carcinoma. 
The authors observed NS I expression and viral burst size similar to wild-type levels in 
colon carcinoma cell lines but a WOO-fold reduction of viral burst size in wnt-inactive 
Ill ' 205 ce mes . 
3.5. Parvovirinae in cancer gene therapy 
The aim of cancer gene therapy is the transduction of a specific cell population with a 
specific gene in order to destroy the tumor, or to protect noncancerous cells and thereby 
enable high-dose chemotherapy. Due to their oncoselectivity and human apathogenicity, 
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ARPs are highly suitable vectors for selective infection of tumor cells and have been 
used especially for immuno- and cytoreductive gene therapy. 
3.5.1. Immunogene therapy 
Unmodified parvoviridae (MVM, H-l) are not able to induce significant cytokine 
production [interferon (IFN), tumour necrosis factor a (TNF-a), IL-6] either in rodent 
or human cells 206. However, induction of heat shock protein release after HI infection 
has been reported 207. Heat shock proteins are intracellular molecules that are released in 
necrotic but not apoptotic cell death; their antigenic peptides are chaperoned into APCs 
and induce an immune response after presentation to CTLs 208. Enhancement of the 
immune-mediated parvoviral antitumor effect can be achieved by transduction of 
tumour cells or APCs with specific transgenes. Both ex vivo and in vivo transduction 
approaches have been used. 
3.5.1.1. Ex vivo transduction 
In ex vivo transduction, tumor cells are explanted, transduced with the therapeutic gene 
and readministered to provoke a host immune response. The vector must be capable of 
mediating relatively short-term gene expression in the explanted tumor cell, a 
requirement fulfilled by ARPs. 
Cytokines such as IL-2, IL-12 and granulocyte-macrophage-colony-stimulating factor 
(GM-CSF) have shown their antitumor potential in different models 209, 210, 211,212,213, 
214,215,216,217. IL-2 and IL-12 mediate their antineoplastic potential mainly by activation 
and expansion of tumor-specific T cells and the activation of the cytotoxic activity of 
natural killer (NK) cells. In addition, they are able to stimulate IFN-y production, induce 
the differentiation of T helper type 1 (Thl) cells and activate lymphokine-activated 
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killer cells (LAKs) 212, 217. GM-CSF stimulates CDllc+ dendritic cells type I (DCI), 
resulting in an enhancement of antigen processing and presentation 110. The use of ARP 
vectors (MVM, H-l) resulted in high, although not stable, IL-2 levels after transduction 
of transformed cells 218,219, and in vivo experiments showed up to 90% tumor reduction 
of human cervical carcinoma (HeLa) xenografts 219, In a subcutaneous melanoma 
xenografts model, tumor growth was inhibited by infection with an IL-2 expressing 
MVM vector prior to implantation; animals were also partially protected against re-
challenge with uninfected tumor cells 220, 
Another widely used family of proteins for cancer gene therapy are the monocyte 
chemotactic proteins (MCP), which belong to the chemokine family. MCP-I mostly 
recruits monocyte/macrophages; MCP-3 exerts its effect on a broader variety of cells 
including monocytes, T cells, basophils, eosinophils, neutrophils, granulocytes, NK 
cells and DCs 221, 222, 223, 224, 225, 226, 227, 228. Transduction of tumor cells with MCPs has 
been shown to have a tumor-suppressive effect. The observation that endogenous MCP-
I is absent in human cervical carcinoma cell lines made it a therapeutic transgene of 
interest for cancer gene therapy 229, 230, Recombinant parvoviruses HI and MVM 
carrying a transgene encoding for MCP-3, were able to delay tumor growth in 
subcutaneous cervical cancer and melanoma xenograft mouse models; however, a 
complete tumor suppression could not be achieved 231,232. 
Another popular approach to enhance tumor immunogenicity is transduction with 
costimulatory molecules, resulting in an induction of an anti tumour CTL response. 
C080 (B7.1) and CD86 (B7.2) stimulate CD28, which is expressed on the T-cell 
surface; the costimulation of CD28 and the TCR leads to expansion of C08+ CTLs. 
Expression of B7 proteins in tumors has been shown to increase antitumor immune 
responses, resulting in rejection, and even protection against tumors not expressing B7 
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proteins 233,234,235,236,237. MVM has been used in vitro for this approach. Recombinant 
MVM coding for CD80 or CD86 resulted in tumor cell-specific expression of these 
proteins. However, their tumorsuppressive potential was not evaluated 238. 
3.5.1.2.1n vivo transduction 
The requirements a vector must fulfil for in vivo transduction are more demanding 
compared with the ex vivo approach. The vector should be transductionally or 
transcriptionally targeted to the tumor. In addition, it has to be sufficiently stable in vivo 
to tolerate systemic administration, although direct intratumoral delivery is also 
possible. MVMp has been used for in vivo transduction of metastatic 
haemangiosarcoma with interferon-inducible protein 10 (IP-IO) with very promising 
results; a significant slowing of recurring haemangiosarcoma growth and metastasis 
suppression was observed in immunocompetent mice, as well as survival up to 6 
months in a third of the animals 239. IP-lO is a chemokine with previously demonstrated 
antitumor potential, which is thought to be mediated by antiangiogenic factors as well 
. . l' 240 241 
as Immune stImu atlOn ' . 
3.5.3. Cytoreductive cancer gene therapy 
Cytoreductive cancer gene therapy is used to reduce the number of tumor cells by 
transducing them with a therapeutic gene encoding a cytotoxic protein or a prodrug-
sensitizing protein 109. To achieve this, a vector requires in vivo stability, high 
transduction efficiency and the ability to target, either by transcriptional control using a 
tumor-specific promoter or transductional targeting, to avoid damage to normal tissue 
121. 122 
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ARPs are characterised by their oncotropism and oncosuppressive potential and provide 
high-level transgene expression. These characteristics make them promising vectors for 
cytoreductive cancer gene therapy. In general, the parvoviral cytotoxicity is not 
sufficiently potent to achieve 100% tumor regression. The resistance of some tumor 
cells to parvoviral cytotoxicity is thought to be in part correlated to the p53 status of the 
cell, as wild-type p53 cells are less susceptible to parvoviral cytotoxicity 200, 242. One 
approach to overcome this problem of tumor cell resistance towards parvoviral 
cytotoxicity is through the use of cytotoxic transgenes. This can be achieved by either 
replacing the capsid-coding region with a therapeutic transgene or by replacing the 
complete parvoviral coding region with a different expression cassette flanked by 
parvoviral palindromic sequences. Great efforts have been made to modulate the 
parvoviral genome to enhance its cytotoxicity and two transgenes that have been used 
are apoptin and HSV-TK. 
Apoptin is a 13.8 kDa protein encoded by the chicken anaemia virus 243. It induces 
apoptosis in tumor cells in a p53-independent manner. Apoptin-induced apoptosis is 
mediated by the caspase-signalling pathway. Interestingly, apoptin does not harm 
untransformed cells most probably owing to a cytosolic localisation in contrast to its 
nuclear localisation in transformed cells. Its antitumoral potential has been shown in 
d 'f~ d I 244 245 246 247 248 Th 'b'l' f HI . 11 I lerent tumor mo e s ' , , , . e susceptt I Ity 0 -resIstant tumor ce 
lines was increased by infection with the recombinant hH l-apoptin resulting in up to 
three-fold higher cytotoxicity than with parvovirus hHl-GFP infection. It remains to be 
determined if this effect can also be achieved in vivo 249. 
In in vitro tumor models of melanoma, breast cancer and glioma, HSV-TK was tested as 
a therapeutic transgene cloned in MVMp 250, Infection of these tumor cell lines with the 
recombinant MVMp-HSV -TK followed by the addition of ganciclovir resulted in up to 
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95% cell killing dependent on the tumor type. Ganciclovir-independent MVM-mediated 
cytotoxicity was 30-65%. 
3.6. Summary 
Parvoviridae are highly promIsmg vectors for gene therapy of cancer. ARPs are 
appealing vectors for cytoreductive gene therapy as well as immunogene therapy 
approaches to target tumor cells. They have the advantage of being oncotropic, 
oncosuppressive, human apathogenic and providing high-level transgene expression. 
A disadvantage of ARPs is the limitation of transgene size owing to inefficient 
encapsidation beyond a size limit of 106% of the wild-type genome size 133,251. 
In summary, parvoviridae have highly advantageous characeristics as cancer gene 
therapy vectors. However, their efficacy is limited by their genomic size restriction and 
immunogenicity. 
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4. Measles virus 
4.1. Introduction 
In the 1970' s, several cases of temporary tumor regressIOn were observed in 
hematologic malignancies during wild type measles virus infection 252-254. However, a 
systemic approach of using measles virus for cancer virotherapy was not pursued until 
2001 107, 255. Measles virus was first isolated by Enders and Peebles in 1954 from a 
throat swap of David Edmonston, an 11 year old child suffering from measles. 
Adaptation of the isolated Edmonston strain of measles virus to chick embryos with 
subsequent serial passaging in chick embryo fibroblasts resulted in the Edmonston B 
strain of measles virus 256,257. Further passaging of the Edmonston or the Edmonston B 
strain of measles virus in different cell culture systems generated a variety of other 
attenuated measles virus vaccine strains (e.g. Schwarz strain, Moraten strain, 
Edmonston-Zagreb strain) 258-261. Adverse effects of measles vaccine are rare and 
include expected effects such as fever (5%), rash (1.6%) and conjunctivitis (2.1 %), as 
well as rare unexpected events as anaphylaxis, thought to be secondary to gelatin 262. 
One of the premises for the generation of engineered measles viruses was the first 
successful rescue of measles virus from an infectious molecular clone of the attenuated 
Edmonston B strain 263. The resulting infectious virus was named Edmonston tag strain 
and will be referred to as MV-Edm 263. Based upon this viral strain, a variety of 
recombinant measles viruses have been generated with additional functions including 
enhanced cytotoxicity, the potential for noninvasive monitoring and retargeted viruses. 
The advances and applications of recombinant measles virus vectors will be discussed 
in the following sections. 
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4.2. l\1easles Virus biology 
4.2.1. Genome and structure 
Measles virus (MV) is an enveloped, negative strand RNA-virus belonging to the 
family Paramyxoviridae, genus Morbillivirus and order Mononegavirales. Its virions 
are characterized by their pleomorphic structure with a diameter of 120 to >300 nm and 
their capacity for polyploidy 264. The envelope carrries protrusions formed by the fusion 
glycoprotein and the viral transmembrane hemagglutinine. Measles virus has a 
nonsegmented RNA genome of negative polarity, which is 15,894 nucleotides in size 
(Fig. 4). The genome is encapsidated by a helical array of nucleocapsid proteins and 
encodes six structural and two non-structural proteins: nucleocapsid protein (N), viral 
RNA-polymerase (L), phosphoprotein (P), matrix protein (M), haemagglutinin protein 
(H) and fusion protein (F). Two non-structural proteins, C and V, are encoded by the P-
cistron 265, 266. The relative position of genes in relation to the 3' -end is negatively 
correlated with their level of protein transcription 267. The viral genome is encapsidated 
by nucleocapsid and associated with polymerase and its cofactor phosphoprotein 
forming the ribonucleoprotein complex. The ribonucleoprotein complex is surrounded 
by matrix proteins, located b~neath the viral envelope, and interacts with the 
cytoplasmic domains of haemagglutinin and fusion proteins 268 (Fig. 5). Measles virus 
infection begins with its binding to its cellular receptors CD46 and SLAM, which are 
discussed in more detail below. H-protein is a type II transmembrane glycoprotein 
responsible for the interaction of measles virus with its cellular target receptors. The 
type I glycoprotein F mediates membrane fusion 269,270. Both glycoproteins are required 
for effective fusion 271. Receptor binding of the H-protein induces conformational 
changes in the F-protein resulting in insertion of hydrophobic fusion domains into the 
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target cell membrane and approximation of the two membranes facilitating membrane 
fusion 272, 273. Subsequently, the ribonuclein complex is released into the cytoplasm 
where transcription of viral mRNA is initiated. Rescue of recombinant measles virus 
vectors is facilitated by the reverse genetics system and has first been described for 
measles virus 
a) MV: 
--I N II p II M III F II H II L tt I-
b) MV-CEA: 
, #1--I hCEA II N II P II M III F II H II / 
c) MV-e~FP: 
1L 
-I .GFP II N II P II M III F II H II L l-II 
d) MV-NIS: 
-I N II P II M III F II H II NIS II L $1-
Figure 4 Measles virus genome. Schematic representation of the genome of unmodified and 
recombinant MV-Edm constructs. Viral proteins and their relative positions within the genome 
are indicated by gray boxes, intergenic regions by white boxes and transgenes by shaded 
boxes. Viral proteins include nucleoprotein (N), phosphoprotein (P), matrix protein (M), fusion 
protein (F), hemagglutinin protein (H), polymerase (L). Two additional proteins C and V protein 
are encoded on the P cistron . a) wildtype MV-Edm, b) recombinant MV-Edm coding for 
carcinoembryonic antigen (hCEA), c) recombinant MV-Edm encoding enhanced green 
fluorescent protein (eGFP). d) recombinant MV-Edm encoding the human sodium iodide 
symporter (hNIS) . 
by Radecke et al. 263 . This rescue ystem uses a stably tran fected cell line expressing 
measles viru N- and P-protein, as well as the T7-polymerase. These helper cells are co-
transfected with plasmids encoding measles virus polymerase (L-protein) and the full-
Blechacz, B (2009). PhD thesis Page 36 
Introduction 
length measles vims antigenome regulated by a T7-promoter. Successful rescue of 
infectious measles vims was shown. The successful establi shment of thi s system 
allowed genetic modification of measles vims. 
• 
• 
• • 
• 
Nucleocapsid Lipid envelope P protein L protein M protein F protein H protein 
Figure 5: Measles viru s structure. Schematic representation of a measles virus particle . 
With in the particle is the genome, which is encapsidated by the nucleoprotein and associated 
with the viral polymerase complex consisting of the polymerase (L) and its cofactor 
phosphoprotein (P) . The resulting complex forms the ribonucleoprotein complex which is linked 
to the envelope by the matrix protein. The two viral glycoproteins hemagglutinin protein (H) and 
fusion (F) project from the envelope are essential for viral attachment and fusion as described in 
the text. 
4.3. Tumor selectivity 
Measles vims tropism is substantially determined by its receptor usage. Two receptors 
have been identified for measles viruses binding: CD46 and SLAM 274-276. However, 
infec tion in the absence of these receptors has been observed, indicating the possibility 
of a th ird receptor 277-279 . Signaling lymphocyte activation molecule (SLAM, CD 150) is 
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a 70 kDa transmembrane glycoprotein expressed on activated T - and B-cells, memory 
lymphocytes, dendritic cells and immature thymocytes 280. It is involved in T-celI 
activation, induction of T-cell proliferation and Th 1 cytokine-production 281. CD46 
(MCP, membrane cofactor protein) is a 57-67 kDa transmembrane glycoprotein 
ubiquitously expressed on all nucleated human cells. It belongs to the complement 
activation regulator family and binds to complement factors protecting the cell from 
complement-mediated destruction 280. CD46 as well as other complement regulatory 
proteins are frequently overexpressed in a variety of human cancers and thought to 
provide a mechanism for protecting tumor cells from complement-mediated lysis 282. 
Wild type measles virus and MV-Edm differ in their receptor usage. Wild type MV uses 
predominantly SLAM receptor for cell entry, whereas MV-Edm preferentially uses 
CD46 283. The ability to use CD46 for cell binding and especially induction of cell-cell 
fusion was shown to be related to a mutation at position 481 resulting in exchange of 
asparagine by a tyrosine residue 283. Virus entry efficiency is positively correlated with 
increasing CD46 density. In the absence of syncytia formation, viral gene expression 
after MV-Edm infection was comparable in normal cells and their transformed 
counterparts despite differences in CD46 density. However, for efficient induction of 
syncytia formation and cytotoxicity, a "threshold" receptor density was required 284,285. 
In addition, syncytia formation resulted in an at least 5-fold amplification of viral gene 
expression 284. The positive correlation between extent of cytopathic effect and CD46 
receptor density was confirmed in primary human multiple myeloma cells 286. 
Additional factors contributing to MV-Edm tumor selectivity are likely. Defects of 
intracellular innate immune response pathways in tumor cells allow efficient 
propagation of RNA viruses in these cells but not in untransformed cells. Wild type 
measles virus has the ability to inactivate these pathways in normal celIs. In contrast, 
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MV-Edm has lost this ability due to mutations in the V protein. This might help to 
explain why MV-Edm propagates efficiently in transformed but not in untransformed 
cells. These pathways will be discussed in more detail in the following section. 
4.4. Measles virus and the immune system 
The interactions between measles virus and the immune system have two major aspects: 
the effect of measles virus on the host and the host's immune response against the virus. 
Wild type measles virus infection is associated with immunosuppression to non-MY 
antigens. Characteristic findings include suppression of delayed-type hypersensitivity 
reactions and marked lymphopenia affecting mainly the T-cell population. Cellular and 
humoral responses to new antigens are impaired. These changes can last from several 
weeks to months and increase significantly the host's susceptibility to secondary 
infections. The mechanisms of measles induced immunosuppression include functional 
abnormalities of immune cells as well as suppression of cytokine synthesis 287,288. 
The other aspect is the antiviral immune defense. During the prodromal phase of the 
disease, the early innate immune response is induced followed by the adaptive immune 
response with MV -specific humoral as well as cellular responses 287. Due to widespread 
measles vaccination, average titers of measles antibodies in healthy humans are 100 ± 
59.2 EU/ml and serum titers of >20 EU/ml are considered measles immune 289. In 
addition, intracellular antiviral response mechanisms are induced inhibiting viral 
replication and protein synthesis as discussed below. The sum of these antiviral 
mechanisms is highly efficient in virus elimination and thereby a major barrier to 
successful measles virotherapy. 
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4.4.1. Circumventing antiviral antibodies 
In order to circumvent these barriers and enhance transduction efficiencies of MV-Edm 
therapy, different delivery strategies have been evaluated. One of the first strategies was 
the use of MV-Edm infected cells as delivery system 290,291, There is a strong rationale 
for this approach since measles virus naturally disseminates via the bloodstream inside 
infected monocytes or T cells, not as cell free virus. Also, passive serotherapy with 
measles hyperimmune serum is ineffective when given more than one week after initial 
exposure to the virus (i.e. before the virus disseminates via the bloodstream) proving 
that antibodies cannot prevent the cell-associated virus from trafficking to distant sites. 
The feasibility of this approach was shown in vitro using different cells as transport 
cells including the monocytic cell-line U-937, the endothelial cell line OEC, PBMCs 
and human T -cells 290, 291. Even in the presence of highly neutralizing anti-measles 
human serum, these infected carrier cells were able to fuse with cancer cells - a process 
referred to as heterofusion - and transfer successfully measles infectivity to lymphoma, 
multiple myeloma or ovarian cancer cells. In vivo, the feasibility of this approach was 
shown in different tumor models. In intraperitoneal xenograft models of multiple 
myeloma, ovarian and hepatocellular carcinoma, as well as in a disseminated lymphoma 
model, successful heterofusion and infection was shown after intraperitoneal treatment 
with MV-preinfected OEC or U-937 cells. The therapeutic efficacy was shown in an 
intraperitoneal ovarian cancer xenograft model in mice, in which tumor regression was 
achieved in more than half of the animals after treatment with only a single 
intraperitoneal dose of 1 x 106 MV-GFP-preinfected U-937 cells. Successful tumor 
infection was also achieved in mice passively immunized with human anti measles virus 
antibodies 291, Data from these studies show the general feasibility of cell delivery 
systems for measles virus treatment in the presence of an immune response. 
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4.4.2. Combating innate immunity 
The intracellular innate immune response system has also been targeted in order to 
enhance MV efficacy 285. Virus infection results in activation of transcription factors 
that regulate immediate early genes including type I interferons (lFN-aJ~) and other 
antiviral cytokines. IFN-aJ~ activate interferon regulated transcription factors through 
JAKJST AT -signaling pathways resulting in expression of antiviral proteins which 
inhibit viral replication and expression 292.293. Wild type measles virus as well as several 
other viruses have developed mechanisms inhibiting the type I interferon response 
pathways 292. Paramyxovirus-induced IFN-response inhibition is mediated by P, V and 
C proteins 294. Measles virus P, V and C proteins have been shown to inhibit IFN-
induced STAT activation and nuclear translocation 295-298. In contrast to wild type 
measles virus, MV-Edm was shown to be impaired in its ability to block the IFN-
response due to PN protein YllOH and V protein C272R mutations 298,299. 
In tumor cells, it has been reported that these intracellular antiviral response pathways 
are defective 300. However, it was shown in vitro that primary ovarian cancer as well as 
myeloma cells produce significant amounts of IFN-a and IFN-P following MV-Edm 
infection 285. Pretreatment of these cells with IFN-a or IFN-~ followed by infection with 
a CEA-expressing recombinant MV-Edm resulted in up to 50-fold reduction of 
trans gene protein expression and an up to two logs lower virus progeny production. In 
order to enhance MV-Edm efficacy, recombinant MV-Edm were generated expressing 
the unmutated wild type P-protein (MV-GFP-Pwt). Maximum titers and cytotoxicity of 
MV-GFP-Pwt were similar to MV-GFP. However, IFN-aJP induction was significantly 
lower and virus growth kinetics of the chimeric measles virus faster than MV-GFP. In 
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vivo comparison of MV-GFP with MV-GFP-Pwt in a human myeloma xenograft model 
in mice showed increased potency and accelerated tumor suppression with wildtype P-
expressing measles virus. 
4.4.3. Boosting antitumor immunity 
The immune system may also have a supportive role in measles VIruS mediated 
oncolysis. Polymorphonuclear neutrophils have been described to mediate tumor 
destruction by direct tumor cell destruction as well as cytokine and chemokine mediated 
activation of reactive cells and inhibition of angiogenesis 301. Intratumoral treatment 
with UV-inactivated MV, an active MV or a recombinant MV expressing murine 
granulocyte macrophage colony-stimulating factor (mGM-CSF) were compared in 
human CD46 transgenic, IFN-aJ~ receptor knockout mice (lfnartm-CD46Ge) bearing 
subcutaneous lymphoma xenografts 302. Intratumoral accumulation of neutrophils was 
observed in mice treated with the active viruses but not in inactivated virus-treated ones. 
In parallel, the rate of tumor regression was positively correlated with the percentage of 
intratumoral neutrophil infiltration. The data of this study indicate that measles virus 
replication stimulates intratumoral infiltration with neutrophils causing an enhancement 
of MV -mediated oncolysis. 
4.5. MV -Edm as a viral vector for cancer gene therapy 
In 1971, a case of transient tumor regression in a patient with Burkitt lymphoma was 
reported; an observation potentially explained by the ability of wild type measles virus 
to propagate in EBV transformed cells 252. However, wild type measles virus fails to 
propagate in other (SLAM-negative) transformed cell lines, e.g. human sarcomas or 
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epithelial malignancies 300. In contrast, MV-Edm has been shown to be oncolytic in a 
variety of different human tumor models in vitro as well as in vivo 107,255,303,304, The 
basis for the wide oncolytic potential of MV -Edm is thought to be its preferential use of 
CD46 and the overexpression of this receptor on transformed cells compared to their 
non-transformed counterparts as discussed above 284. Infection of transformed cells by 
MV-Edm results in syncytia formation. The recruitment of surrounding cells into 
syncytia causes an enhancement of the cytotoxic effect through a bystander effect. 
Syncytia formation is followed by cell death through apoptosis or a bioenergetic form 
. . 303 305 306 
of cell death wIth necrOSIS ' , . 
The following section will give an overview of different human malignancies in which 
the oncolytic potential of MV-Edm was evaluated. A summary of preclinical studies 
evaluating the therapeutic potential of MV-Edm is provided in table 7. 
4.5.1. MV -Edm for hematologic malignancies 
B-cell Non-Hodkin lymphoma. MV-Edm was evaluated for its therapeutic potential for 
B-cell Non-Hodgkin lymphoma (NHL) 255. Infection with MV-Edm or a p-
galactosidase expressing recombinant MV-Edm (MV-IacZ) at a MOl as low as 0.001 
resulted in efficient MV-Edm amplification, multinucleated giant cell formation of the 
suspension cells and cytotoxicity. The tumor suppressive effect was confirmed in mice 
bearing established tumors. Intratumoral treatment resulted in complete tumor 
regression in up to 25% of treated animals and systemic treatment was also able to slow 
tumor-progreSSIOn. 
Multiple Myeloma. The therapeutic potential of MV-Edm has also been shown for 
multiple myeloma (MM) 107. Replication, syncytia formation and cytotoxicity were 
Blechacz, B (2009). PhD thesis Page 43 
Introduction 
shown in vitro in a variety of established and primary human multiple myeloma cell 
lines after infection with a GFP-expressing recombinant MV-Edm (MV-GFP). In vivo 
tumor formation could be inhibited by preinfection of the human MM cell lines. 
Intratumoral as well as intravenous treatment of established subcutaneous MM 
xenografts resulted in complete tumor regression in up to 100% of animals. In a murine 
MM xenograft model resistant to MV-Edm as well as radioiodine monotherapy, 
combined radiovirotherapy using human sodium iodide symporter gene (NIS) 
expressing MV-Edm in combination with 131 1 achieved complete tumor regression in 
40% of treated animals 304. NIS is a membrane ion channel transporter mainly expressed 
in the follicular cells of the thyroid where it facilitates iodine uptake in the thyrocytes 
307. The promising results of these studies resulted in an FDA-approved protocol for 
clinical phase I testing of MV-NIS as systemic therapy in MM-patients. 
Cutaneolls T-cell lymphoma. Measles virus Edmonston-Zagreb strain (MV-EZ) - a 
vaccine strain derived from the Edmonston-Enders strain - was evaluated for its 
virotherapeutic potential in a non-randomized phase I dose-escalation study in five 
patients with cutaneous T-cell lymphoma (CTCL) 308. Treatment was well tolerated. 
Evaluation of overall response showed partial response in one, stable disease in 2 and 
progressive disease in 2 patients. Preclinical data showing therapeutic efficacy of 
measles in a CTCL xenograft model was reported in a later manuscript 309. 
4.5.2. MV-Edm for gynecologic malignancies 
Ovarian cancer. Using a trackable measles virus expressing the extracellular domain of 
carcinoembryonic antigen (MV-CEA), recombinant measles virus was evaluated for its 
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potential as a viral therapeutic for ovarIan cancer 107. Intratumoral treatment of 
established subcutaneous ovarian cancer xenografts in mice resulted in complete tumor 
regression in 80% of treated mice and enhancement of median survival by 105% 
compared to the negative controls. Enhancement of survival by more than 250% was 
shown in an orthotopic model of ovarian cancer. Currently, MV-CEA is being evaluated 
in a clinical phase I study in patients with ovarian cancer. 
Tumor type Virus Transgene Retargeted 
B-cell NHL MV-Edm 
- -
MV-lacZ B-gal 
-
MVHaCD20 
--
CD20 
MV2 
- CD38 
MV-PNP Hblindan"CD20 PNP CD20 
Fibrosarcoma MV-Edm 
- -
MVHaCD20 
- CD20 
MVgr •• n -MMP-A 1 GFP MMP-2 
MV",··n GFP 
-
Multiple MV-Edm - -
Myeloma MV-GFP GFP 
-
MV-NIS NIS 
-
MV-ERV 
-
Echistatin 
MV-aCD38 
- CD38 
Cutaneous T- MV-GFP GFP 
-
cell lymphoma 
Ovarian MV-CEA CEA 
-
cancer MV-GFP GFP 
--
MV-FRa 
- Folate receptor 
MV-aHER GFP HER2 
Breast cancer MV-CEA CEA 
Glioblastoma MV-CEA CEA 
-
multiforme MV-GFP GFP 
-
MV-GFP-H ..... -scEGFR GFP EGFR 
MV-GFP-HsNs-scEGFRvlli GFP EGFRvll1 
Colon MV-PNP-antiCEA PNP CEA 
carcinoma 
MHC-peptide MV-m33 (scTCR) GFP MHC-peptide 
complex complex 
Table 7 Preclinical studies evaluating MV-Edm as a cancer therapy agent (for further 
details. see section 4.5.) 
Blechacz, B (2009). PhD thesis Page 45 
Introduction 
Breast cancer. MV-CEA was also evaluated for its potential as a therapeutic agent for 
breast cancer 310. In vitro infection of several established human breast cancer cell lines 
resulted in infection, virus replication and transgene expression as well as cytotoxicity. 
Significant therapeutic potential was also confirmed in vivo. 
4.5.3. MV-Edm for neurologic malignancies 
Glioblastoma multi forme: In vitro as well as in vivo evaluation of MV -CEA in human 
glioblastoma multiforme (GBM) cell lines has shown strong cytopathic effects 303. 
Intravenous treatment of mice bearing subcutaneous GBM xenografts resultcd in 
complete tumor regression in all of the treated animals and significant prolongation of 
median survival. Similarly, evaluation in an orthotopic model with stereotactic 
intratumoral injection showed also complete tumor regression and prolongation of 
survival in the majority of treated animals. The oncolytic effect of MV-CEA was 
synergistically enhanced by combination with radiation treatmcnt in vitro and in vivo 
311. The synergistic effect was shown to be due to increased MV -CI;A propagation in 
tumor cells and enhanced apoptosis. Measles virus is currently being evaluated in a 
clinical phase 1 study of intratumoral inoculation in patients with glioma. 
4.6. Trackable MV -Edm for pharmacodynamic and pharmacokinetic 
analysis 
In order to gain understanding of the mechanisms responsible for different tumor 
response rates as well as for optimization of dosing and administration schedules in 
virotherapy, it is important to monitor viral replication and gene expression. Marker 
genes expressed in tumor cells after successful infection enable noninvasive monitoring. 
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Recombinant measles viruses were generated expressing marker genes including the 
soluble extracellular domain of carcinoembryonic antigen (CEA), the p-chain of human 
chorionic gonadotropin (PhCG) and the human sodium iodide symporter (NIS) 106,304, 
312. Serum markers CEA and phCG are non-immunogenic, have no relevant biological 
function and have relatively short half-life. Intraperitoneal administration of MV-CEA 
or MV -phCG in CD46 transgenic mice followed by serum analysis showed that serum 
concentrations of these proteins correlate with viral gene expression and reflect total 
number of viable cells expressing the viral genome 106. Peak serum concentrations of 
marker proteins were virus-dose dependent. Treatment of mice bearing measlcs-
susceptible myeloma or measles-resistant human fibrosarcoma xenografts showed 
correlation of serum marker concentrations with tumor response rates after infection 
with trackable measles virus. In animals with resistant tumors, no marker proteins were 
detected in serum. In mice bearing susceptible tumors, serum levels of marker proteins 
were elevated and their expression pattern correlated with the tumor response. Rapid 
tumor response was associated with a brisk rise and fall of marker protein levels, slow 
responding tumors showed prolonged expression with lower peak levels 313. In an 
orthotopic ovarian cancer mouse model, a significant correlation between 
intraperitoneal tumor burden and serum marker protein concentration was shown 312. 
MV -CEA gave valuable insight in viral kinetics at different treatment doses, showing 
that high viral doses achieved more efficient initial cell killing in an intraperitoneal 
SKOV3ip.l ovarian cancer xenograft model. However, the final outcome of therapy 
over a wide range of different virus doses was shown to be an equilibrium between the 
virus and the tumor confirming experimentally previously formulated mathematical 
I ' 'h 312 314 models of onco ytIc VIrot erapy , . 
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The human sodium iodide symporter (NIS) is another marker gene used for non-
invasively tracking measles virus in vivo 304. As described above, it is a membrane 
transporter facilitating intracellular iodine uptake. For in vivo monitoring, treatment 
with MV-NIS is followed by the application of 1231 and gamma-camera imaging. This 
approach enables monitoring of viral gene expression, replication and virus spread. In 
summary, the generation of trackable measles virus allows non-invasive monitoring of 
virus spread and will provide valuable pharmacodynamic information. These data will 
be helpful in adjusting viral doses, treatment schedules and to monitor tumor as well as 
viral biostribution. 
4.7. Summary 
The Edmonston strain of measles virus is a highly promising viral vector system for 
gene therapy of cancer. It has shown significant oncolytic potential in a variety of 
different models of human malignancies. The possibility of genetic engineering MV-
Edm and the stability of recombinant MV-Edm allow the generation of viral vectors 
with enhanced oncolytic potential. In addition, genetic engineering of MV-Edm has 
allowed the generation of trackable measles viruses allowing non-invasive monitoring 
of virus replication and spread. These viruses will provide valuable pharmacokinetic 
information for the optimization of virotherapy. MV-Edm has an excellent safety 
record. Based upon the experience of the last four decades during which MV vaccine 
strains were safely administered to millions of patients as well as current experimental 
data evaluating measles virus as an oncolytic virotherapy platform in CD46 transgenic 
mice, virus-mediated adverse effects in humans are not expected. Valuable information 
is expected from ongoing clinical phase I trials. In addition, recent advances in targeting 
strategies for MV-Edm allow complete retargeting of MV-Edm. The immune system is 
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a significant barrier for viral gene therapy systems. It still needs to be determined if the 
immune system will negate the therapeutic effect of MV-Edm by virus neutralization or 
enhance the therapeutic effect by elimination of virus infected tumor cells. Several 
strategies for immune evasion have been developed and evaluated for measles virus 
showing promising results. Concomitant immunosuppression is another strategy 
currently being evaluated in a clinical phase I study in multiple myeloma patients. 
In conclusion, MV-Edm is an ideal oncolytic virotherapy platform for cancer therapy 
characterized by its oncolysis, tumorselectivity and non-pathogenicity. Currently, it is 
being evaluated in several clinical phase I trials with additional clinical studies in the 
planning stages. 
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5. Non-viral gene deliver systems 
5.1. Introduction 
Non-viral gene delivery vector systems are an attractive alternative to viral vectors. In 
contrast to viruses, they are characterized by low toxicity and immunogenicity, lack of 
pathogenicity, and ease of production 315. However, multiple biologic barriers impair 
the efficiency of systemic gene transfer systems. In order to overcome these barriers, an 
immense variety of different transfer strategies were developed. Non-viral gene delivery 
systems are classified into two distinct groups: 1. physical transfer of uncomplexed 
DNA and 2. carrier-molecule mediated DNA transfer. Both systems have been shown to 
possess in vivo gene transduction potential but differ in biodistribution and transduction 
efficiencies. In the following section, biologic barriers and different non-viral gene 
delivery systems will be reviewed. 
5.2. Biologic barriers 
Gene delivery systems are exposed to biologic barriers on multiple levels starting from 
f d ... I 316-318 h fi b . the moment 0 vector a mmlstratIOn to nuc ear transport . T e 1rst aITlers are 
found in the intravascular and intercellular compartments. Serum nucleases rapidly 
degrade DNA after intravenous administration 319. Large amounts of intravenously 
administered DNA are taken up and degraded by non-parenchymal hepatic cells, 
especially Kupffer cells, resulting in further decrease of input DNA 319. Interaction of 
positively charged non-viral delivery systems with negatively charged blood 
components such as albumin results in charge neutralization and particle size increase. 
This can result in dissociation of carrier molecule and DNA, or particle aggregation 
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with other blood components and secondary size increase; size increases to >5 ~m can 
result in capillary filtration 320, 321. Administered DNA is further reduced through 
unspecific cell interactions and filtration in first pass organs such as lungs and spleen. 
Extravasation is the next barrier and its efficacy depends on the endothelial type; 
discontinuous and fenestrated endothelium allow passage of small DNA complexes, 
while continuous endothelium does not 104. Interstitial transport is another limiting 
factor. Once the vector reaches the target-cell, it needs to bind and be taken up by the 
cell. Dependent on the type of non-viral vector system, cellular binding can be receptor 
mediated, non-receptor mediated through electrophilic interactions, or both. The main 
mechanisms of cell entry of non-viral vectors are clathrin and caveolae-mediated 
endocytosis, and macropinocytosis 322. Following endocytosis, endosomal release is 
vital for the vector as lysosomal enzymes can inactivate and degrade DNA. Endosomal 
release is followed by cytosolic trafficking to the nucleus. This constitutes another 
barrier. The cytoskeleton inhibits diffusion of extended plasmid DNA molecules though 
the cytosol and cytosolic nucleases degrade DNA at a fast rate 323-325. The last major 
barrier in gene delivery is nuclear transport. In dividing cells the nuclear membrane 
breaks down during mitosis allowing nuclear import of DNA. In non-dividing cells, 
nuclear DNA import has been shown to occur through nuclear pore complexes in an 
d · d d 326 327 H '" II .. energy an tIme- epen ent manner ' . owever, In mItotIc as we as non-mItotIc 
cells nuclear import is an inefficient system with cell line-dependent nuclear import of 
1-60% of input DNA 328,329. 
The sum of these barriers results in a significant inefficiency of non-viral gene delivery 
systems. Different non-viral vector systems were developed targeting different 
components of this barrier cascade in order to increase transduction efficiency. The 
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most relevant in vivo non-viral gene delivery systems will be discussed in the following 
sections. 
5.3. Uncomplexed DNA gene delivery 
The most direct way of DNA administration is injection of uncomplexed DNA. This 
system has been used with some success in tissues such as skeletal muscle, liver and 
skin although overall expression levels are suboptimal. Intravenous administration of 
uncomplexed DNA for systemic gene delivery is highly inefficient. Various physical 
methods have been developed in order to improve gene transfer efficiencies. 
5.3.1. Sonoporation 
Sonoporation describes the enhancement of gene transfer by ultrasound. This method 
has been used for gene therapy since the mid 1990's. Biophysically, ultrasound creates 
cavitation - defined as growth, oscillation and/or collapse of microbubbles - radiation 
pressure and acoustic microstreaming causing shear forces. Cavitation resulting in 
microbubble collapse is thought to be one of the main mechanisms of sonoporation. 
Energy released during microbubble collapse permeabilizes adjacent cells and results in 
transient pore formation in the cell membrane 330.332. DNA uptake is enhanced by the 
use of contrast agents containing stabilized microbubbles 333,334. Transfection efficiency 
depends on transducer frequency, acoustic pressure, pulse duration and exposure 
duration. Different tissue types have successfully been transfected in vivo including 
skin, skeletal muscle, kidneys, liver and subcutaneous tumor xenografts 335-340, The 
advantages of sonoporation include bypassing of endosomal cell entry and thereby 
evasion of lysosomal degradation. However, it does not protect against cytosolic 
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nuclease degradation and also the influence of sonoporation on nuclear entry is not well 
understood. For cancer gene therapy its use is limited as it is a localized, non-systemic 
approach. 
5.3.2. Electroporation 
Electroporation as a method for gene transfer was first described in vitro 25 years ago 
341. Since the 1990's, it is also used as a tool for in vivo DNA transfer 342. The principle 
of electroporation is a transient and localized destabilization of the cell membrane 
through generation of a high-intensity electrical field. During destabilization, the cell 
membrane becomes permeable for exogenous molecules such as DNA 343. Exact 
mechanisms of electric field-induced membrane pore generation as well as DNA uptake 
are not completely understood 344. Also, intracellular DNA trafficking and nuclear 
uptake during and following electroporation is relatively unknown 345. In vivo, this 
approach has been used for a variety of different internal and external tissues. The most 
commonly targeted tissues are tumors and muscle. Efficient in vivo gene transfer has 
been described in a variety of different tissue types including cardiac and skeletal 
muscle, lungs and subcutaneous tumor xenografts 346.349. Intratumoral biodistribution 
patterns in tumor xenografts using this method were heterogenous 348. Similar to 
sonoportion, electroporation bypasses endosomal uptake and lysosomal degradation but 
does not protect from cytosolic degradation. Also, it does not provide systemic gene 
transfer. 
5.3.3. Hydrodynamic gene transfer 
Hydrodynamic gene transfer was first described in 1998 by Butker et al. and is based on 
the use of hydrodynamic pressure for enhancement of endothelial and cell permeability 
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350. Butker and his group used a combination-approach of blood vessel occlusion and 
high-volume rapid DNA injection, and achieved transfection of all limb muscles with 
transfection efficiencies of up to 50%. The same group had also shown that portal vein 
injection of plasmid DNA with increased osmotic and hydrostatic pressure causing 
widening of sinusoidal fenestrae results in enhanced DNA extravasation 351. Bascd on 
these observations, Liu et al. and Zhang et al. established the hydrodynamic gene 
delivery method 352,353. This method involves tail vein injection of DNA dissolved in a 
volume equivalent to 8-10% of the animals bodyweight over an injection time of 5-7 
seconds 352,353. The result of this rapid volume overload is a transient cardiac congestion 
leading to a reverse flow in the inferior vena cava and the hepatic veins. This leads to 
disruption of hepatic sinusoids allowing DNA extravasation 354,355. Pericentrally locatcd 
hepatocytes are preferentially transfected during hydrodynamic gene delivery, likely 
due to the close proximity of sinusoidal capillaries and peri-central hepatic parenchymal 
cells 356. On a cellular level, hydrodynamic injection results in transient membrane 
permeabilization with pore formation facilitating cellular DNA entry 355, 357. More 
recently, intracellular vesicle formation has been observed and endosomal uptake 
mechanisms following hydrodynamic gene transfer have been proposed 354, 358. 
Hydrodynamic gene delivery is mainly being used for gene delivery to the liver but it 
has also been used successfully in other tissue such as kidney, myocardium and skeletal 
muscle 359-361. Advantages of this technique include the enhancement of extravasation 
and, dependent on the uptake mechanism, the bypassing of lysosomal degradation. It 
does not protect against cytosolic degradation and does not enhance nuclear import. 
Hydrodyamic gene delivery has been used in larger animals such as pigs and even 
monkeys. In these studies, target organs were selectively catheterized and efferent 
k d b fi fi 361-363 vessels bloc e e ore gene trans er . 
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5.3.4. Particle bombardment 
Particle bombardment - also known as gene gun - was first described in 1987 in plant 
cells and was used in eukaryotic cells since the 1990's 364-366. Its principle is the 
transport of DNA on an accelerated carrier molecule, l,lsually gold particles. These 
DNA-coated particles are deployed by a "gene gun" into the target tissue 343. They 
penetrate the cell membrane and deliver the DNA directly into the cytosol and 
eventually into the nucleus bypassing the endosome/lysosome and thereby avoiding 
lysosomal degradation. Efficiency of this approach depends on particle size, total 
number of DNA-coated particles, degree of particle coating and timing of delivery 367, 
368. Further, transfection efficiency is tissue dependent; e.g. epidermal cell and muscle 
transduction efficiencies have been reported to be 10-20% and 1-5%, respectively 365, 
366,369. In vivo, it is mainly used for gene transfer to skin and liver tissue due to the 
shallow penetration depth of this method 369-371. It has mostly been applied in cytokine 
. d .. th . 371 372 H ..' h' I h expreSSIOn an vaccmatton eraples ' . ow ever, In VIVO It ac leves on y s ort-
term and low-level gene expression. The shallow penetration depth and its localized, 
non-systemic approach are additional limiting factors in its use for cancer gene therapy. 
5.3.5. Other physical methods 
Other physical gene transfer methods include laser irraditiation mediated gene transfer 
and magnetofection. In comparison to other gene delivery methods, these methods are 
not widely used. The use of laser irradiation for gene transfer dates back to the 1980's 
373,374. Its principle is based on the thermal force of a laser beam causing penetration of 
the cell membrane. Membrane pores can be up to 2 !-lm in diameter and are only 
transient 373,375. More recently, use of this technique has also been described in vivo in 
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accessible tissues such as skin and muscle 376,377, Magnetofection uses a magnetic field 
for transfer of DNA complexed to iron oxide particles, This method has successfully 
been applied in vitro and in vivo. Gene delivery using magnetofection was shown in a 
variety of different tissues such as endothelium, gastrointestinal and respiratory tissue 
378-380. However, similar to the other physical gene transfer methods, these methods 
achieve gene transfer only in a localized field. They do not provide systemic treatment 
and are therefore of only limited use in cancer gene therapy. 
5.4. Synthetic gene delivery systems 
Another alternative approach for non-viral gene transfer is the use of synthetic gene 
delivery systems. These systems use chemical carriers for nucleic acid transfer. Carrier 
molecules fulfill several functions including protection of DNA from serum nucleases 
and other blood components, enhancement of cell binding, cell type-specific targeting, 
enhancement of endosomal escape and thereby protection from lysosomal degradation. 
Cationic lipids and polymer-based systems are the most commonly used chemical 
carriers for that purpose_ In the following sections principles of these delivery systems 
will be discussed. 
5.4.1. Lipoplex 
Lipoplex DNA transfer systems are based on liposomes, which are defined as vesicular, 
colloidal particles composed of self-assembled amphiphilic molecules. Currently, the 
majority of liposomal systems use cationic lipids. Cationic lipids are amphiphilic 
molecules consisting of a positively charged polar head group linked to a hydrophobic 
domain of alkyl chains_ They associate with negatively charged DNA via electrostatic 
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interaction resulting in positively charged lipoplexes. The charge of the cationic lipid 
depends on its amine groups. The ratio of lipid amine groups to DNA phosphate groups 
- known as the NIP-ratio - defines the lipopJex net charge and thereby its 
physicochemical and transfection properties. The use of cationic lipids for gene transfer 
was first described in vitro by Feigner et at. two decades ago 38\. Since then, a great 
variety of different liposomal formulations have been described mostly differing in the 
type of cationic lipid; these different types are similar in regard to their hydrophobic 
region but vary in regard to polar linker and cationic head groups 317. For liposome 
synthesis, lipid solutions are being hydrated in aqueous solution. Neutral helper lipids 
such as dioleoyl-L-a-phosphatidylethanolamine (DOPE) or cholesterol are added to 
these formulations for endosomal escape as discussed below 382. While single-chain 
amphiphilic molecules form micelles in aqueous solution, double-chain amphiphiles 
form lipid bilayers. Hydration concomitant with agitation results in formation of large 
multi lamellar vesicle (LMV). During lipoplex formation, lipid restructuring occurs. 
Smaller vesicles are preferred due to their higher amenability to transformation. Size 
reduction of LMVs can be achieved through different methods, e.g. sonication, 
extrusion or homogenization. Resulting particles are small unilamellar vesicles (SUV) 
or large unilamellar vesicles (LUV) (Fig. 6). Combination of liposomes with DNA 
results in generation of lipoplexes 317. Characteristics of the resulting lipoplex are 
influenced by thermodynamic and kinetic factors, charge ratios, lipid concentration, 
ionic strength, pH and temperature. Cationic lipid-to-DNA charge ratio determines 
lipoplex size as well as the ability of the lipoplex complex to protect DNA from 
nuclease degradation. 
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suv 
Figure 6 Liposome preparation. Shown is the generation of liposomes. Lipids are mixed in an 
organic solvent, dried and hydrated . Hydration and agitation results in formation of large , 
multilamellar vesicles (LMV). Through different methods such as sonication, extrusion or 
homogenization , small unilamellar vesiles can be generated for lipoplex synthesis (image 
obtained from http://www.avantilipids.com). 
Cell membrane binding of Jipoplex vectors is mediated through unspecific ionic 
interactions between the positively charged complex and negatively charged 
b 328 383 384 H . proteoglycans of the cell mem rane ' , . ence, overall net charge mfluences the 
transfection efficiency. Following cell binding, lipoplexes enter the cell via endocytosis 
328, 385. Endosomal escape is a key step in gene transfer as failure of this step results in 
lysosomal degradation. Fusogenic helper lipids, such as DOPE or cholesterol, . are 
thought to facilitate this escape. DOPE forms stable lipid layers at pH of - 7 but 
transitions to an inverted hexagonal form at pH 5 to 6. This transition results in fusion 
and destabilization of the endosomal membrane re ulting in release of the lipoplex 382 . 
The mechanism of DNA-dissociation from the liposome is not well understood but 
thought to occur either during or after endosomal escape 386, 3 7. Nuclear entry is not 
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well understood in lipoplex gene transfer but thought to follow DNA release over 
nuclear pores or passively during mitosis 387. Lipoplexes have been tested for safety and 
efficiency in a multitude of preclinical studies by various routes of administration 
including intratumoral, intrapulmonary, intracerebral, intraperitoneal and intravenous 
administration 388. Lipoplex are advantageous in their simplicity of preparation, their 
ability to complex large amounts of DNA, and their versatility for use with any size or 
type of DNA/RNA. A great variety of different liposomal formulations has been 
described and reported to have efficient in vivo transfection potential in tumor 
xenografts 389. One of their main advantages is their relative non-immunogenicity 
compared to viral vectors allowing repetitive treatment. Their efficiency is limited due 
to relatively low transgene expression levels after systemic application. 
5.4.2. Polyplex 
polyplexes describe complexes of polymers and DNA. They are similar to lipoplexes as 
their assembly is based on the association of negatively charged DNA to positively 
charged polymers through electrostatic interactions. In contrast to cationic liposomes, 
cationic polymers condense DNA more efficiently, and as they do not contain 
hydrophobic moieties, they are water-soluble. Polymers can be modified in regard of 
their length and their geometry, e.g. linear or branched. Linear polymers differ from 
branched polymers in DNA compaction, nuclear uptake, transfection efficiency and 
toxicity. The positive charge of cationic polymers facilitates binding to extracellular 
proteoglycans, e.g. heparinlheparan sulfate proteoglycans 390. As for liposomes, the 
NIP-ratio is critical for transfection efficiency. At high NIP ratios, the positive net 
charge of polyplexes increases resulting in improved cell interaction as well as 
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enhanced cellular and nuclear uptake, and retention 391. An NIP ratio of > 1 results in 
optimal efficiency, while a ratio of <1 yields only low level efficiency 384. 
Examples of frequently used polymers include include poly(L-lysine) and 
poly(ethylenimine). Poly(L-lysine) (PLL)-based polypI exes were shown to bind to 
DNA and protect it from nuclease digestion 392. However, their use was limited due to 
complex aggregation and precipitation, rapid systemic clearance due to non-specific 
interaction with serum proteins, their high cytotoxicity and low transfection efficiency. 
Modifications such as the use of high molecular weight PLL, conjugation with 
polyethylene glycol (PEG), synthesis of PLL-based polyion complex micelles (PIC) and 
conjugation of targeting molecules resulted in improvement of transfection efficiencies; 
however, other polycations such as poly( ethylenimine) (PEl) were found to achieve 
higher transfection rates 393. PEl is a polyamine molecule synthesized from 
ethylenemine (aziridine) or oxazoline monomers. Polymerization of these monomers 
results in the formation of a branched or linear backbone of repeating 43 Da CH2-CH2-
NH ethyleneimine motifs. Particle size depends on molecular weight of the branched 
PEl derivative, method of particle formation, and NIP ratio. The polyplex size decreases 
with increasing molecular weight, excess of polyamine and low ionic strength media. 
Polymer size is correlated with transfection efficiency. PEl of molecular weight 
between 10 and 22 kDa achieve the highest transfection efficiencies; below 10 kDa 
transfection efficiency decreases and above 22 kDa toxicity increases 394. 395. Cell 
binding of PEIIDNA complexes is facilitated through the polyanionic heparan sulfate 
moieties of syndecans, ubiquitous transmembrane adhesion molecules. Cell uptake of 
PEIIDNA complexes is mediated by phagocytosis, followed by endosomal trafficking 
396. Endosomal escape of PEl-based polyplexes is facilitated by their buffering capacity 
within the normal pH range, a process known as the "proton sponge" hypothesis 383. 
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Protonation of ionizable amine groups causes intraendosomal chloride ion accumulation 
resulting in osmotic swelling and endosome rupture allowing endosomal escape of the 
PEI/DNA complex into the cytosol. Within the cytosol, complexion of DNA to PEl 
allows the cytosolic transport and protects DNA from degradation 396. DNA dissociates 
from the polyplex-complex spontaneously. Kinetics and location are thought to be 
polymer dependent and have been observed cytosolic as well as intranuclear 397. 
Polypi ex gene delivery systems are commonly used for in vitro gene transfer and have 
also been evaluated in vivo as gene delivery vector systems 398-404. Their high DNA-
compaction ability, their intrinsic endosomolytic activity and their ability for efficient in 
vivo gene transfer, make them a highly promising non-viral gene delivery system. 
5.4.3. Other synthetic gene delivery systems 
The field of synthetic non-viral gene delivery systems is rapidly evolving. In order to 
enhance transfection efficiencies, different cationic or anionic lipids are being explored, 
changes in liposomal or polycationic formulations are evaluated for their effect on 
physicochemical properties, and existing liposomes and polypI exes are being modified. 
In general, the purpose of these modifications is to overcome the above-discussed 
biologic barriers. Poly( ethylene glycol) and targeting ligands are conjugated to non-
viral vectors in order to prolong circulation times and decrease unspecific binding 405, 
406. Incorporation of nuclear localization signals aims at enhancement of nuclear 
ffi ' . 407,408 Th f d·f'l'. fu . I"d d I . . transport e IClencles . e use 0 I lerent sogemc Ipl s an po ycatIons alms 
at improvement of endosomal release. A variety of new molecules have been 
established as synthetic gene transfer systems such as protamine, chitosan and 
dendrimers 409, 410. Recently, biodegradable polymers, virosomes and lipopolyplexes 
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have been added to the armory of non-viral gene transfer systems 411-413. These new 
innovative approaches have resulting in improved transfection efficiencies. However, 
the remaining biologic barriers continue to impair the feasibility of these approaches for 
efficient clinical tools in oncology. 
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6. Specific aims of the thesis 
6.1. Background 
Hepatocellular carcinoma is a devastating malignancy. Its high global prevalence and its 
increasing incidence in Western countries make this neoplasm a highly significant 
disease. Its devastating prognosis and the lack of effective non-surgical treatments 
warrant the development of new therapeutic approaches to this malignancy. 
In contrast to other oncologic approaches such as chemo- and radiation therapy, genetic 
approaches are a highly specific. A variety of different viral and non-viral gene delivery 
systems have been developed and tested in HCC. The majority of these studies used 
viral vector systems such as adenovirus, herpes simplex virus type 1 (HSV -1) and 
. .. . (VSV) 414-416 D'f~ h . h vesIcular stomatItIS VIruS . 1 lerent cancer gene t erapy strategIes ave 
been studied in HCC including tumor-suppressor gene p53 transfer, suicide gene 
transduction, antiangiogenic strategies, immunogene therapy as well as oncolytic viral 
therapy 417-422. Very few of these vectors were tested clinically, and although biologic 
responses were observed, their overall efficacy was low 423-426. Failure of efficacy was 
attributed to insufficient tumor transduction and antibody formation efficiently 
. . d . d d . 423 427 428 AI' fi neutrahzmg vectors unng repeate osmg , . . ternattve gene trans er systems 
are urgently needed. The overall goal of this thesis is the development and evaluation of 
alternative viral and non-viral gene delivery systems for this devastating disease. 
6.2. SpecifiC aim 1 
Specific aim 1 of this thesis is the establishment, evaluation and comparison of different 
non-viral gene delivery systems in vivo. The rationale of non-viral gene delivery is the 
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low immunogenicity and toxicity of these vectors allowing repetitive dosing regimens. 
A variety of non-viral gene delivery systems are described in the current literature. 
However, the majority of these non-viral gene delivery systems suffer from their low 
transduction efficiency. Identification of the most promising non-viral gene delivery 
system is the overall goal of the first part of this thesis. Feasibility and transduction 
efficencies will be used as criteria for identification of the most promising approaches. 
These systems will be established according to published methodologies and evaluated 
in vivo using subcutaneous murine tumor xenograft models. 
6.3. Specific aim 2 
Specific aim 2 of this thesis is the development and evaluation of non-viral, expanded 
parvoviral genome-based rep Ii con vectors. Parvovirus MVM is human apathogenic, 
tumor selective, oncolytic and provides high-level transgene expression. Their efficacy 
is limited by their immunogenicity and genomic size restrictions. Genomic size 
limitation to 106% of the wild type size are due to significant decrease in virion 
packaging efficiency. The rationale of the second aim of this thesis is the avoidance of 
parvoviral limitations through their use as replicating plamid expression vectors while 
oncotherapeutically advantageous charateristics will be maintained. Tolerance to 
genomic expansion would allow enhancement of parvoviral cytotoxcity through the use 
of therapeutic transgenes. Efficient replication and high-level transgene expression 
could potentially compensate for low transduction efficiencies of non-viral gene 
delivery systems. Expanded MVM-based replicon vectors will be generated and 
evaluated for their replication and transgene expression. Maintenance of tumor 
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selectivity and cytotoxicity will be analyzed and comparison to other expressIOn 
systems performed. 
6.4. Specific aim 3 
Specific aim 3 of this thesis is the evaluation of recombinant MV-Edm as an oncolytic 
viral vector for HCC. The rational for the choice of this viral agent is its previously 
shown therapeutic potential in different models of human malignancies (Table 7). These 
preclinical studies have resulted in clinical phase I studies for ovarian cancer, multiple 
myeloma, and glioblastoma multiforme. Its potential as a virotherapeutic agent for HCC 
has never been evaluated. Infectivity and cytotoxicity of recombinant MV-Edm will be 
evaluated in vitro using human HCC cell lines. Mechanisms of cell death and 
expression of transgenes will be evaluated. In vivo oncolytic effects and tumor 
suppression will be analyzed. 
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II. Material & Methods 
1. Cell biological methods 
1.1. Cell lines 
HVH-7 and Hep-3B cells were a kind gift of Dr. G. J. Gores. Transformed cell lines 
Wi38V13 and Mcl-5Vl were a kind gift of Prof. Rommelaere (DKFZ, Heidelberg). All 
other cell lines were obtained through the American Type Culture Collection (ATCC, 
Manassas, VA) and CellzDirect (Durham, NC). Growth media, serum and supplements 
were purchased from Gibco BRL (Grand Island, NY). All cells used in this study were 
cultured at a humidified atmosphere of 5% CO2 and 370 C. Cell culture medium was 
supplemented with 10% heat-inactivated FBS, and 1 % Sodium-Pyruvat. All media used 
in this study contained 100 Vlml penicillin-streptomycin. 
1.2. Long-term storage of cells 
Cells can be frozen and stored in liquid nitrogen for several months without impairment 
of their viability. Cells can either be stored directly in the liquid phase of nitrogen at -
1960 C or above within the gas phase between -150° C and -160° C. The following 
points are important for optimal results: prolonged freezing process, fast thawing, a high 
protein concentration and addition of 5-10% DMSO to the freezing medium. These 
measurements will increase membrane permeability, prevent partial dehydration of 
cyoplasma and prevent intra- as well as extracellular crystal formation. 
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Cell line Type Culture medium Origin 
Hep-38 Human HCC MEM Dr. G.J . Gores 
HUH-7 Human HCC OM EM Dr. G.J. Gores 
Hepatocytes Primary human hepatocytes Williams medium E CellzDirect 
293-T SV40-transformed human kidney cells DMEM ATCC 
A9 Mouse fibroblast DMEM ATCC 
McI-5 Human lung fibroblast MEM ATCC 
McI-5N1 SV40 transformed McI-5 MEM Dr. Rommelaere 
NIH-3T3 Rat fibroblast DMEM ATCC 
V12-3T3 SV40 transformed NIH-3T3 DMEM ATCC 
Wi38 Human lung fibroblast DMEM ATCC 
Wi38N13 SV40 -transformed human lug fibroblast DMEM Dr. Rommelaere 
N2A Mouse neuroblastoma DMEM ATCC 
Vero African green monkey kidney DMEM ATCC 
Table 8: Cell lines used in for experiments. 
For recovery of frozen cells, cryo-tubes containing aliquots of the cell suspension were 
thawed in a 37° C water bath. For prevention of an osmotic shock, prewarmed medium 
was added to the cell suspension. Cell culture medium was exchanged 24h after cell 
adhesion. 
1.3. Passaging of established cell lines 
After removal of medium, cells were washed with Ix PBS, 2 ml of 2% TrypsiniEDTA 
added and cells incubated for 2 min at 37° C. TrypsiniEDTA was removed and the cells 
dissolved in 10 ml of the corresponding medium for inactivation of remaining trypsin. 
Cell clumps were dissociated through several cycles of pipetting. Cells were diluted to 
the density required for the corresponding experiment. 
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1.4. Assessment of cell numbers 
After detachment of adherent cells with trypsin, 20 J..lI of the cellsuspension were mixed 
with 0.4% Trypan-blue solution (w/v) at a ratio of 1: 1. Trypan-blue is an acidic dye, 
which binds easily to proteins due to its anionic characteristics. The dye is only taken up 
by non-viable cells, thereby facilitating the distinction between viable and non-viable 
cells. Counting of the cell number was performed using a Neubauer chamber. Number 
of viable cells in 1 ml of the cell suspension, equals the product of stastical mean value 
of the 4 main quadrants, the chamber factor (104 cells/ ml) and the dilution. Total 
number of cells is being calculated as the product of cell concentation (cells per mt) and 
the total volume of the cell suspension. 
1.5. Cell staining 
1.5.1. Fixation of cells 
Before staining, cells required fixation. Medium was removed, cells washed once with 
Ix PBS. Acetic-ethanol mixture, pre-chilled to 4° C, was added to the cells and cells 
incubated at 4° C for 20 min. Cells were washed carefully with Ix PBS and once with 
H20 , followed by removal of excess fluid and staining. 
1.5.2. Crystal violet stain 
Crystal violet is a methyl aniline dye with a high degree of blue. It has the ability to 
bind DNA and can be used for cell viability assays. After fixation, cells were incubated 
with 0.13% crystal violet solubilized in ethanol-formaldehyde (2: 1). The stained 
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product was subsequently washed twice with H20 and air-dried. Cell viability was 
evaluated optically and documented by digital photography 
1.5.3. DAPI-stain 
4,6-Diamidino-2-phenylidone (DAPI)-stain is used for nuclear staining of chromatin 
allowing morphologic analysis of chromosomal changes. This method can be used for 
identification of cells underoing apoptosis. After fixation of cells, cells were incubated 
with DAPI-dye for 5 min at RT under the exclusion of light. DAPI-dye was removed, 
cells washed twice with Ix PBS and excess fluid removed. Analysis was performed 
using fluorescence-microscopy. 
1.5.4. Tunel-stain 
Apoptotic data were confirmed by a TdT-mediated dUTP nick-end labeling (TUNEL) 
assay using TUNEL Label Mix (Roche Diagnostics). The assay is based upon nuclear 
DNA cleavage into oligonucleosome-sized fragments during apoptosis. In the TUNEL-
assay, DNA-strand breaks are being labeled with fluorescein-dUTP and analyzed by 
fluorescence microscopy. TUNEL-assay was performed according to manufacturers 
recommendations. After fixation, cells were permeabilized in freshly prepared 0.1 % 
sodium citrate containing 0.1 % X-IOO Triton for 2 min at 4° C. Cells were washed 
twice followed by addition of 50 III TUNEL-reaction mixture containing the TUNEL-
enzyme and labeling solution. Cells were incubated for 60 min at 37° C. After washing 
the cells for three times in PBS, they were analyzed using fluorescence microscopy at 
an excitation wavelength of 450-500 nrn and detection range of 515-565 nm. 
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1.5.5. Immunohistochemistry 
Paraffin-embedded liver sections of HCC- and healthy patients were incubated with 
mouse anti-human CD46 primary antibody (SO Siosciences, Pharmingcn) for 30 min at 
37°C, then incubated with fluorescein isothiocyanate-conjugated anti-mouse IgG 
secondary antibody (l :300 dilution) (Santa Cruz Biotechnology, Santa Cruz, CA) for 30 
min at room temperature. Cells were washed in phosphate-buffered saline three times 
each for 3 min. Immunofluorescence microscopic analysis was performed with a Zeiss 
LSM 510 using a 100x Pan-Apochromat 1.4-nm oil objective (Carl Zeiss Inc., 
Thornwood, NY). 
1.6. Cytotoxicity assays 
Cytotoxicity was evaluated quantitatively as well as morphologically using different 
modes of detection. Viability of cells was evaluated using crystal violet staining. For 
quantitative confirmation, viability of cells was analyzed using the CellTiter 96 
AQueous nonradioactive cell proliferation assay kit (Promega Corp., Madison, Wis.). 
For mechanistic cell death analysis -apoptosis versus necrosis- cells were analyzed 
morphologically using fluorescence microscopy after DAPI- (1.5.3.) or TUNEL-
staining. Apoptosis was confirmed by quantitation of caspase 317 activities using the 
Apo-ONE® Homogenous Caspase-317 Assay (Promega Corp., Madison, Wis.). 
1.6.1. CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay 
The CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay is a colorimetric 
method for determining the number of viable cells in proliferation or chemosensitivity 
assays. The assay is composed of tetrazolium compound. 3-( 4,5-dimethylthiazol-2-yl)-5-
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(3-carboxymethoxyphenyl)-2-( 4-sulfophenyl)-2H-tetrazolium (MTS) and an electron 
coupling reagent (PMS). MTS is reduced to aqueous, soluble formazan by cellular 
dehydrogenase in metabolically active, viable cells. The amount of formazan product 
can be quantitated by fluorometric analysis with the absorbance at 490nm being directly 
proportional to the number of viable cells. The CellTiter 96 AQueous nonradioactive 
cell proliferation assay kit was performed according to manufacturers 
recommendations. Briefly, cells were cultured and treated in 96-well tissue culture 
plates. At the designated time points, cells were incubated with 20 ilL of MTS reagent 
solution for 2 h at 37° C. Absorbance at 490 nm was recorded using an ELISA plate 
reader. 
1.6.2. Caspase 3/7 assay 
Apo-ONE® Homogenous Caspase-317 Assay (Promega Corp., Madison, Wis.) contains 
pro fluorescent, rhodamine 11O-labeled caspase-3/7 substrate bis-(N-CBZ-L-aspartyl-L-
glutamyl-L-valyl-L-aspartic acid amide) (Z-DEVD-RI10). Activated caspase-3/7 
cleaves non-fluoroescent Z-DEVD-RII0 resulting in release of fluorescent rhodamine-
110. Fluorescence is positively correlated to caspase-3/7 activity and can be quantitated 
by spectrofluorometric analysis at an excitation wavelength of 499 nm with an emission 
maximum at 521 nm. The assay was performed according to manufacturers 
recommendations. Briefly, cells were cultured and treated in black 96-multiwell cell 
culture plates. At the experimental time points, the Apo-ONE reaction buffer was added 
to the sample at a 1:1 ratio, followed by incubation for 1-18h at RT. Caspase-317 
activity in the sample was quantitated by spectrofluorometry and statistically analyzed. 
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1. 7. Flow cytometry 
Cells were harvested, washed twice in cold 2% BSA-PBS, and incubated with a FITC-
labeled monoclonal mouse anti-human CD46 antibody (PharMingen, San Diego, USA) 
for 1h on ice. Following, the cells were washed twice and run on a Becton-Dickinson 
F ACScan Plus cytometer and analyzed using the Cell Quest software (Becton-
Dickinson, San Jose, USA). 
1.8. In vitro 1231 uptake studies 
Cells were infected with MV-NIS at MOl 0.01, 0.1 and 1.0 for 2 h in Opti-MEM. 
Virus-suspension was removed and growth medium added to the cells. In vitro iodine 
uptake studies were performed 24h, 48h and 72h after infection as previously described 
429. Briefly, cells were washed twice in Hanks balanced salt solution (HBSS) and 
resuspended in HBSS with 10 mM HEPES (N-2-hydroxyethylpiperazine-N'-
ethanesulfonic acid, pH 7.3). Potassium perchlorate was added to half of the samples to 
a final concentration of 1 J1M. 1 x 105 cpm 1251 were added to each sample. After 50 min 
incubation at 37° C, cells were washed twice with cold HBSS and lysed by addition of 
1M NaOH. Activity in the cel1lysates was determined using a gamma counter. 
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2. Molecular biological methods 
2.1. Nucleic acid transduction 
2.1.1. Bacterial cells 
For amplification of plasmid DNA, the chemically competent, recombinase deficient 
(ree A) E. coli strain SURE® 2 supercompetent cells (Stratagene, CA) were used. For 
transformation of DNA into the bacterial cells, competent bacteria were rapidly thawed 
at RT and 10-100 ng plasmid DNA or 1-5 \-ll ofligation mix added. Sample was gently 
mixed and incubated on ice for 30 min, followed by 30 sec incubation at 42° C. 250 \-ll 
prewarmed S.O.C. medium were added to transformed bacteria and the suspension 
incubated at 37° C on a shaker at 225 rpm for 1 h. 100 \-ll of the bacterial suspension was 
transferred to a prewarmed antibiotic containing LB-agar plates (antibiotic 
corresponding to resistance gene encoded by transformed plasmid). Plates were 
incubated overnight at 37° C, resulting bacterial clones were collected (I-lO/plate) and 
further amplified by overnight incubation at 37° C on a rotary shaker in 3 ml antibiotic-
containing LB-medium. Following incubation, DNA was isolated and analyzed as 
described below. 
2.1.2. Eukaryotic cells 
For transfection of plasmid DNA in eukaryotic cell lines, Lipofectamine ™ 2000 
(Invitrogen, CA) was used according to the manufacturers recommendations. 
Lipofectamine™2000 is a cationic lipid formulation. Briefly, cells were plated the day 
prior to transfection so that cell density at day of transfection was 60-75%. Plasmid 
DNA as well as Lipofectamine™2000 reagent were diluted in Opti-MEM (Invitrogen, 
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CA), incubated for 5 mm at RT and then combined and mixed; optimal DNA: 
Lipofectamine™2000 ratio was predetermined by preliminary experiments for 
optimization of transfection efficiency. For cotransfection experiments with two 
plasmids, equal copy numbers of each plasmid were used; however, total amount of 
DNA was sustained in order to preserve the DNA-to-lipid ratio. The DNA-lipid 
suspension was added to medium and cells were incubated for 4h at 37° C in a C02 
incubator. After 4h of incubation, transfection medium was exchanged with regular cell 
culture medium. 
2.2. Isolation and purification of nucleic acids 
2.2.1. Bacterial cells 
For isolation and purification of nucleic acids "Plasmid Mini Prep", "Endofree Plasmid 
Maxi Prep" and "Endofree Plasmid Giga Prep"-Kits (QIAGEN, CA) were used 
according to manufacturers recommendations. Briefly, after transformation, transduced 
bacteria were amplified in antibiotic containing LB-medium (volume: 3 ml for mini-
culture, 500 ml for Maxi-prep, 5 L for Giga-prep); antibiotic was chosen according to 
antibiotic resistance gene encoded on the plasmid DNA. The bacterial culture was 
incubated at 37° C on a rotational shaker until reaching the log-phase, mostly 14-18 h. 
850 Jll of the bacterial culture were removed and mixed with 150 Jll of autoc1aved 
glycerol. Sample was stored at - 80° C for long-term storage. The rest of the bacterial 
culture was centrifuged using a Sorvall GSA-rotor with 5000 RPM for 10 min at 4° C. 
Supernatant was discarded and the bacterial sediment was resuspended in buffer PI. 
Lysis-buffer P2 was added and the culture incubated for 5 min at RT. Neutralization 
buffer P3 was added, the culture mixed by invertion and incubated for 20 min on ice. 
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The lysed bacterial culture was centrifuged at 16,500 RPM at 4° C, followed by 
filtration of the clear supernatant using a QBT-equilibrated anion exchange column. The 
columns were washed twice with QC-buffer, followed by elution of the plasmid DNA 
with QF-buffer. Plasmid DNA was precipitated using 0.7 volume parts isopropanolol 
followed by centrifugation with 10,000 RPM for 10 min at 4° C. DNA was washed with 
70% ethanol and dried at room air. DNA was resuspended in an appropriate volume of 
TE-buffer and DNA concentration determined by photometric analysis. 
2.2.2. Eukaryotic cells 
Isolation of low molecular weight DNA from eukaryotie cells was performed as 
described by Hirt 430. Cells were washed with Ix PBS, lysed in Hirt-Iysis buffer (10 mM 
Tris/HCI pH 7.4, 10 mM EDTA pH 8.0, 0.6% SDS) and transferred to a 1.8 ml 
Eppendorf tube. 250 ~g/mi Proteinase K was added to the lysed cells and samples 
incubated for Ih at 37° C. NaCI concentration was adjusted to 1.25 M, samples 
incubated for 12h at 4° C followed by centrifugation for 30 min at 12,000 RPM at 4° C. 
Supernatant was transferred to a new tube and low molecular weight DNA extracted by 
phenoVchoroform extraction followed by isopropanol precipitation. DNA was washed 
with 70% ethanol and resuspended in TE-buffer. DNA concentration was determined by 
photometric analysis. 
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2.3. Nucleic acid analysis 
2.3.1. Concentration and purity of nucleic acids 
AbsolJllion. The DNA concentration in solutions was measured using UV-
spectrophotometry. Nucleic acids have an absorption maximum for UV-light at a 
wavelength of 260 nm. The absorption maximum of proteins is at a wavelength of 280 
nm. The concentration of a nucleic acids can be estimated by measuring the absorbance 
at 260nm (A260), adjusting the A260 measurement for turbidity (measured by absorbance 
at 320nm), multiplying by the dilution factor, and using the relationship that an A260 of 
1.0 = 50llg/ml pure DNA (Concentration (Ilg/ml) = (A260 reading - A320 reading) x 
dilution factor x 50Ilg/ml). DNA purity can be estimated from the A2601 A280 ratio after 
correction for turbidity (DNA Purity (A2601 A2S0) = (A260 reading - A320 reading) -:- (A2S0 
reading - A320 reading)). An A260/A280 ratio between 1.7 and 2.0 generally represents a 
high-quality DNA sample. Lower ratios indicate the presence of proteins in the solution, 
higher ratios the presence of RNA. 
PicoGreen assay. For measurement of DN A concentrations between 25 and 1000 pg/ml 
fluorescent PicoGreen® reagent (Molecular Probes, OR) was used. PicoGreen® reagent 
is not specific for dsDNA, but it shows a > 1000-fold fluorescence enhancement upon 
binding to dsDNA, and much less fluorescence enhancement upon binding to single-
stranded DNA (ssONA) or RNA, making it possible to quantitate dsONA in the 
presence of equimolar amounts of ssDNA, RNA or proteins. The assay was performed 
according to the manufacturers recommendations. Briefly, PicoGreen® reagent was 
added to samples and DNA standard curve dilutions, mixed and incubated for 5 min at 
RT. Fluorescence was measured using a spectrofluorometer at an excitation wavelength 
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of 480 nm and an emission wavelength of 520 nm. Based upon measured fluorescence 
of the standard curve DNA, concentration of DNA in the samples was calculated. 
2.3.2. Nucleic acid sequence analysis 
Nucleic acid sequencing analysis was required for confirmation of complete parvoviral 
DNA sequence -especially in the palindromic 5'- and 3'- termini. Parvoviral clones 
were sequenced by the Molecular Core Facility at Mayo on an ABI 377 sequencer and 
analyzed for sequence alterations. 
2.3.3. Agarose gel electrophoresis 
For analysis of DNA or isolation of DNA fragments for further cloning, DNA was 
separated using agarose gel electrophoresis. Agarose was dissolved in T AE or TBS 
buffer by boiling the solution in a microwave oven. Agarose concentration was chosen 
in dependence of DNA fragment size (100-500 bp: 2% agarose, 500-10,000 bp: 1 % 
agarose). After agarose was completely dissolved, ethidiumbromide was added to a 
final concentration of 1 Ilg/ml and solution transferred to a gel electrophoresis 
apparatus. DNA was separated at an electrical current of 8 V fern. DNA fragments 
migrate through the agarose gel negatively proportional to their size and were visualized 
after intercalation with ethidium bromide under UV-light (wavelength 312 nm). 
2.3.4. Southern blot 
Southern blot technique was used for transfer of DNA to nylon membranes. Briefly, 
after separation of DNA by agarose gel electrophoresis, DNA was denatured by 
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incubation of the gel in denaturation solution (1.5 M NaCl/0.5 M NaOH) for 30 min 
followed by 30 min incubation in neutralization solution (1.5 M NaCl/0.5 M Tris'ct, pH 
7.0). If DNA fragments were >15 kb, gel was prior to denaturation, depurinated by 30 
min incubation in 0.25 M HCl. For capillary transfer of DNA, gel was transferred to a 
Southern blot apparatus and placed on a bridge consisting of Whatman 3MM filter 
paper sheets continuously in contact with 20x SSC buffer (3 M NaCI, 0.3 M tri-sodium 
citrate). A nylon membrane (Hybond-N+, Amersham) was placed on the gel, followed 
by three layers of Whatman 3 mm blotting paper and a stack of paper towels allowing 
buffer transfer by capillary action from a region of high water potential to a region of 
low water potential. The blot was performed overnight, followed by permanent fixation 
of DNA to the nylon membrane through UV-crosslinking (UV transilluminator, 254-nm 
wavelength). 
2.3.5. Hybridisation 
For DNA-DNA hybridization, the non-radioactive DIG labeling and detection method 
was used according to the manufacturers recommendations. Briefly, using the PCR DIG 
Probe Synthesis kit (Roche Applied Science, IN) a Digoxigenin (DIG)-labeled 
hybridization probe was synthesized by PCR; the probe was designed to bind to a 390 
bp area in the parvoviral NS I-coding region. Labeling efficiency was analyzed by 
agarose-gel electrophoresis. The Southern blot nylon membrane was incubated for 30 
min in prewarmed prehybridisation buffer (DIG Easy Hyb, Roche Applied Science, IN). 
Optimal hybridisation temperature was calculated according to the formula THyb = T m-
(20°C to 25° C) with Tm = 49.82+0.41 (% G+C)-600/Iength of hybrid in bp. 
Meanwhile, 2 ~l of the PCR DIG-labeled DNA hybridization probe was diluted in 50 ~l 
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H20 , boiled for 5 min at 95° e for denaturation and chilled on ice. The hybridization 
probe was diluted in prewarmed hybridization buffer (DIG Easy Hyb, Roche Applied 
Science, IN) and the solution was added to the membrane after discarding the 
prehybridization buffer. Hybridisation was performed overnight at the appropriate 
hybridization temperature in a designated rotating hybridization oven. Following the 
hybridization, the membrane was washed twice for 5 min each in low stringency buffer 
(2x sse, 0.1% SDS) at RT, followed by washing of the membrane twice for 15 min 
each in high stringency buffer (0.5% sse, 0.1 % SDS) at 65° e. For chemoluminescent 
detection of the probe bound to the membrane, ready-to-use eSPD assay (Roche 
Applied Science, IN) was used according to the manufacturers recommendations. 
Membrane was washed for 2 min at RT in detection washing buffer (0.1 M Maleic acid, 
0.15 M NaCl pH 7.5, 0.3% Tween 20), followed by incubation for 0.5 to 3h in blocking 
buffer. The washing buffer was replaced with antibody solution containing anti-
Digoxigenin antibody at a 1:10,000 dilution and incubated for 30 min at RT. Then, the 
membrane was washed twice for 15 min each with washing buffer and incubated for 3 
min in detection buffer (0.1 M Tris-HC1, 0.1 M NaCl pH 9.5). After removal of the 
detection buffer, 1 mlll00 cm2 ready-to-use CSPD was added onto the membrane, the 
membrane incubated at 37° C for 10 min followed visualization by exposure to a X-ray 
film. 
2.4. Nucleic acids cloning 
Plasmid DNA can be modified through cloning strategies aiming at introduction or 
deletion of nucleic acid sequences. The following techniques were used for cloning 
strategies in the studies described in this thesis. 
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2.4.1. Restriction hydrolysis 
Restriction endonucleases are bacterial enzymes that cut double-stranded DNA 
molecules at specific recognition sites. There are three types of restriction 
endonucleases; Type II cuts at the recognition site and is therefore the most important 
for molecular biologic techniques. All enzymes were obtained from New England 
Biolabs (NEB, MA) and used according to the manufacturers recommendations. For 
analytical restriction hydrolysis of plasmid DNA, 0.5 to 2 ~g were used, for preparative 
restriction hydrolysis an amount was chosen which would result in approximately 1 ~g 
of the desired product. Reaction volume was for most reactions 20 ~1 and the reaction 
time at least 1 h. Restriction enzymes were given at a concentration of at least 2 
Units/~g DNA but did not exceed 10% (v/v) of the reaction volume. 
2.4.2. Polymerase chain reaction 
For generation of modified nucleic acid sequences, polymerase chain reaction (PCR) 
was used. Briefly, primers were designed according to desired application (e.g. ligation, 
DNA sequencing) and template DNA. Primers were synthesized by the Mayo Clinic 
DNA synthesis core facility. 10-100 ng template DNA was combined with primers, 
dNTP, 5x reaction buffer and Pfu polymerase or Platinum®Pfx polymerase. The reaction 
mix was filled up to 20 microliter with H20. For DNA amplification, primer-annealing 
temperature was calculated based upon primer G/C and NT content, duration of primer 
extension based upon length of PCR-product (1 minlkb) and cycle number dependent 
PCR efficiency and application between 25 and 30 cycles. 
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2.4.3. Reverse-transcriptase polymerase chain reaction 
Reverse-transcriptase polymerase chain reaction (RT-PCR) is a two-step process during 
which RNA is reverse-transcribed to eDNA, followed by PCR amplification, thereby 
allowing quantification of transcription. For RT-PCR, Omniseript transverse 
transcription (QIAGEN, CA) was used according to manufacturers recommendations. 
Briefly, RNA was isolated using RNeasy kit (QIAGEN, CA) followed by analysis of 
RNA concentration. 50 J-lg RNA was combined with IOx reaction buffer, 5 mM of each 
dNTP, 10 Units RNase inhibitor, 1 J-lM oligo dT-primer, 4 Units ofOmniscript reverse 
transcriptase and RNase-free water to a final volume of 20 J-l.l. The sample was 
incubated at 37° C for 60 min. The resulting cDNA product was subsequently used in a 
PCR reaction using NS I-specific primers (nucleotide sequences: forward pnmer: 
TCACTG CCTGACACAAGAACC; reverse primer: 
TTGTGGTCATGATGACTGGTGTTG). 
2.4.4. Mutagenesis 
Mutagensis was used for generation or deletion of restriction sites within nucleotide 
sequences. For mutagenesis, QuickChange® XL Site-directed Mutagenesis Kit 
(Stratagene, CA) was used according to the manufacturers recommendations. Briefly, 
mutagenic primers were designed to contain the mutated sequence in the middle and 10-
15 nt in 5'- and 3'-prime direction to a total primer length of 25-40 nt. Final reaction 
sample volume was 50 J-li containing IOx reaction buffer, 10 ng of DNA template, 125 
ng of forward and reverse mutagenic primer, I J-li dNTP mix, 3 J-l.I QuickSolution and 
H20 ad 50 J-l.I, and 5 Units Plu turbo DNA polymerase. Mutated DNA sequences were 
amplified in a thermal block over 18 cycles, followed by DpnI restriction hydro Isis for 
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removal of unmutated, parental methylated DNA, and transformed in XLIO-Gold 
ultracompetent bacteria for amplification. 
2.4.5. Blunt-ending of restriction sites 
The generation of blunt-ended double-stranded DNA was required for ligation of 
sticky-end restriction hydrolysed, non-cohesive DNA fragments. Two strategies were 
used: 1. fill-in of 5' -overhang DNA fragments or 2. removal of 3' -overhangs. 
2.4.5.1. Fill-in of 5 '-overhang DNA fragments 
For fill-in of a 5'-overhang DNA fragments, Klenow-fragment of E. coli -DNA-
polymerase I was used. This enzyme has DNA-polymerase activity, and no 5'-3'-
exonuclease activity. Its 3'-5' -exonuclease activity is 200x-times less than T4 
polymerase. DNA was diluted in Klenow reaction buffer to a final concentration of 50 
ng/~l, 33 ~M of each dNTP as well as 1 Unit/~g DNA added and the reaction incubated 
at 25° C for 15 min. DNA was then isolated by agarose gel-electrophoresis followed by 
gel-extraction. 
2.4.5.2. Removal of 3 '-overhangs 
T4 DNA-polymerase has 200x more 3'-5'-exonuclease activity than Kenow DNA-
polymerase; in addition it has 5'-3'-polymerase activity and no 5'-3'-exonuclease 
activity. For removal of 3'-overhangs, DNA was diluted in T4 DNA-polymerase 
reaction buffer reaction buffer to a final concentration of 50 ng/~l, 33 ~M of each dNTP 
as well as 1 Unit/~g DNA of T4 DNA-polymerase was added and the reaction 
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incubated at 37° C for 30 min. DNA was then isolated gel-extraction following agarose 
gel-electrophoresis. 
2.4.6. Ligation of DNA fragments 
Ligation was used for linking double-stranded DNA-fragments - with either cohesive 
overhanging or blunt ends - after restriction hydrolysis or for linking PCR-fragments to 
restriction hydrolyzed DNA-molecules. T4-DNA-ligase was used for catalyzing 
covalent phosphodiester bonds between 5' -phosphate and 3' -hydroxyl groups of 
nucleotides. Ligations were performed overnight at 14° C in a reaction volume of 20 ~I 
containing 1 Unit T4 DNA ligase (Invitrogen, CA), 14 ~l 5x ligase buffer (250 mM 
Tris-HCI pH 7.S, 50 mM MgCh, 5 mM ATP, 5 mM DDT, 25% w/v PEG-SOOO), 50-
200 ng DNA at a vector to insert ratio of 1:3. 
2.4.6. Removal of 5' terminal phosphate groups 
In order to avoid undesired re-ligation of vector DNA with cohesive ends, 5' terminal 
phosphate groups were removed by treatment with calf intestinal phosphatase (ClAP). 
Briefly, following restriction hydrolsis of vector DNA, 1 Unit of ClAP (Promega, WI) 
and lOx reaction buffer (50 mM Tris-HCl pH 9.3, I mM MgCh, 0.1 mM ZnCh, 1 mM 
spemidine) were added to reaction sample. H20 was added to a total volume of 50 JAl. 
Sample was incubated at 37° C for 60 min, followed by agarose gel-electrophoresis and 
isolation by gel extraction. 
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2.4.7. Gel extraction 
For isolation of DNA fragments, agarose gel-electrophoresis was performed followed 
by gel-extraction. For gel extraction, QIAEX II-gel extraction kit (QIAGEN, CA) was 
used according to manufacturers recommendation. The method is based on binding of 
DNA to silica under high salt conditions. Briefly, DNA was separated by agarose gel 
electrophoresis, visualized by UV transillumination and bands of interest excised using 
a scalpel blade. Band was weighed and dissolved in 3 volumes buffer QX I followed by 
incubation at 50° C for 10 min. The sample was centrifuged for 30 sec at 12,000 RPM, 
followed by removal of supernatant The pellet was washed once with 500 t-tl wash 
buffer QX 1 followed by two wash steps using 500 t-tl buffer PE. The resulting pellet 
was air-dried and resuspended in 20 t-tl H20 by incubation for 5 min at RT or 50° C in 
dependence of DNA size. 
2.4.8. Nucleotide annealing 
For annealing of oligo nucleotides, DNA was first 5'-phosphorylated usmg T4 
polynuleotide kinase (T4 PNK) followed by step-down PCR. Briefly, 0.25 t-tg of each 
DNA strand was combined with T4 PNK kinase, lOx T4-ligase reaction buffer and H20 
to a final volume of 50 t-t1. The sample was incubated at 37° C for 30 min. In a thermo 
cycler, sample was denatured for 10 min at 94° C followed by decrease of temperature 
at a rate of 0.01° C/sec until Tm where it was held for 5 min followed by decrease to 24° 
C at a rate of 0.01° C/sec. Annealed DNA was gel-purified after agarose gel-
electrophoresis. 
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3. Virologic methods 
Virologic methods described in this section were used for experiments using 
recombinant measles virus. 
3.1. Amplification of recombinant measles virus 
Recombinant measles viruses including MV-Edm encoding the soluble extracellular 
domain of human CEA (MV-CEA), MV-Edm encoding the green fluorescent marker 
protein GFP (MV-GFP) and MV-Edm encoding the human NlS protein (MV-NlS) were 
generated and propagated on Vero cells as described previously 431. Briefly, Vero cells 
were infected with virus stocks (generous gift by Dr. K.-W. Pen g) at a MOl of 0.02 to 
0.05 and incubated for 2h at 370 C. Subsequently, 5% FCS containing DMEM medium 
was added and cells incubated under normal culture conditions until 80-90% syncytia 
formation was observed. Cell-syncytia were harvested in Opti-MEM using a cell 
scraper and lysed by two freeze-thaw cycles followed by centrifugation with 1500 RPM 
for 2.5 min. Supernatant was transferred to a new reaction tube and stored at -80 0 
Celsius. Titers of viral stocks were determined by 50% end point dilution assays 
(TCIDso) on Vero cells. 
Virus stocks were only thawed once in order to avoid alterations of virus concentration. 
3.2. Infection of eukaryotic cells 
For virus infection assays, 2xIQs cells were incubated with recombinant MV-Edm 
diluted in 1.0 ml of Opti-MEM (Life Technologies, Inc.) at a predetermined MOl for 2 
h at 370 C. At the end of the incubation period, the virus was removed, and the cells 
maintained in standard medium until further analysis. 
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4. Biochemical methods 
4.1. Stabilized plasmid lipid particles 
Stabilized plasmid lipid particles (SPLP) were synthesized by the detergent dialysis 
method as described previously 432. DOPE, DODAC and PEGC20 were mixed at a ratio 
of82.5:7.5:10 and dissolved to a final lipid concentration of 10 mg/ml in sterile-filtered 
Ix HBS-buffer (10 mM HEPES, 150 mM NaCl, pH 7.4) containing 200 mM OGD 
detergent. DNA was added to a final concentration of 400 ~g DNAIl 0 mg lipid. In 
order to detennine the required ionic conditions for maximum packaging efficiency, 
aliquots of the sample were dialyzed overnight at RT against H8S-buffcr containing 
NaCI at concentrations between 100 and 150 nM. Percentage of entrapped DNA was 
analyzed by PicoGreen Assay perfonned prior to and after Triton mediated lysis of 
particles; percentage of DNA entrapment was calculated according to the following 
formula: % encapsulation = ([+Triton]-[-Triton])*100)/[+Triton]. Particle size was 
analyzed by QELS (= Quasi-Elastic Light Scattering) analysis. Once the optimal buffer 
conditions were detennined, Lipid/DNA sample was dialyzed against the corresponding 
HBS-buffer for 48h at RT; buffer was exchanged every 12h. Untrapped DNA was 
removed by DEAE-sepharose CL-68 chromatography, followed by purification of 
plasmid DNA containing SPLP by sucrose gradient centrifugation (1 %, 2.5%, and 
10.0% w/v sucrose in 1 x HBS) at 28,000 rpm for 18 h at 20° C. DNA-containing SPLP 
particles accumulate at the 2.5% and 10% interface and empty liposomal particles and 
unbound lipids in the 1.0% and 2.5% cellulose layers (Fig. 7). DNA entrapping-SPLP 
were collected, pooled and dialyzed against Ix HBS overnight at RT for removal of 
sucrose. DNA content and entrapment were analyzed by PicoGreen analysis as 
described above. SPLP particle size was confinned by QELS analysis (Fig. 8). 
Blechacz, B (2009). PhD thesis Page 86 
Material and Methods 
Figure 7: SPLP-purification. SPLP were synthesized by the detergent dialysis method. 
Following encapsulation of DNA in SPLP, free DNA was removed by DEAE-sepharose CL-6S 
chromatography. SPLP containing DNA were isolated from empty SPLP and free lipids by 
sucrose gradient centrifugation. DNA entrapping SPLP were located at the 2.5% and 10% 
interface as indicated in figure 7. The 2.5% and 1 % layers contained empty SPLP and lipids . 
The DNA encapsidating SPLP were recovered by perforation of the centrifuge tube at the 
bottom of the band and collection in reaction tubes . 
Sample was concentrated using an Amicon®Ultra-15 centifugal column (Millipore, 
Billerica, MA) and adjusted to a final concentration of 0.5 mg DNA/Illl. After 
preparation was complete, SPLP were reanalyzed for particle size by QEL -analys is. 
As shown in Fig. 8, SPLP particles population had a mean diameter of 64.5 nm. 
4.2. PEI-Polyplexes 
PEl-based polyplexes were synthesized as previously described :193. Linear 
polyethylenimine with molecular weight of 22 kDa (PEI22) as well as branched, 25 kDa 
PEl conjugated to transferrin ligand (Tf-PEI25) were a generous gift from Dr. E. 
Wagner. Briefly, DNA was dissolved in 0.5 HBS buffer (75 mM NaCl, 20 mM Hepes 
pH 7.4) to a final concentration of 0.4 ~lg/~l. Tf-PEI25 and PEI22 were combined at a 
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ratio of 1:3 and dissolved in 0.5 HBS buffer. PEl-solution and DNA-solution were 
combined by flash-mixing; resulting NIP-ratio was 4 .8. The solution was incubated for 
20 min at RT. For ill vivo application, complexes were dissolved in 0.5 HB containing 
2.5% glucose. 
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Figure 8: SPLP size analysis. SPLP size was measured by quasi-elastic light scattering 
(QELS) analysis. This. technique is us~d ~o deter~ine t.he size di~tribution profile . of small 
particles in solution. It IS based on the principle of diffuse light scattering by small particles and 
uses a laser light source for analysis. The scattered light undergoes either constructive or 
destructive interference by the surrounding particles, and within this intensity fluctuation 
information is contained allowing calculation of size and size distribution of the particles 
contained in a solution. As figure 8 indicated , 87.6% of SPLP in the solution have a mean 
SPLP-size of 64.7 nm. 
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4.3. LipT complexes 
Transferrin-liposome-DNA (LipTcomplex) were synthesized as previously described 
389 Briefly, 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP) and 
dioleoylphosphatidyl-ethanolamine (DOPE) (Avanti Polar Lipids, Alabaster, AL) were 
dissolved in chloroform and mixed at a I: I ratio. Chloroform was evaporated and lipids 
rehydrated with H20 to a final concentration of 2 !-tmol/ml followed by sonication at 4° 
C for 10 min. Liposomes were mixed with holo-transferrin (Sigma, st. Lois, MO) at a 
ratio of 12.5 !-tg holotransferrin per 10 nmol of liposome, incubated for 10 min at RT 
followed by addition of 1 !-tg DNA. LipT complexes were used wthin an hour of 
preparation. For in vivo experiments, LipT complexes were dissolved in sterile 5% 
dextrose to a final concentration of I Ilg DNA-LipT per 10 III dextrose. LipT complexes 
were administered via tail vein injection in a total injcetion volume of 300 III per 
animal. 
4.4. Protein concentration analysis 
Analysis of protein concentrations was required for corrections of total protein content 
in quantitative enzymatic assays of cell and tissue lysates. Analysis was performed 
using BioRad Protein Assay (Bio Rad,Hercules, CA) according to the manufacturers 
recommendations. It is a colorimetric assay based upon color change of Coomassie 
Brilliant Blue G-250 dye in response to various concentrations of proteins due to a shift 
of its absorption maximum from 465 nm to 595 nm. As the reaction is not linear over a 
range of different protein concentrations, measured absorption has to be correlated to a 
protein standard. Briefly, different dilutions were made of the protein solution of 
interest and a bovine serum albumin solution. 200 III dye reagent was added to 800 !-tl of 
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protein solution and absorption measured at a wavelength of 595 nm. Protein 
concentration was read on the standard curve obtained from bovine serum albumin 
absorption values. 
4.5. Luciferase assay 
For analysis of luciferase activity Steady-Glo® Luciferase Assay System (Promega, 
Madison, WI) was used according to the manufacturers recommendation. This assay 
allows high throughput analysis in multiple samples, such as ain 96-well plates. Briefly, 
Steady-Glo® substrate was directly added to cell culture medium at a 1: 1 ratio, 
followed by incubation for 5 min at RT and luciferase activity measurement in a 
luminometer. In experiments in which cells were co-transfected with a control vector 
for correction of transfection efficiency, medium was removed, cells washed once and 
lysed in Glo-Lysis buffer (Promega, Madison, WI) by incubation for 5 min at RT. The 
cell lysate was transferred to a luminometer tube and Steady-Glo® substrate added at a 
1: 1 ratio. After an additional incubation period of 5 min at RT, luciferase activity was 
analyzed using a luminometer. 
4.6. ~-Galactosidase assay 
In studies in which correction for differences in transfection efficiencies was required, 
co-transfection with ~-galactosidase expressionvector pSV -~-gal was performed. ~­
galactosidase was analyzed using ~-Galactosidase Enzyme Assay System (Promega, 
Madison, WI) according to the manufacturers recommendations. Briefly, cells were 
lysed in Glo-Lysis buffer (Promega, Madison, WI) by incubation for 5 min at RT. 
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Assay reaction buffer containing substrate ONPG (o-nitrophenyl-beta-D-
galactopyranoside) was added to cell lysate at a I: I ratio. 
5. Animal experimental methods 
5.1. Subcutaneous tumor xenograft implantation 
All procedures involving animals were approved by and performed according to 
guidelines of the Institutional Animal Care and Use Committee of the Mayo Clinic. 
Animals were kept under pathogen-free conditions, fed standard food, and given free 
access to sterilized water. Female SCID and nude mice (4-6 weeks of age; Harlan 
Laboratories, Indianapolis, IN) were injected with 5 x 105 HUH-7 cells/lOa Jll PBS and 
5 x 105 Hep-3B cells/IOO JlI PBS subcutaneously in the right flank with a 27-gauge 
needle. Mice were examined daily for tumor growth. Length, width and height of 
tumors were measured with calipers. Tumor volume was calculated according to the 
formula n/6 x width x length x height 433. When tumors reached a maximum diameter of 
0.5 cm, treatments were initiated. Animals were euthanized when tumor diameter 
reached 1 cm or mice lost 10% of body weight. 
5.2. Tumor marker analysis 
For in vivo experiments, blood samples were collected from mice by retro-orbital 
bleeding and serum analyzed for CEA concentration. For in vitro experiments, 
supernatant from MV-CEA infected and uninfected HCC cells was collected and 
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analyzed for CEA concentration. CEA levels were measured using the Bayer Centaur 
Immunoassay System. 
5.3. In vivo iodine uptake studies 
Subcutaneous HCC-xenografts were implanted as described above. Once the tumors 
reached a maximum diameter of 0.5 em, animals were treated with a single-shot dose of 
2 x 106 TCID50 of MV-NIS by intravenous tail vein injection. 3, 7,10 and 14 days after 
MV-NIS treatment, mice were injected intraperitoneally with 500 ~Ci 1231. 1 h after 
injection of the isotope, whole-body imaging for 1231 activity was performed using a 
gamma camera (Helix System; Elscint, Haifa, Israel). 
5.4. In vivo gene expression analysis 
5.5. Statistical Methods 
The statistical analysis for significance of differences in survival of mice treated with 
recombinant MV-Edm and UV-inactivated MV-Edm was performed using the log-rank 
test in the JMP-program. P ~ 0.05 indicates significant difference. 
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III. Results 
1. N onviral gene delivery systems 
1.1. Introduction 
Nonviral gene delivery systems possess lower immunogenicity and toxicity than viral 
vectors, thereby allowing use of higher doses and repetitive treatments. There are a 
great variety of different non-viral gene delivery systems. However, the majority of 
these systems are suboptimal due to their low transduction efficiency caused by 
multiple in vivo barriers. It was the initial goal of this thesis to identify the most 
promising of these delivery systems based upon their reported in vivo transduction 
efficiency, establish these systems independently in the laboratory, and compare them 
in vivo for identification of the most efficient one. Selection of the most promising 
appearing systems was based on thorough review of the current literature. These 
systems included conjugated and physical, non-conjugated gene delivery systems. All 
systems were evaluated in vivo in mice bearing subcutaneous tumor xenografts as 
specified in the following sections. 
1.2. Un-conjugated plasmid DNA transfer 
1.2.1. Intravenous injection of naked plasmid DNA 
Intravenous injection of naked plasmid DNA was evaluated in the subcutaneous N2A 
neuroblastoma xenograft mouse model. Luciferase expressing plasmid pCi-Iuc was used 
as an expression vector. Plasmid DNA was prepared using endotoxin-free Maxi Prep 
Kits (QIAGEN, CA) for avoidance of endotoxin mediated complications. 
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Once tumors had a maximum diameter of 0.5 cm, animals were treated with 50 Ilg of 
plasmid DNA dissolved in a total volume of 100 III sterile PBS per animal by 
intravenous tail vein injection. Luciferase activity in tumor, liver, spleen, lung, kidneys, 
muscle, heart and brain tissue was analyzed 8, 24, and 48h after injection. In order to 
correct for unspecific background luciferase activity, luciferase activity in organs of 
untreated mice was subtracted from luciferase activity of lysates from the corresponding 
organs of treated animals. 
After intravenous injection of naked plasmid DNA, very low levels of luciferase 
activity were observed in all organ systems including the tumor (Fig. 9). Intratumoral 
luciferase activity was 197.8 ± 73.9 RLU/g tissue 8h after treatment, increased to 333.1 
± 182.0 RLU/g tissue 24h after treatment and decreased to undetectable levels 48h after 
treatment. Comparable or higher luciferase activity was dctected in lungs and splecn. 
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Figure 9: Gene expression after intravenous Injection of naked plasmid DNA. Animals 
bearing subcutaneous N2A-xenografts were treated with 50 I-Ig of pCi-luc plasmid DNA by direct 
intravenous tail vein injection. 8, 24 and 48h after injection, organs were harvested and 
analyzed for luciferase expression. Shown are means with standard error (n = 3). 
(~ = 8h p.i., 0 = 24h p.i., • = 48h p.i.) 
Blechacz, B (2009). PhD thesis Page 94 
Results 
Luciferase activity in lung lysates was 475.0 ± 115.5 RLU/g tissue 8h after injection, 
and decreased to 292.0 ± 101.3 RLU/g tissue and 157.9 ± 82.1 RLU/g tissue 24h and 
48h after injection. Luciferase activity in splenic lysate was 198.9 ± 73.1 RLU/g tissue, 
140.6 ± 25.0 RLU/g tissue and 383.3 ± 184.9 RLU/g tissue at 8, 24 and 48h after 
intravenous DNA injection. Lower luciferase activities were observed in kidney, heart, 
brain and muscle tissue between with luciferase activity varying between 71 and 193 
RLU/g tissue. The lowest luciferase activity was observed in liver tissue lysates with 
activities between 10.7 and 21.3 RLU/g tissue. 
1.2.2. Intra-arterial injection of naked plasmid DNA 
As shown above, intravenous DNA transfer achieved only very low-levels of transgene 
expression. Entrapment of systemically administered vectors in first pass organs 
contributes to vector reduction in the circulation. The results of intravenous DNA 
treatment showed the highest transgene expression in the lungs indicating entrapment of 
a significant amount of administered plasmid DNA in this organ. It was hypothesized in 
this thesis that bypassing the lungs would result in an increased amount of plasmid 
DNA in the arterial system resulting in increased vector delivery to tumor tissue. In 
order to achieve arterial delivery, naked plasmid DNA was transthoracically injected in 
the left cardiac ventricle. 50 Ilg of pCi-Iuc dissolved in 100 III sterile PBS was used per 
animal. Luciferase activity was analyzed 8, 24 and 48h after injection in tumor, liver, 
spleen, kidneys, heart, lungs, brain and muscle tissue. 
In comparison to the intravenous route, intra-arterial injection of plasmid DNA resulted 
in higher luciferase activity in all organs. The distribution pattern of luciferase 
expression differed between the two routes of administration (Fig. 10). With the 
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exception of muscle tissue, the highest transgene expression was observed 48h after 
injection. Intratumoral luciferase activity was 301.2 ± 169.1 RLU/g tissue 8h after 
treatment, increased to 977.8 ± 578.1 RLU/g tissue in the following 16h and decreased 
to 187.3 ± 43.7 RLU/g tissue 48h after injection. The highest luciferase activity was 
observed in cardiac lysates with 1151.2 ± 128.4 RLU/g tissue 8h after treatment, 
followed by an increase to 23265.1 ± 23027 .8 RLU/g tissue 24h after treatment. 48h 
after injection, luciferase activity had decreased to 131.7 ± 38.7 RLU/g tissue. High 
luciferase activity was also observed in the spleen with 111.0 ± 28.1 RLU/g tissue, 
3609.6 ± 3364.8 RLU/g tissue, 154.5 ± 13.0 RLU/g tissue 8, 24 and 48h after injection. 
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Fig ure 10: Gene expression after intraarteri al injection of naked plasmid DNA. Animals 
bearing subcutaneous N2A-xenografts were treated with 50 ~g of pCi-luc plasmid DNA by direct 
intraarterial injection in the left cardiac ventricle . 8, 24 and 48 h after injection, organs were 
harvested and analyzed for luciferase expression. Shown are means with standard error (n = 3). 
( [ll= 8 h p.i., 0 = 24 h p.i., .= 48 h p.i.) 
Intra-arterial treatment resulted in higher hepatic luciferase expression than intravenous 
injection. Luciferase activity was 25 .6 ± 13.2 RLU/g tissue, 614.1 ± 605.7 RLU/g tissue 
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and 6.0 ± 2.0 RLU/g tissue at 8, 24 and 48h after vector administration. Luciferase 
expression was also observed in lung lysates with 113.9 ± 62.5 RLU/g tissue at 8h, 
2129.7 ± 2031.3 RLU/g tissue at 24h and 61.7 ± 11.8 RLU/g tissue at 48h after intra-
arterial injection. Luciferase expression in kidneys was 185.6 ± 65.7 RLU/g tissue, 
1627.3 ± 1530.5 RLU/g tissue, 106.4 ± 47.8 RLU/g tissue 8, 24 and 48h after treatment. 
Low but persistent transgene expression was observed in muscle lysates with maximum 
luciferase activity of 192.5 ± 28.6 RLU/g tissue. Brain was the only organ in which 
lower trans gene expression was observed than after intravenous treatment with a 
maximum of 83.4 ± 18.0 RLU/g tissue 24h after treatment. 
1.2.3. Hydrodynamic injection of naked plasmid DNA 
Hydrodynamic gene transfer has first been described in 1999 352, 353. Naked plasmid 
DNA, diluted in a large volume, is being injected intravenously via tail vein injection 
over a very short time period. It results in temporary increased venous pressures and 
asystole with transient inversion of intrahepatic flow and sinusoidal blood stasis. Stasis 
causes enlargement of liver fenestrae followed by generation of membrane pores in 
hepatocytes resulting in enhancement of membrane permeability and DNA uptake 354, 
355,434. Side effects are minimal and include transient cardiac irregularity and transient 
elevation of hepatic transaminases 352, 355. This technique is commonly used for 
transfection of the liver. However, trans gene expression has also been observed in other 
organs after hydrodynamic gene transfer 352. Therefore, it was hypothesized that 
hydrodynamic gene transfer might also result in transduction of tumor tissue. 
Experimental conditions were chosen as previously reported 352, 353. 50 Ilg of pCi-Iuc 
plasmid DNA was used per mouse. DNA was diluted in sterile PBS in a volume in 
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milliliters equivalent to 10% of bodyweight in gram. Injection site was the tail vein. 
Injection time was 5-10 sec. The method was well tolerated by mice with a mortality of 
0% . Transgene expression analysis was performed 8, 24 and 48h after injection. Organs 
of interest were tumor, liver, spleen, kidney, heart, lungs, brain and muscle tissue (Fig. 
11 ). 
The highest luciferase activity was observed in the liver with 188808.6 ± 38798.1 
RLU/g tissue 8h after injection, followed by a continuous decrease of luciferase activity 
to 14188.2 ± 12079.2 RLU/g tissue and 1032.9 ± 1026.5 RLU/g tissue 24 and 48h after 
treatment. Intratumoralluciferase activity was low after treatment. 8h after injection, 
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Figure 11: Gene expression after hydrodynamic injection of naked plasmid DNA. Animals 
bearing subcutaneous N2A-xenografts were treated with 50 I-Ig of pei-Iuc plasmid DNA by 
hydrodynamic gene transfer. DNA was dissolved in a volume equivalent to 10% body weight in 
milliliters. 8, 24 and 48h after injection, organs were harvested and analyzed for luciferase 
expression. Shown are means with standard error (n = 3). 
( ~ = 8 h p.i., 0 = 24 h p.i., • = 48 h p.i.) 
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luciferase activity was 1l3.0 ± 38.6 RLU/g tissue and decreased to 56.7 ± 30.9 RLU/g 
tissue and 56.0 ± 35.9 RLU/g tissue 24 and 48h after treatment. Higher levels of 
trans gene expression were measured in other organs. In splenic lysates, luciferase 
activity fluctuated between 241.6 ± 44.1 RLU/g tissue at 24h and 1418.4 ± 1278.0 
RLU/g tissue at 48h after injection. Very high levels of luciferase activity were seen in 
lung tissue with a peak luciferase activity of 1458.9 ± 761.1 RLU/g tissue 24h after 
injection. Lower levels of luciferase activity in the range of 129 and 687 RLU/g tissue 
were observed in renal and cardiac lysates. The lowest luciferase activity levels with a 
maximum of 347.2 ± 111.9 RLU/g tissue were observed in muscle tissue and in brain 
lysates. 
1.2.4. Intratumoral injection of naked plasmid DNA 
Systemic treatment with naked plasmid DNA resulted in intratumoral gene expression, 
but overall activity was low. Therefore, gene expression after direct intratumoral 
injection was evaluated. Mice bearing subcutaneous N2A tumor xenografts were treated 
with direct intratumoral injection of 50 Ilg plasmid DNA per mouse. Expression 
plasmid was pCi-Iuc, injection volume was 100 III per mouse. Tumor-size at time of 
injection was 0.5 cm. Analysis was performed 8, 24 and 48h after treatment. 
Luciferase activity was highest in tumor tissue (Fig. 12). 8h after treatment, luciferase 
activity was 179087.5 ± 148338.1 RLU/g tissue. In the following 48h, luciferase 
activity decreased continuously to 22684.2 ± 18540.4 RLU/g tissue and 10018.5 ± 
5786.1 RLU/g tissue 24 and 48h after treatment. Low luciferase activity was observed 
in all other organs ranging between 10.8 ± 2.4 RLU/g tissue in the liver and 330.5 ± 
97.1 RLU/g tissue in muscle tissue. 
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Figure 12: Gene expression after direct intratumoral injection of naked plasmid DNA. 
Animals bearing subcutaneous N2A-xenografts were treated with 50 ~g of pCi-luc plasmid DNA 
by direct intratumoral DNA injection. DNA was dissolved 100 ~I of sterile PBS. 8, 24 and 48h 
after injection, organs were harvested and analyzed for luciferase expression. Shown are 
means with standard error (n = 3). 
( ~ = 8 h p.i., D = 24 h p.i. , • = 48 h p.i.) 
1.3. Conjugated DNA transfer systems 
The results of the previous studies show the feasibility of unconjugated DNA transfer. 
However, transgene expression levels are extremely low unless DNA is intratumorally 
injected. This strategy might be of use for solitary tumors but will not be sufficient for 
metastatic disease. In the case of proven or suspected metastatic disease, most non-
surgical therapeutic approaches to malignancies - including gene therapy - aim at 
systemically active agents. Conjugation of DNA to different molecules is supposed to 
protect DNA from extra- and intracellular degradation and clearance, and thereby 
increase transduction efficiency. 
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1.3.1. LipT cationic liposomes 
LipT cationic liposomes are based on the cationic lipid 1,2-dioleoyl-3-
trimethylammoniumpropane (DOT AP), and dioleoylphosphatidyl-ethanolamine 
(DOPE) conjugated to holo-transferrin 435. Using an optimized Tf/liposome/DNA ratio, 
this nonviral gene transfer system was reported to achieve transfection efficiencies up to 
30% in subcutaneous SCCHN (= squamous cell carcinoma of the head and neck) 
xenografts in mice 389. LipT liposomes were synthesized using luciferase expressing 
plasmid pCi-luc conjugated with DO TAP, DOPE and holo-transferrin at a 
DNA:lipid:transferrin ratio of I Jlg: 10nmol: 12.5Jlg. Lipsosomes were prepared by 
sonication, dissolved in sterile 5% dextrose and administered systemically via tail vein 
injection within an hour of preparation. Per mouse a total volume of 300 Jll of 
LipT/pCi-luc was used containing 30 Jlg of plasmid DNA. 24, 48 and 72h after 
treatment, organs were analyzed for luciferase expression. As in previous experiments, 
organs of interest included tumor, liver, spleen, kidneys, lungs, brain, heart and muscle. 
No luciferase activity above background was detected at any time point in any of the 
organs using this gene transfer system. 
1.3.2. DNAlTf-PEI25/PEI22-polyplexes 
DNAlTf-PEI25/PEI22-polyplexes are based on the cationic polymer polyethylenimine 
(PEl) that has been shown to possess high transfection potential in vitro and in vivo 399. 
Further optimization including the use of low molecular weight PEl molecules (22 and 
25 kDa) and coupling to cell-binding ligand transferrin, resulted in increased 
transduction efficiency and specificity, as well as decreased toxicity 393,436. PolypI exes 
were synthesized according to original description by Kircheis et at. using luciferase 
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expressing plasmid pCi-Iuc, PEI22 and transferrin conjugated PEI25 393 . Molar ratio of 
PEl nitrogen to DNA phosphate was 4.8. Polyplexes were dissolved in sterile 0.5x HBS 
with 2.5% glucose to a DNA concentration of 200 Ilg/ml. Animals bearing 
subcutaneous N2A xenografts were treated systemically with 250 III of DNAfff-
PEI25/PEI22 (= 50 Ilg DNA) via tail vein injection directly after synthesis of 
polyplexes. 24, 48 and 72h after treatment, organs were analyzed for luciferase 
expression. As in previous experiments, organs of interest included tumor, liver, spleen, 
kidneys, lungs, brain, heart and muscle. 
The highest transgene expression was observed in tumor tissue (Fig. 13). 24h after 
injection of the polyplexes, intratumoral luciferase activity was 24138.24 ± 8116.7 
RLU/g tissue. In the following 24h, luciferase activity increased to 146244.3 ± 28803.9 
RLU/g tissue and decreased to 17351.9 ± 9723.3 RLU/g tissue at 72h after treatment. 
1.CIE+a5 
Figure 13: In vivo gene expression after systemic therapy with DNAlTf-PEI25/PEI22-
polyplexes. Animals were treated with 50 ~g of pCi-luc conjugated to Tf-PEI25/PEI22-
polyplexes per mouse. 24, 48 and 72h after intravenous injection, organs were harvested and 
analyzed for luciferase expression. Shown are means with standard errors (n=3). 
( ~ = 24h p.i. , 0 = 48h p.i. , • = 72h p.i.) 
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Luciferase expression was also detected in lungs, hear, kidney and spleen. However, 
overallluciferase expression was lower with a maximum of 7526 RLU/g tissue. While, 
luciferase expression was decreasing over time in most organs, luciferase showed an 
increasing expression pattern over time in spleen. Low-level luciferase activity was 
observed in liver, brain and muscle tissue. Luciferase activity in liver lysates fluctuated 
around 1000 RLU/g tissue with 1200.0 ± 720.0 RLU/g tissue, 720 ± 240 RLU/g tissue 
and 1680 ± 1200 RLU/g tissue at 24, 48 and 72h after polypI ex injection. Also in 
muscle lysates, luciferase activity was around 1000 RLU/g tissue. The lowest levels of 
luciferase expression were measured in brain tissue. 
1.3.3. Stabilized plasmid lipid particles 
Stabilized plasmid lipid particles (SPLP) were first described by Wheeler et al. 437. 
SPLP describe liposomal particles in which DNA is encapsulated in a unilamellar lipid 
bilayer. They consist of the cationic lipid dioleoyldimethylammonium chloride 
(DODAC), the fusiogenic lipid dioleoylphosphatidylethanolamine (DOPE) and 
pegylated ceramide C20 (PEGCerC20) which are combined at a ratio of 
DOPE:DODAC:PEGCerC20 = 82.5:7.5:10. Particles are synthesized by detergent 
dialysis method. The final DNA:lipid ratio per SPLP-particle is 62.5 J.lg/J.lmol. The 
resulting particles have a homogenous size of 64 ± 9 nm and contain one plasmid copy 
number per SPLP. Polyethyleneglycol (PEG)-coating of particles stabilizes SPLP 
particles in aqueous media. SPLP have been shown to protect encapsidated DNA from 
nuclease digestion, have a systemic half-life of 6.4 ± 1.1 h, preferentially transfect 
tumor tissue after systemic injection and are non-toxic. In addition, particles can be 
stored at 4° C for up to 2 years 438,439. 
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SPLP were synthesized following description by Fenske et al. 432. Correct particle size 
was confirmed by QELS-analysis with a mean particle size of 64.7 nm. SPLP 
encapsulation efficieny was 92% of input DNA. In the following purification steps, 
56% was lost, so that of the total input DNA 36% was finally encapsulated in SPLP. 
The encapsidation efficiencies achieved in this thesis are in accordance with the 
maximum packing efficiencies achieved by the original laboratory (Dr. MacLachlan, 
personal communication). Animals were treated systemically with 100 ).11 of SPLP-
solution (= 100 ).1g DNA) via tail vein injection directly after synthesis of polyplexes. 
24, 48 and 72h after treatment, organs were analyzed for luciferase expression. As in 
previous experiments, organs of interest included tumor, liver, spleen, kidneys, lungs, 
brain, heart and muscle. 
1.3.3.1. Biodistribution 
Initial interest was to evaluate the biodistribution of SPLP after intravenous injection in 
mice bearing subcutaneous N2A-tumors. For this purpose, SPLP were synthesized 
using DOPE conjugated to fluorescent rhodamine dye. Mice bearing subcutaneous N2A 
xenografts were treated with SPLP encapsidating GFP-expressing plasmid EGFP-N 1. 
Route of administration was intravenously via tail vein injection, dose per animal was 
100 J.lg. Biodistribution was analyzed over a time course of 72h following treatment. 
Animals were sacrificed in 24h intervals, organs harvested and analyzed by 
fluorescence microscopy. 
As shown in Fig. 14, SPLP were found to be distributed in all organs. Though, the 
extent of accumulation per organ differed. 24h after systemic administration, the highest 
accumulation of SPLP was observed in the liver. At later time points, the highest 
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accumulation was found to be in the kidneys and spleen. SPLP accumulation in the 
spleen started 48h after injection and persisted at a steady state. In the kidneys, SPLP 
accumulation was observed already after 24h and increased over time. The pattern of 
Figure 14: SPLP biodistribution. Mice bearing subcutaneous N2A xenografts were treated 
intravenously with SPLP conjugated to rodamine . 24, 48 and 72h after treatment animals were 
sacrificed , organs harvested and analyzed using fluorescence microscopy. Shown is 
representative SPLP biodistribution at 72h after systemic administration. 
renal SPLP-distribution was between cortex and medulla. Relatively high accumulation 
of SPLP was found within the tumor tissue. Particles were predominantly located 
perivascular distribution. Lower accumulation was observed in liver (following the 
initial high accumulation in the initial 24h) and lungs. Very low accumulation of SPLP 
was seen in heart and brain tissue. In the brain, PLP were observed ill the meningeal 
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vessels to a high degree at 24h post administration, but none were detected within the 
brain parenchyma thoughout the 72h time course. Low SPLP accumulation was 
observed in muscle tissue. 
1.3.3.2. Transge11e expression after systemic SPLP treatment 
After evaluation of SPLP biodistribution, transgene expression after systemic SPLP 
therapy was analyzed. Experimental settings were identical to the previous SPLP-
biodistribution studies. Briefly, mice bearing subcutaneous N2A-tumor xenografts were 
treated systemically with SPLP. Dose per mouse was 100 pCi-Iuc DNA, route of 
administration was intravenously via tail vein injection. Total observation time was 72h, 
with analysis of transgene expression every 24h. 
Highest transgene expression levels were observed in tumor tissue. 24h after treatment, 
intratumoral transgene expression was 90936.9 ± 1507l.6 RLU/g tissue. Expression 
increased to 257293.4 ± 35097.5 RLU/g tissue and 355536.2 ± 37580.2 RLU/g tissue at 
48 and 72h after treatment. Hepatic transgene expression was 13800.0 ± 16122.0, 
2370.0 ± 1994.0 and 240.0 ± 339.4 RLU/g tissue at 24, 48 and 72h after treatment. 
Transgene expression levels measured in spleen were 1415.1 ± 50.0, 667.6 ± 97.0 and 
632.3 ± 14.3 RLU/g tissue at the same time points. In the kidneys, transgene expression 
was highest after 48 h with 2964.8 ± 3078.0 RLU/g tissue followed by a decrease to 
1047.8 ± 148l.8 RLU/g tissue. In all other organs except muscle, expression was 
highest after 24h and decreased rapidly over the next 48h to less than 1000 RLU/g 
tissue. In muscle tissue, transgene expression was stable over time with 1596.7 ± 116.6 
RLU/g tissue after 24h, 1055.1 ± 260.9 RLU/g tissue after 48h and 2026.1 ± 1442.6 
RLU/g tissue after 72 h. 
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Figure 15: In vivo gene expression after systemic therapy with SPLP. Each animal was 
treated with 1 00 ~g DNA encapsidated in SPLP. 24, 48 and 72h after intravenous injection , 
organs were harvested and analyzed for luciferase expression. Shown are means with standard 
errors (n=3). 
( 121 = 24h p.i. , 0 = 48h p.i. , • = 72h p.i.) 
1.3.3.3. intratul110ral distribution of transduced cells 
Intratumoral biodistribution of transduced cells is an important factor for the therapeutic 
efficacy of an agent. The aim of the following experiment was to evaluate the 
intratumoral distribution of transduced cells after treatment with PLP. With the 
exception of the encapsidated plasmid (GFP-expressing pCi-GFP), experimental 
conditions were identical to the previous SPLP-studies. Briefly, mice bearing 
subcutaneous 2A-tumor xenografts were treated systemically with pCi-GFP packaged 
in SPLP. Dose per mouse was 100 Ilg pCi-GFP DNA, route of administration was 
intra enously ia tail ein injection. Analysis was performed after 72h, based upon 
pre ious experiments showing this to be the time point with the highest transgene 
expression. Analysis was performed by fluorescence microscopy. 
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Intratumoral biodistribution of transduced cells was very low. The tumor was sectioned 
in multiple layers. In several layers, single GFP-expressing cells were identified . In one 
layer, an accumulation of seven cells was observed as shown in figure 33. Intracellular 
GFP-expression was strong. A distinct pattern of intratumoral distribution was not 
identifiable. 
Figure 16: Intratumoral distribution of transduced cells after SPLP treatment. Animals 
bearing subcutaneous N2A xenografts were treated intravenously with 1 00 ~lg of GFP-
expressing plamsid EGFP-N1 encapsidated in SPLP. 72h after treatment, animals were 
sacrificed , tumors harvested and analyzed for GFP-expression using fluorescence microscopy. 
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2. Expanded parvoviral replicons as novel nonviral gene therapy 
vectors 
2.1. Introduction 
The evaluation of non-viral gene delivery systems was able to identify promising non-
viral gene delivery systems. However, intratumoral biodistribution and maximum 
transgene expression were low. Therefore, it was hypothesized in the course of this 
thesis that the use of replicating expression systems might be able to compensate in part 
for the low transduction efficiency. In order avoid adverse effects in organ systems 
other than the tumor, tumor-selectivity was desired. Autonomously replicating 
parvoviruses are known for their oncoselectivity, cytotoxicity and human 
apathogenicity. However, their use is impaired by viral immunogenicity. Expansion of 
parvoviral genome by 6% results in a 10% decrease in encapsidation efficiency of 
recombinant parvoviruses 133. This size limitation restricts the choice of transgenes to 
genes of approximately 0.3 kb as exceeding this size will lead to a significant decrease 
of viral titers 133,251. One of the hypotheses of this study is that the use of the parvoviral 
genome as a non-viral replication-competent plasmid will allow expansion of the size 
above these limitations and facilitate the use of large trans genes or trans gene 
combinations. Transfection with parvoviral replicon vectors is hypothesized to result in 
tumor specific DNA-replication, high-level transgene expression and cytotoxicity. In 
order to test this hypothesis, recombinant MVMp replicon vectors were generated with 
expansion of their genome up to 3.5-fold the size of the wildtype. 
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2.2. Generation of recombinant MVM-replicons 
2.2 . 1. Restoration of the left palindrome 
The MVMp genome is available as an infectious plasmid 440 . Parvoviral plasm ids used 
in this study are based on this MVMp plasmid. The original pUC-MVM plasmid was 
provided by Dr. A. Brandenburger. It contains a pUC i8-based plasmid-backbone and 
the MVMp genome. It has been described that existing infectious parvoviral MYMp 
clones had an incomplete origin of replication with a defective NS I-nicking site 
resulting in incomplete parvoviral genome excision (Fig. 17). 
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Figure 17: Parvovirus MVM left palindrome. Figure 1 shows an overview over the left 
palindrome of parvovirus MVM. Indicated are the ATF binding sites as well as the incomplete 
NS1-nicking site. The "bubble' is also shown 
Reconstitution of the NS I consensus sequence was reported to results in 5-20 times 
higher parvoviral excision and replication rates 133. In order to optimize and enhance 
amplification of MVM-based replicon vectors, the origin of replication site was restored 
by exchange of the incomplete left palindromic sequence of pUC-MVM with the 
corresponding sequence of pORI3375 , a MVMp-clone containing the correct left 
palindromic sequence (provided by Dr. A. Brandeburger) 441 . A 407 bp fragment 
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including the left palindromic sequence was excised from pUC-MVMp using restriction 
enzymes KpnI and EcoRV, and replaced with the corresponding DNA fragment from 
KpnIlEcoRV-treated pORI3375. Control digest as well as sequencing analysis 
confirmed intact sequence of right and left MVMp palindromes. The resulting modified 
MVM-vector was named pUC-MVMp+. 
2.2.2. Genetic modification ofpUC-MVMp+ 
2.2.2.1. Deletioll of illterfering restrictioll sites 
In order to achieve transgene expression under control of the P38 promoter and 
maintain the functional elements within the MVM genome, HindIII and XbaI restriction 
sites of the parvoviral genome were chosen for transgene insertion 218. Additional 
HindIII and XbaI restriction sites were also identified within the multi cloning site of the 
pUC 18-backbone of pUC-MVMp+ requiring their deletion; both restriction sites are 
located in 5' -direction of a BamHI restriction site. Deletion of the XbaI and HindIII 
restriction sites was achieved by restriction hydrolysis of pUC 18 plasmid with these 
enzymes, followed by blunt-ending with exonuclease treatment and religation. The 
MVMp+ genome was excised from the original pUC-MVMp+ vector by restriction 
hydrolysis with BamHI and inserted in the corresponding site of the modified pUC 18 
plasmid vector. Successful deletion of the XbaI and HindIII restriction sites in the 
modified pUC 18 backbone of the newly generated pUC-MVMp+ was confirmed by 
restriction hydrolysis with HindUI and XbaI followed by agarose gel electrophoresis. 
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2.2.2.2. Insertioll ofpolylillker sequence 
In order to expand the parvoviral genome without interference of transcriptionally 
essential sequences, a region between the functional element AlB and the right end 
palindrome was chosen as insertion site for stuffer DNA (Fig. 18). Tn order to create an 
insertion site for stuffer DNA of different length, a polylinker containing unique 
restriction sites was designed (AscI, NheI, AvrIl , BsiWT, Af1II , Sacll , AscI). This 
1 . Mutagenesis 
~ 
0",' ~ P,hAl ( ( iii 
2. Polylinker insertion 
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Figure 18: Cloning strategy for insertion of stutter DNA. MVM PshAI was subcioned into 
pUC18. A Asci restriction site was inserted between the Oral and PshAI site by mutagenesis. 
The modified PshAI fragment was cloned back into the original MVM vector. Subsequently , a 
polylinker was cloned into the Asci site . The polylinker was later used for insertion of stuffer 
DNA derived from A-DNA. 
polylinker contained restriction sites neither present in the shIffer DNA nor in the pUC-
MYMp+ sequence. For insertion of this poly linker, an Ascl restriction site needed to be 
created in between the DraT and PshAI restriction sites of pUC-MVMp+. This was 
achie ed by restriction hydrolysis of pUC-MVMp+ with PshAJ , followed by subcloning 
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of the resulting 4.25 kb parvoviral PshAI-fragment into the SmaI restriction site of 
pUC18 by blunt-end ligation. An AscI restriction site was inserted between the DraI and 
PshAI restriction site by mutagenesis. After confirmation of successful generation of the 
AscI site by restriction hydrolysis, the modified PshAI fragment was reinserted in the 
parvoviral genome in its prior position. Next, the above-described polylinker was 
generated by nucleic acid synthesis followed by annealing of the complementary DNA 
strands. The resulting polylinker was inserted in the AscI restriction site of pUC-
MVMp+. Restriction analysis confirmed the successful insertion of the polylinker into 
MVMp+. The new vector was named pUC-(MVMp+)poly. 
2.2.3. Insertion of trans genes into parvoviral MVM-based replicons 
For quantification of transgene expression as well as potential future diagnostic and 
therapeutic use of parvoviral replicon vectors, different transgenes were inserted into 
the HindIlIlXbaI site of pUC-(MVMp+)poly. Transgenes of interest included carcino 
embryonic antigen (CEA), luciferase, green fluorescent protein (GFP), gibbon ape 
leukemia virus-fusogenic membrane glycoprotein (Galv-FMG) and the human sodium 
iodide symporter gene (hNIS). Luciferase and GFP are marker genes commonly used 
for detection of gene expression. Soluble human carcinoembryonic antigen (hCEA) is a 
677 amino-acid glycoprotein of molecular weight 180kD with a circulating half-life of 
36 hours and no known biological activity in humans. Its normal serum concentrations 
are less than 5 ng/ml but it is commonly elevated in gastrointestinal and gynecologic 
human malignancies and therefore used as a tumor-marker in these conditions 106. Its 
cloning into a gene therapy vector provides important information about successful 
tumor tranduction as well as tumor growth and viral amplification kinetics 106. The 
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human sodium iodide symporter (hNIS) is an intrinsic membrane glycoprotein mainly 
expressed in the follicular cells of the thyroid. It facilitates iodine uptake in thyrocytes 
by a symporter mechanism transporting one iodine ion together with two Na-ions 
against the Na-gradient maintained by the Na-K-ATPase resulting in an intracellular 
concentration of iodide 20- to 40-fold above plasma concentration. Its function as an 
iodine transport protein makes it an intresting candidate as a cancer gene therapy 
transgene. Expression of this transgene followed by administration of radioiodine 
results in accumulation of the isotope in hNIS-expressing cells. Tumor-selective hNIS 
expression can be used diagnostically or for therapeutic purposes. For example, 
administration 1231 followed by imaging analysis allows non-invasive detection of hNIS 
overexpressing cells. If administered by a systemic gene therapy vector, it can also 
provide information about systemic and intratumoral biodistribution. If hNIS expression 
is followed by systemic administration of 1311, it serves as a tumor specific therapeutic 
gene for radio-sensitive malignancies 431. The potential of this trans gene has been 
shown in several tumor models including myeloma and prostate cancer 108. 304. 307. 431. 
Viral fusogenic membrane glycoproteins (FMG) and (NIS) are therapeutic genes which 
proved their strong antitumor potential in different tumor-models. Galv-FMG normally 
restricts fusion of the envelope until it is cleaved during viral infection. By truncating 
the C-terminus of the wildtype-protein, GALV-FMG becomes highly fusogenic to 
human cells. Its expression in human tumor cells results in syncytia formation and 
induction of immune stimulatory heat shock proteins, leading to cell death. Transgenes 
were synthesized by PeR-techniques, gel-purified and directly cloned in the pUC-
(MVMp+)poly plasmid. 
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Figure 19 (see below): Cloning strategy of recombinant parvovira l repl icons vectors. A) 
Shown is a schematic overview of the MVMp genome (middle) . The internal repeats (IR) are 
indicated as black boxes, the coding regions of the non-structural proteins 1 and 2 (NS1/2) as 
light-grey box, the cod ing regions for capsid proteins (VP1/2) as dark-grey box and the poly A 
location as a white-and-black-hatched box. Also shown are the relative position of the promoter 
P4 and P38 as well as the restriction sites used for insertion of the transgenes. For insertion of 
transgenes, a DNA fragment of the coding region for VP1/2 was excised with Hindlll and and 
Xbal restriction hydrolysis, followed by insertion of PCR-generated transgenes into the 
correspond ing restriction sites. Transgenes included marker genes such as carcinoembryonic 
antigen (CEA), green-fluorescent protein (GFP) and luciferase, and the diagnostic as well as 
therapeutic human iodide symporter (hNIS) and therapeutic gibbon ape leukaemia virus 
hyperfusogenic glycomembrane protein (Galv-FMG). Insertion of the genes resulted in 
alterations of the parvoviral genome size as indicated next to the transgenes . In a second step , 
a polylinker sequence was inserted between the poly A sequence and the right IR. Using the 
polyl inker restriction sites, 6 kb or 13 kb Lambda DNA-derived stuffer DNA was inserted into 
predefined polylinker restriction sites. 8 ) Schematic overview of generated , recombinant MVM 
repl icon vectors . For further details, see text. 
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2.2.4. Expansion ofparvoviral MVM-based replicon vectors 
In order to evaluate the expansion potential of parvoviral replicon vectors, 6 and 13 kb 
stuffer DNA was inserted into the parvoviral genome of pUC-MVMp+-Iuc (Fig. 20). 
Stuffer DNA was obtained by restriction hydrolysis of A-DNA. Restriction hydrolysis 
with AscI generated a 13 kb DNA fragment and restriction hydrolysis with AflII a 6 kb 
DNA fragment. These DNA fragment were separated by agarose gel electrophoresis, 
isolated and cloned in the corresponding restriction sites contained in the polylinker 
region of pUC-MVMp+-luc. Successful insertion of the stuffer DNA and maintenance 
of the right and left palindrome were confirmed by control digest followed by agarose 
gel-electrophoresis. 
2.3. Functionality of recombinant parvoviral replicon vectors 
Infectious MVMp plasmids can be transfected into permissive cells resulting in P4-
promoter driven NS I-expression. NS I-recognition sequences in the origin of replication 
allow excision of the parvoviral genome from the recombinant plasmid by NS I-directed 
DNA nicking 133.440, Subsequently, parvoviral DNA is replicated via the rolling-hairpin 
mechanism and viral proteins are expressed. The following experiments aimed at 
functional evaluation of recombinant parvoviral vectors by analysis of parvoviral DNA 
replication and transgene expression. 
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Figure 20: Parvoviral replicons vectors. Plasmid vector maps of luciferase expressing 
parvoviral replicon vectors pUC-MVMp+/luc as well as the expanded parvoviral replicons pUC-
MVMp+/luc/Lambda 6 and MVMp+/luc/+13. Indicated are internal repeats (IR, black box), 
coding reg ions of viral non-structural proteins 1 and 2 (NS1/2, grey box) , the luciferase 
transgene (black-and-white-hatched box) and promoters P4 and P38 . The plasmid backbone is 
shown as black double line and stuffer DNA, derived from Lamda vector, is shown as blue-and-
white-hatched box. Also , different restriction sites are shown which have been used for cloning 
of these recombinant parvoviral vectors . The circle in the inside of the vector map indicates the 
parvoviral genome (solid black line) and the backbone derived from pUC18 (interrupted black 
line). 
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2.3 .1. Excision and amplification of parvoviral DNA 
Excision and replication was analyzed by Southern blot technique. Plasmid DNA had 
been amplified in the bacterial strain E. coli dam+. DNA adenine methylase (Dam) 
methylates adenine moieties of the tetranucleotide d(pGA TC) on both strands of duplex 
D A 442. In contrast, DNA methylation is not being observed in eukaryotic cells . The 
restriction enzyme DpnI recognizes and hydrolyzes the methylated DNA sequence 
d(pGm A TC). Hemi- or non-methylated DNA is not a substrate for DpnI 443 . Therefore, 
DNA isolated from transfected cells was restriction hydrolyzed with DpnI in order to 
separate eukaryotic amplified DNA from bacterial amplified input DNA. 
293-T cells were transfected with recombinant pUC-MVMp+ vectors. 4, 24 and 48h 
after transfection, low molecular weight DNA was isolated, DpnI treated and analyzed 
by Southern Blot. As shown in figure 21, parvoviral replicons were successfully excised 
and amplified after transfection. Differences in molecular weight of the shown 
replicati e 
pUC-MV M-CEA pUC-MVM-luc 
I I 
wt MVM 4 h 24 h 4 8 h 4 h 24 h 48 h 
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Figure 21: Excision and amplification of recombinant parvoviral replicons. 293-T cells 
were transfected with pUC-MVMp+-CEA and pUC-MVMp+-luc. 4, 24 and 48 h after 
transfection , low molecular weight DNA was isolated from cells, Dpnl-digested and analyzed by 
Southern blot technique. As a size marker, pUC-MVMp+ was digested with BamHI resulting in 
excision of parvoviral genome from its backbone (left lane). It serves as a size marker for 
identification of parvoviral DNA in the other lanes. Molecular size of MVMp+-CEA is 0.46 kb 
larger than MVMp+. The first replication intermediate appears after 4h followed by increasing 
intensity of the band. pUC-MVMp+-luc replication intermediates can first be seen clearly at 24h 
post transfection. It also increases in its intensity over time. 
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forms are consistent with length differences of recombinant parvoviral vectors: 
MVMp+ is 5.1 kb, MVMp+-Iuc is 5.1 kb and MVMp+-CEA is 5.6 kb in size. Very low 
intensity signals of monomeric replicative intermediates of parvoviral DNA were 
observed 4h after transfection. Clear detection of monomeric forms was observed 24h 
after transfection and signal intensity increased over the following 24h indicative of 
continuous intracellular parvoviral DNA amplification. As expected, single-stranded 
parvoviral DNA was not detected, as generation ssRF requires VP2 protein. 
2.3.2. Transgene expression 
Analysis of transgene expression showed high-level transgene expression of all 
recombinant MVM-based replicon vectors (Fig. 22-24). 
2.3.2.1. pUC-MVAlp+-hNIS 
In order to evaluate NIS-transgene expression, 293-T cells were transfected with pUC-
MVMp+-NIS. 24 and 48h after transfection, cells were incubated with 1 x lOs cpm of 
1251 for 45 min at 37°C followed by analysis of isotope uptake. As shown in figure 22, 
isotope activity in lysates ofpUC-MVMp+-NIS transfected cells was 1976 ± 285.2 cpm 
at 24h after transfection and remained stable 48h after transfection with 1950 ± 340.1 
cpm. In comparison, isotope activity in lysates of un trans fee ted cells incubated with mI 
was 287 ± 58.4 cpm at 24h and 367.7 ± 34.4 cpm at 48h. In order to test NIS-specificity 
of 1251-uptake, cells were co-incubated with 1251 and potassium perchlorate - a known 
inhibitor of hNIS-mediated iodine uptake. pUC-MVMp+-NIS transfected cells were co-
treated with 1 x 105 cpm 1251 and 111M potassium perchlorate followed by gamma 
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counter analysis of cell lysates. 24 and 48h after transfection, 125r-activity in cell lysates 
was 129.7 ± 59.8 cpm and 653 ± 22 .9 cpm. 
The results of these studies show that transfection with pUC-MVMp+-NrS results in 
expression of hNIS-protein facilitating a 5.3 to 6.9-time increase in iodine uptake in 
transfected cells. 
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Figure 22: 1251_uptake after pUC-MVMp+-NIS transfection. 293-T cells were transfected with 
pUC-MVMp+-NIS followed by incubation with 1251 or co-treatment with 1251 and NIS-inhibitor 
potassium perchlorate 24h and 48h after transfection . As a negative control, untransfected 293-
T cells were also treated with 1251 in the presence and absence of potassium perchlorate 
treatment at the same time points . Isotope incubation of cells was followed by cell lysis and 
gamma radiation emission analysis using a gamma counter. 
( 0 = 24h post transfection , 0 = 48h post transfection) 
2.3.2.2. pUC-MVMp +-CEA 
CEA-expression after pUC-MVMp+-CEA transfection was analyzed 111 293-T cells. 
Analysis was performed by quantification of CEA concentration in the cell supernatant 
as described in material and methods. 24h after transfection , CEA concentration was 
194.3 nglml and increased to 532.2 nglml 48h post transfection. In contrast, CEA 
concentration in the supernatant of untransfected 293-T cells was <0.5 ng/ml at all time 
points (Fig. 23) . 
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Figure 23: CEA expression after pUC-MVMp+-CEA transfection. 293-T cells were 
transfected with pUC-MVMp+-CEA. 24 and 48h after transfection, CEA concentration was 
measured in cell supernatant. As a negative control, supernatants of untransfected 293-T cells 
were analyzed for CEA concentration at the same time points. 
( • = transfected, 0 = untransfected) 
2.3.2.3. P UC-MVMp+-GF P 
GFP-expression after transfection with pUC-MVMp+-GFP was evaluated in 293-T 
cells. Cells were transfected using lipotransfection methods followed by fluorescence 
microscopic e aluation. Transfection with pUC-MVMp+-GFP resulted in strong GFP-
expression in transfected cells . GFP-expressing cells were first detectable 24h after 
transfection and continuously increased over the following 48h in number of cells 
expressing GFP and intracellular intensity of GFP-expression (Fig. 24). 
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Figure 24: Transge ne expression after transfection w ith recombinant parvoviral 
replicons . Shown are 293-T ce lls after transfection with recombinant parvoviral repl icons 
vectors. The bottom panel represents lightmicroscopic analysis of 293-T cells 48h after 
transfection with pUC-MVM-FMG showing extensive syncytia formation and cell death . The 
upper panel represents fluorescence microscopic analysis of cells 48h after transfection with 
pUC-MVM-GFP. Left on th e upper and bottom panel , untransfected cells are shown serving as 
a negative contro\. 
_.3.2.4. pUC-MVM-FMG 
Expression of Gal -FMG-expression was analyzed by light microscopy after 
transfection of 293 -T cells with with pUC-MYMp+-FMG. Expression of Galv-FMG 
causes syncytium formation fo llowed by cell death 305 . Transfection of 293-T cell s with 
P C-MYMp+-FMG resulted in sign ificant syncytia formation starting 24h after 
transfection ~ ith continuou ly increasing syncy ti a size and number (Fig. 24) . 72h after 
transfection the complete cell layer was destroyed. 
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2.3.3. Summary 
The data demonstrate, that the recombinant parvoviral replicons are functional. 
Parvoviral genome excision, replication and protein expression are not negatively 
influenced by above described genetic modifications. 
2.4. Effect of palindrome restoration on ~lVl\1-replicon efficacy 
Previously, it was reported that restoration of the left palindrome resulted in higher 
replication rates as well as higher viral titers \33. Further, it was reported that transgene 
expression of parvoviruses with restored left-palindromic sequences was at least 6-timer 
higher than with defective viruses 44-+. Within the 3' -end of existing infectious clones, a 
NS I-nicking site is deleted, causing decreased excision of parvoviral DNA from the 
plasmid backbone. Based upon the previous observation of increased replication rates 
following restoration of the left palindrome, it was hypothesized for this thesis that 
restoration of the left palindrome will also result in increased MVM genome copy 
numbers, higher trans gene expression levels and thereby increased efficacy of MVM-
replicons. Restoration of the left palindrome was achieved as described in section 2.2.1 .. 
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2.4.1. Replication 
A9-cells were transfected with pUC-MVMp/luc containing the incomplete left 
palindromic sequence or with pUC-MVMp+/luc containing the restored NS 1 nicking 
site. 24 and 48h after transfection, low-molecular weight DNA was isolated, Dpnl 
treated and analyzed by Southern blot analysis (Fig. 25) . 24h post transfection, 
24h 48h 24h 48h 
23 kb-
9 kb -
6.6 kb -
Figure 25: Comparison of parvoviral DNA-replication with incomplete and restored left 
palindrome. A9-cells were transfected with parvoviral replicons wi th incomplete (MVMp/luc) or 
restored left palindrome (MVMp+/luc). 24 and 48h after transfection , low molecular weight DNA 
was isolated , Dpnl treated and analyzed by Southern blot technique. Hind lll treated A-DNA was 
used as a size marker (6.6, 9 and 23 kb DNA fragments are shown on the left) . Parvoviral 
replicative intermediates are indicated on the right side (mRF :: monomeric replicative form, 
dRF = dimeric replicative form). 
monomeric, replicative intennediate forms of parvoviral DNA were detected in cells 
transfected with pUC-M Mp+-luc and pUC-MVMp/luc. However, signal intensity was 
higher in cells transfected with pUC-MVMp+-luc. In the following 24h, signal intensity 
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of monomeric as well as duplex replciative intermediates continued to increase. Also 
48h after transfection, signal intensity of intracellular amplified parvoviral DNA was 
significantly higher after transfection with pUC-MVMp+-Iuc than after transfection 
with pUC-MVMp/luc. A single band was detected in cell lysates of pUC-MVMp/luc 
transfected cells at -7.0 kb. This band was also seen at increased intensity 48 h after 
transfection and 
correlates most likely with unspecific replication intermediates 251. 
2.4.2. Transgene expression 
F or quantification of the effect of left palindrome restoration on transgene expression, 
A9 cells were transfected with luciferase expressing MVM replicon vectors with 
incomplete (pUC-MVMp/luc) or restored left palindrome (pUC-MVMp+/luc). 
Luciferase activity was analyzed every 24h over a total time period of 96h (Fig. 26). 
Differences in transfection efficiencies were corrected by co-transfection with the ~­
galactosidase expression vector pSV -Gal. 
24h after transfection with pUC-MVMp/luc, luciferase activity in A9 cell lysates was 
6.69 x 106 RLU/mg protein/I~-gal. Luciferase activity increased in the following 72h to 
1.66 x 107, 2.46 X 107 and 2.96 x 107 RLU/mg protein/I)-gal at 48, 72 and 96h after 
transfection. In comparison, luciferase activity in cells transfected with MVMp+/luc 
was 3.59 x 107, 8.48 X 107, 2.02 X 108 and 2.50 x 108 RLU/mg protein/I)-gal at 24, 48, 
72 and 96h after transfection. 
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Figure 26: Effect of left palindrome restoration on transgene express ion. A9 cells were 
transfected with MVMp/luc containing the incomplete left palindrome or MVMp+/Iuc containing 
the restored left palindrome. Differences in transfection efficiency were corrected by 
cotransfection with pSV-Gal. Luciferase and ~-Gal activity were analyzed 24, 48, 72 and 96h 
after transfection (p.t.) , n=8 . 
( • = neg. control , 0 = pUC-MVMp/luc, 0 = pU C-MVMp+/luc) 
In summary, restoration of the left palindrome results in an increase in transgene 
expresSIOn of factor 5.4 already 24h after transfection. 96h after transfection, this 
difference in expression level increased to an 8.4-fold difference. These data 
demonstrate that restoration of the left palindrome resu lts in significant improvement of 
parvoviral expression plasmids with almost IO-fold difference in expression levels. 
2.4.3 . Summary 
The results of these studies show that restoration of the left palindrome of MVMp-based 
non-viral replicons achieves a significant increase in parvoviral replication and 
transgene expression levels, thereby increasing their efficacy. 
Blechacz, B (2009). PhD thesis Page 127 
Results 
2.5. Expanded parvoviral replicons 
Parvovirus H I and MVM are restricted as viral gene therapy vectors by genome size 
limitations severely limiting the choice of therapeutic transgenes 133.441. Expansion of 
the parvoviral genome to > I 06% of the wildtype genome size results in decrease of 
viral titers due to decreased packaging. One of the hypotheses of this thesis is that the 
use of MVMp-based non-viral replicon vectors will facilitate expansion beyond this 
size limit, thereby allowing insertion of therapeutic transgenes of any size. The 
following studies aimed at analyzing the effect of parvoviral genome-expansion on 
DNA replication, transcription and transgene expression. Expanded MVMp+-based 
replicon vectors were generated as described above (section 2.2.4.); the genome sizes of 
these vectors were 255% and 355% of the wildtype MVMp genome. 
2.5.1. Transcription 
293-T cells were transfected with 4.5x104 plasmid copy numbers per cell of pUC-
MVMp+/luc, pUC-MVMp+/luc/+6kb or pUC-MVMp+/luc/+13kb; the non-replicating 
expression plasmid pCilluc was used as a negative control. 48 and 72h after 
transfection, cellular RNA was isolated and analyzed by Reverse Transcriptase-PCR 
(RT -PCR) using parvoviral NS I-specific primers. 
No transcription product was observed in pCi-luc transfected cellular RNA at any 
timepoint (Fig. 27). In contrast, the first transcription products in parvoviral DNA 
transfected cells were observed 48h after transfection. Intensities ofRT-PCR products 
Blechacz, B (2009). PhD thesis Page 128 
Results 
~ ~ ~ ..f2 
CJ 0 >t (j 
~ ~.::5 ~.::5 ~.::5 ~ ~ CJ " " " 
.:::qj .,;;:-.::5 ~q ~q ~q ~ 
cJ i i i .:::qj -oq q 
-oq ~ 
" 
~ 
48h 72h 48h 72h 48h 72h 48h 72h " 
Figure 27: Transcriptional efficiency of expanded parvoviral replicon vectors. 293-T cells 
were transfected with pCi-luc, pUC-MVMp+/luc or expanded parvoviral replicon vectors pUC-
MVMp+/luc/+6 kb or pUC-MVMp+/luc/+6 kb. 48 and 72h after transfection , RNA was isolated 
and transcription products visualized by RT-PCR followed by gel-electrophoresis. The very left 
and the very right lane are loaded with a 100 bp DNA-marker. No band was observed in pCi/luc 
transfected cellular RNA. In contrast. in parvoviral and expanded parvoviral DNA transfected 
cellular RNA. the N S 1-specific band can be identified . 
differed between all three plasmids. 48h post transfection, the lowest intensity was 
observed in pUC-MVMp+-luc transfected cells and the highest in MVMp+-Iuc/+ 13 
transfected cells. ignal intensity of MVMp+-Iuc and MVMp+-Iuc/+6 RNA RT-PCR 
product increased markedly 0 er the following 24h. Interstingly, RT-PCR product of 
M Mp+-Iuc/+ 13 transfected cells were found to be the highest 48h after transfection 
followed by a mild decrease. Overall comparison of the three parvoviral constmcts 
shO\ ed efficient transcription in all of them. Expansion of the parvovira l genome had 
re ulted in mildl decreased transcription efficiency and had also altered transcription 
kinetic . 
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2.5.2. Replication 
293-T cells were transfected with 4.5xl04 plasmid copy numbers per cell of pUC-
MVMp+/luc, pUC-MVMp+/luc/+6kb or pUC-MVMp+/luc/+ 13kb. 24 and 48h after 
transfection, cellular DNA was isolated, DpnI digested, and analyzed by Southern blot 
technique (Fig. 28). A 390 bp NS 1 specific probe was used for hybridization. 
Replicative intermediates were observed as early as 24h after transfection with pUC-
MVMp+/luc. Intensity of mRF and dRF bands increased over the following 24h. In 
DNA-extracts of MVMp+/luc/+6 transfected cells, parvoviral replication intermediates 
were observed 48 h after transfection. The intensity of the band corresponding to mRF 
was decreased in comparison to the corresponding bands of MVMp+/luc. In DNA 
extracts of cells transfected with pUC-MVMp+/luc/+ 13, the first parvoviral replicative 
intermediates were observed 48h after transfection. The intensity of this mRF-
corresponding band of MVMp+/luc/+ 13 was very low compared to corresponding 
bands in MVMp+/luc and MVMp+/luc/+6kb DNA extracts. Unspecific bands were 
seen. These bands have been described previously by Brandenburger et al. as 
multimeric replicative forms 251. Our data demonstrate, that parvoviral replicon vectors 
tolerate expansion of up to 355%. However, size increase results in reduction of 
genome replication. 
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Figure 28: Replication of expanded parvoviral replicon vectors. Figure 28 shows results of 
the southern blot analysis of total cellular DNA isolated from 293-T cells transfected with pUC-
MVMp+/luc or expanded parvoviral replicons pUC-MVMp+/luc/+6kb and pUC-
MVMp+/luc/+13kb Time points of analysis are 24 and 48h after transfection . Hindlll digested "'-
DNA was used as a size marker. On the left, 6.6, 9 and 23 kb fragments are indicated . On the 
right , parvoviral replication intermediates are indicated (mRF = monomeric replicative form, dRF 
= duplex repl icative form). 
2.5.3. Transgene expression 
After confirmation of functional replication and transcription of expanded parvoviral 
replicon vectors, transgene expression of expanded parvoviral replicons was evaluated. 
293-T cells were transfected with l.3 x 105 plasmid copy numbers of MVMp+/luc, 
MVMp+l1ucl+6 and M Mp+/luc/+13 per cell. Cells were co-transfected with p V-Gal 
for correction of differences in transfection efficiency. 24, 48 and 72h after transfection , 
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transfected cells were analyzed for transgene expressIOn (F ig. 29) . 24h after 
transfection, luciferase activity in pUC-MVMp+/luc transfected cell s was 5.3 1 ± 0.5 1 x 
108 RLU/mg protein/~-Gal. At the same timepoint, luciferase activ ity was 2.89 ± 0.29 x 
107 RLU/mg protein/~-Gal in pUC-MVMp+/luc/+6 transfected cell s and 1.64 ± 0.26 x 
107 RLU/mg proteinJ~-Gal in pUC-MVMp+/ luc/+ 13 transfected ce ll s. 48h after 
transfection, luciferase activity after transfection wi th pUC-MVMp+/1uc increased to 
9.78 ± 0.85 x 108 RLU/mg protein/~-Ga1. Also in expanded parvovira l rep li con vectors, 
an increase in luciferase activity was observed. Luciferase activi ty in pU -
MVMp+/lucl+6 transfected cells was 6.53 ± 0.45 x 107 RLU/mg prote irv'~-Ga l and in 
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Figure 29: Transgene expression afte ~ tra~sfectio~ with expanded parvoviral replicon 
vectors. 293-T cells were transfected with wlldtype-slzed and expanded parvoviral replicon 
vectors . Co-transfection was performed with pSV-Gal for correction of differences in transfection 
efficiency. 24 , 48 and 72 h after transfection, cells were analyzed for luciferase expression 
( 0 = pUCMVMp+, ~ = pUC-MVMp+lluc/+6kb,. = pUC-MVMp+lluc/+13kb) 
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pUC-MVMp+/luc/+13 transfected cells 6.69 ± 0.37 x 107 RLU/mg proteinlp-Gal. 72h 
after transfection, transgene expression slightly decreased. In pUC-MVMp+/luc 
transfected cells, luciferase activity was 2.61 ± 0.03 x 108 RLU/mg protei nip-Gal. At 
the same time point, luciferase activity in pUC-MVMp+/luc/+6 transfected cells was 
3.93 ± 0.2 x 107 RLU/mg proteinlp-Gal and in pUC-MVMp+/luc/+13 3.35 ± 0.2 x 107 
RLU/mg protei nip-Gal. Comparison between wildtype-sized and expanded parvoviral 
replicon vectors shows that expansion to 255% of the wildtype size results in 18.3, 14.9 
and 6.6-fold reduction of transgene expression levels at 24, 48 and 72 h after 
transfection. Expansion up to 355% results in reduction of transgene expression of 
factor 32.4, 14.6 and 7.7 at 24, 48 and 72 h after transfection. 
2.5.4. Summary 
The results of these studies demonstrate that expansion of parvoviral genome up to 
355% of the wildtype size is tolerated if being used as non-viral replicon vectors. 
However, the increase in genome size does result in decreased replication rates. Also, 
expanded replicon vectors achieve high-level transgene expression. However, 
expression levels are reduced up 30-fold in comparison to normal size MVM replicon 
vectors. 
2.6. Pan'oviral replicons in comparison to other expression systems 
In permissive cells, parvoviral replicon vectors provide high-level transgene expression 
due to their persistent replication and amplification through NS I-mediated 
transactivation of the P38-promoter, which regulates transgene expression in the 
MVMp+-based vectors. In order to compare their expression potential and pattern, 
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parvoviral replicon vectors were compared with other replicating and non-replicating 
expression plasmids chosen for their ability to provide high-level transgene expression. 
These included pCi-tuc, a non-replicating plasmid expressing luciferase under the 
control of an enhanced CMV promoter, as well as the replicating expression plasmid 
pCEP4/1uc. pCEP4/luc is based on EBV and contains the EBV sequences DriP and 
EBNA-I which facilitate plasmid replication. pCEP41luc expresses luciferase under the 
control of the CMV promoter. Cotransfection of the beta-gal expressing plasmid pSV-
GAL was performed in order to correct for differences in transfection efficiency. 
Transfection of MRC-5 cells with pCi-tnc resulted in maximum luciferase activity 24h 
after transfection with 1.42 ± 0.52 x 108 RLU/mg protein/~-gal followed by a continous 
decrease of luciferase activity to 7.70 x 106 ± 2.45 x 106 RLU/mg protein/~-gal at 96h 
after transfection. Transfection with pCEP4/1uc resulted in relatively stable luciferase 
expression starting 24h after transfection with 6.59 ± 4.07 x 107 RLU/mg protei nip-gal 
followed by 1.22 ± 0.6 x 108, 7.51 ± 1.80 x 107 and 6.94 ± 3.82 x 107 RLU/mg 
protein/~-gal at 48, 72 and 96h after transfection. Transfection with pMVMp+/luc 
resulted in luciferase expression levels in the range of the negative control due to the 
non-malignant origin of the cell line. In the negative control group, luciferase 
expression fluctuated around 6 x 106 RLU/mg proteinlp-gal over the 96h time course. 
Maximum luciferase activity in pUC-MVMp+/luc transfected cells was 4.45 ± 0.5 x lOS 
RLU/mg protein/~-gal (Fig. 30 a). 
As shown in figure 30 b, transfection of A9 cells with pCi-luc results in luciferase 
expression up to 8.41 ± 0.12 x 107 RLU/mg protein/~-gal within the first 24h. 
Luciferase activity stayed stable during the following 24h, followed by a sharp decrease 
in luciferase activity to 3.91 ± 0.34 x 107 RLU/mg protein/~-gal after 96h. Transfection 
with pCEP4/1uc resulted only in low-Ievelluciferase activity up to 8.72 X 106 RLU/mg 
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Figure 30: Comparison of parvoviral repl icon vectors with replicating and non-replicating 
high-level expression vectors. MRC-5 (Fig. a) and A9 (Fig. b) cells were transfected with non-
replicating expression vector pCi-luc or repl icating parvoviral vector pMVMp+-luc or EBV-based 
vector pCEP4/1uc. Differences in transfection efficiency were corrected by co-transfection with 
~-Gal expressing plasmid pSV-Gal. 24, 48, 72 and 96h after transfection, transfected and 
untransfected cells (neg . centr.) were ana lyzed for luciferase expression (n=3) . 
( E3 = 24 h p.t. , 0 = 48h p.t. , 121 = 72h p.t., .= 96h p.t. ) 
proteil ~-gal. Transfection wi th the parvoviral replicon vector pUC-MVMp+/luc 
re ulted in increasing high-Ie el luc iferase expression. 24h after transfection , luciferase 
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activity was 3.59 ± 0.13 x 107 RLU/mg protein/~-gal. During the following 24h, 
luciferase activity increased 2.4-fold to 8.48 ± 0.42 x 107 RLU/mg protein/~-gal. 
Increase in luciferase activity continued with a further 2.4-fold increase to 2.02 ± 0.05 x 
108 RLU/mg protein/~-gal 72h after transfection. 96h after transfection, luciferase 
activity continued to increase with a luciferase activity of 2.5 ± 0.31 x 108 RLU/mg 
protein/~-gal. 
In summary, the results show that parvoviral expression plasmids provide high-level 
transgene expression with a continuously increasing transgene expression pattern. pUC-
MVMp+-Iuc replicon vectors achieved 2.81-fold higher expression levels than pCi-Iuc 
in permissive cells but protein expression was suppressed in non-malignant human 
cells. In comparison to the replicating expression vector pCEP4/1uc, pUC-MVMp+-Iuc 
demonstrated continuously increasing transgene expression following transfection. In 
contrast, pCEP4/luc achieved maximum expression levels 48 h after transfection 
followed by an approximately 40% decrease of trans gene expression. 
2.7. Tumor selectivity ofparvoviral replicon vectors 
Autonomously replicating parvoviruses such as MVM and HI are known for their 
oncoselectivity. It is unknown if their oncoselectivity is preserved if parvoviruses are 
used as non-viral, infectious DNA plasmids. Therefore, the following studies aimed at 
evaluating the tumor-selectivity of non-viral MVMp-based replicon vectors. 
Transformation of cells has been shown to sensitize them toward autonomously 
parvoviruses allowing parvoviral replication and expression. Therefore, normal cell 
lines (NIH-3T3, Wi38 and MRC-5) and their transformed derivatives (V 12-3T3, 
Wi38N13 and MRC-5Nl) were used for analysis. Parvoviral replicon vectors 
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MVMp+-GFP and MVMp+-Iuc were used for fluorescence microscopic analysis and 
quantification of oncoselectivity. Non-tumor selective expression vectors EGFP-N 1 and 
pCi-Iuc were used as controls for specificity of parvoviral tumor-selectivity 
As shown in figure 31, transfection of untransformed NIH-3T3 and Wi38 cells as well 
as transformed V12-3T3 and Wi38N13 cells with EGFP-Nl resulted in strong GFP 
expression. In contrast, no GFP-expression was observed after transfection of 
untransformed NIH-3T3 and Wi38 cells with MVMp+/GFP. However, transfection of 
their transformed derivatives V12-3T3 and Wi38N13 with pUC-MVMp+/GFP resulted 
in strong GFP-expression. 
Transformation of MRC-5 cells and Wi38 with MVMp+/luc resulted in sensitization to 
parvoviral replicon mediated transgene expression (Fig. 32). 24h after transfection, 
luciferase activity in MRC-S cells was 8 RLU/~-Gal compared to 7151 RLUI ~-Gal in 
MRC-SNI cells. 48h after transfection, luciferase activity in MRC-S cells was 
relatively unchanged with 16 RLU/p-Gal compared to increasing transgene expression 
with 8614 RLUI ~-Gal in MRC-5NI cells. 24h later, luciferase activity was 47 RLUI P-
Gal in MRC-5 cells and in MRC-SNI cells had continued to increase to 12393 RLU/ P-
Gal. Similar results were obtained in Wi38 and their transformed counterpart 
Wi38N13. 24h after transfection, luciferase activity in Wi38 cells 8 RLUI p-Gal, and in 
Wi38N13 cells 8526 RLUI p-Gal. Luciferase activity 48h after transfection was stable 
at 8 RLU/ p-Gal in Wi38 cells and increased to 15622 RLU/ p-Gal in Wi38N13 cells. 
nh after transfection, luciferase activity in Wi38 cells was 119 RLUI p-Gal and in 
Wi38/V 13 24949 RLU/ ~-Gal. 
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Figure 31: Tumorselectivity of parvoviral replicon vectors. Untransformed NIH-3T3 and 
Wi38 cells were transfected with parvoviral repl icon vector pUC-MVMp+/GFP or expression 
plasmid EGFP-N1. 48 h after tra~sfection , cells were analyzed by fluorescence microscopy for 
GFP-expression. For demonstration of background fluorescence , untransfected cells are shown 
(bottom row). As a positive c~ntro l, cells were transfected with EGFP-N 1 (middle row) . Top row 
shows normal cells and their transformed counterparts transfected with parvoviral repl icon 
vector pUC-MVMp+-GFP. 
These results confi rm the results of the first experiment uSlllg pUC-MVMp+-GFP. 
Tran fOffilation of cell lines MRC-5 and Wi38 resulted in their sensitization toward 
par 0 iral replicon vectors. Comparison between normal cells and their transformed 
counterparts shows that transfection with parvoviral replicon vectors results in up to 
893.9-fo1d higher transgene expression in MRC-5/V 1 cells compared to MRC-5 cells, 
and up to 1952.8-fold higher transgene expression in Wi38 13 cells compared to Wi38 
cell . 
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Figure 32: Tumorselectivity of parvoviral replicon vectors. Untransformed MRC-5 and Wi38 
cells and their transformed counterparts MRC-5N1 and Wi38N13 were transfected with 
parvovira l replicon vector pUC-MVMp+-luc. For correction of differences in transfection 
efficiency, cells were co-transfected with ~-Gal expressing pSV-Gal. 24, 48 and 72 h after 
transfection, luciferase activity was analyzed . a) Cell lines MRC-5 and MRC-5N1 . b) Cell lines 
Wi38 and Wi38N13 . 
( • = normal cell line, 0 = transformed cell line) . 
In summary, no significant transgene expression was observed in normal cells after 
transfection with parvo iral replicon ectors. Transformation of normal cells re ulted in 
en itization to\ ard parvo iral replicon vectors with high-level transgene expression. 
The e re ult demon trate that tumor selectivity is conserved if parvoviral vectors are 
used a replicating, double- tranded DNA expression plasmids. 
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2.8. l\IVl\I-replicon cytotoxicity 
Parvovirus MVM is known for its tumor-selective cytotoxicity. A key mediator of 
parvoviral cytoxicity is the NS 1 protein shown to cause cytoskeletal changes and to 
interfere with intracellular signaling pathways resulting in cytopathic effects and cell 
death 161. 445-4~7. Maintenance ofNS 1 integrity was therefore hypothesized to enable also 
parvovirus MVM replicons to elicit a cytopathic effect on susceptible target cells. For 
the evaluation of cytotoxicity, A9 and 293-T cells were chosen based upon their 
susceptibility toward parvoviral cytotoxicity. Using lipotransfection, 2x 104 cells were 
transfected with 2xlO lO plasmid copy numbers of pUC-MVMp+/luc or one of its 
expanded derivatives pUC-MVMp+/luc/+6 and pUC-MVMp+/luc/+ 13. As a control, 
cells were transfected with the non-toxic, non-replicating plasmid pCi-Iuc. Cell viability 
was analyzed by MTS-assay 24, 48, 72 and 96h after transfection. Viability of 
transfected cells was assessed in correlation to viability of untransfected A9 and 293-T 
cells. 
The data show that none of the parvoviral replicon vectors elicited a cytotoxic effect on 
transfected cells. Viability of MVM-transfected cells fluctuated between 99.3±16.7% 
and 162.3±37.3% ofuntransfected cells over the time course of96h (Fig. 33). Statistical 
analysis showed no significant difference in viability of cells transfected with parvoviral 
versus non-parvoviral plasmids (p>0.05). 
In summary, parvoviral replicon vectors do not maintain the cytotoxic potential of the 
parental virus. 
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Figure 33: MVM replicon cytotoxicity. Cells were transfected with pCi-luc as a control , or with 
one of the MVM-replicons pUC-MVM, pUC-MVM/+6 or pUC-MVM/+13. 24 , 48, 72 and 96h after 
transfection (p .t.) , cell viability was measured using MTS-assay. Viabi lity is shown as percent of 
untransfected cells. A) Viabili ty of A9 cells, B) viability of 293-T cells . (n=16 , shown are average 
values with standard deviation). (0 = pCi-luc, 0= pUC-MVMp+-luc,.= pUC-MVMp-luc/+6, ~= pUC-MVMp-luc/+ 13) 
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3. Viral gene therapy using recombinant measles virus 
3.1. Introduction 
The results of this thesis have shown that current non-viral gene delivery systems are 
suboptimal vectors for systemic gene transfer due to their low transduction efficiencies 
and poor intratumoral biodistribution. Parvoviral replicon vectors were developed for 
encapsidation in non-viral gene delivery systems. However, the parvoviral data show 
that their use as plasmids is impaired by decreasing replication and gene expression 
with genome size expansion, contradicting one of the originally hypothesized 
advantages of such a system. Further, wildtype parvovirus typical cytotoxicity was lost. 
Maintained were the ability for replication and the tumorselectivity. However, 
comparison with existing gene expression systems showed only 2.8-fold higher 
maximum expression levels through the use of parvoviral replicons. Therefore, the 
focus of this thesis was shifted toward viral therapeutic systems. Oncolytic measles 
virus has proven its tumor suppressive potential in several human malignancies. 
However, its potential for HCC has never been evaluated. Therefore, recombinant, 
oncolytic measles virus was selected for evaluation of its potential as a therapeutic 
vector for HCC. 
Three different recombinants of measles virus were used, all of them based on the 
Edmonston strain of measles virus (MV-Edm) and genetically modified to express 
different transgenes as previously described: CEA-expressing measles virus (MV-
CEA), GFP-expressing measles virus (MV-eGFP) and NIS-expressing measles virus 
(MV-NIS) (Fig. 34). 
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Figure 34: Schematic representation of recombinant MV-Edm. Schematic representation of 
the genome of recombinant MV-Edm constructs showing the coding regions for viral proteins 
and the intergenic regions. N, nucleoprotein gene ; P, phosphoprotein gene; M, matrix protein 
gene; F, fusion protein gene ; H, hemagglutinin gene; L, polymerase gene. The P cistron 
encodes two additional proteins: C protein and V protein . Figure a) is an overview of the 
genome of recombinant MV-Edm coding for the human carcinoembryonic antigen (hCEA) as 
described previously (Peng et aI. , 2002). Figure b) shows the genome of recombinant MV-Edm 
encoding enhanced green fluorescent protein (eGFP) as described previously (Duprex et aI. , 
2000). Below in figure c) , the genome of recombinant MV-Edm coding for the human sodium 
iodide symporter (NIS) is shown , as described previously (Ding Ii et aI. , 2002) . 
3.2. Human HCC express high levels of CD46 
MV-Edm induced syncytia formation requires CD46 overexpresslOn. Therefore, the 
initial studies focused on the evaluation of CD46 expression by human HCC cell lines 
compared to primary human hepatocytes, and in intraoperatively obtained human HCC 
tumor samples. CD46 expression levels of human HCC cell lines, HUH-7 and Hep-3B, 
and primary human hepatocytes were analyzed by flow cytometry. Human HCC cell 
lines express high levels of CD46 compared to primary human hepatocytes. In 
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comparison to isotype control, a 2.68-fold increase in median fluorescencnce in primary 
human hepatocytes incubated with a FITC-Iabeled monoclonal anti human D46 
antibody was observed. In HUH-7 cells, the increase in median fl uorescence was 17.47-
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Figure 35: CD46-overexpression in HCC in comparison to normal hepatic tissue. Figure a) 
shows high expression of the CD46-receptor on human HCC cell lines HUH-7and Hep-38 but 
low expression on primary human hepatocytes. Analysis was performed by flowcytometry using 
a monoclonal CD46-antibody (red histogram: anti-CD46 FITC antibody; green histogram: 
isotype control). b) Immunofluorescence for CD46-receptor in HCC-tissue samples and non-
malignant hepatic tissue using a anti-human CD46 primary antibody and a fluorescein 
isothiocyanate-conjugated secondary antibody. The arrows highlight the border between normal 
hepatic tissue and tumor-tissue. 
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fold and in Hep-38 cells 16.36-fold (Fig. 35a). CD46 expression in HCC in comparison 
to non-malignant hepatic tissue was analyzed by immunohistochemistry in human 
hepatic tissue samples of HCC patients (n = 3). As shown in Fig. 35b, CD46 is 
overexpressed in HCC-tissue compared to surrounding normal hepatic tissue. This 
result was confirmed in 100% of analyzed human tissue samples. 
3.3. Infectivity, syncytia formation and cytotoxicity of MV-Edm in HCe 
To determine the infectivity of recombinant MV-Edm on human HCC cell lines, HUH-
7 and Hep-38 cells were infected with MV-eGFP at an MOl of 0.05 and 0.5. Fig. 34b 
shows a schematic diagram of the full-length construct of MV-eGFP 40tH. Analysis using 
light- and fluorescence microscopy was performed every 24h over a total time of 120h. 
All human HCC cell lines were successfully infected by MV-eGFP (Fig. 36a). As early 
as 24h after infection, GFP-expression was observed in infected cells even at a low 
MOl of 0.05. Infection of human HCC cell lines with MV-eGFP resulted in fusion of 
infected cells with neighboring cells (Fig. 36a). Syncytia formation was more dramatic 
and showed a faster kinetic in Hep-38 cells compared to HUH-7 cells. In Hep-38 cells, 
large size syncytia were detected already 48h after infection followed by almost 
complete eradication of the cell layer after 96h. In HUH-7 cells, infected cells as well as 
small size syncytia were observed which expanded over the next 48h in size and 
number. 
MV-Edm mediated ePE on HCC cells was quantified. Hep-38 and HUH-7 cells were 
infected with MV-eGFP at MOl 0.05 and 0.5. Analysis was performed every 24h over a 
total time course of 120h using crystal violet staining and CellTiter 96 AQueous 
nonradioactive cell proliferation assay. On both cell lines, recombinant MV-Edm 
elicited a strong CPE in a MOl dependent manner (Fig. 36b and c). Differences between 
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Figure 36: Infectivity, syncytia-induction and CPE of MV-Edm in HCC. a) Human HCC cell 
lines HUH-7 and Hep-3B were infected with MV-eGFP at an MOl of 0.5. Serial fluorescence 
microscopic analysis was performed every 24h . The figu re shows GFP-expression and syncytia 
formation in human HCC cells 48 and 96h after MV-GFP infection . Fig. b) and c) show the CPE 
of recombinant MV-Edm on human HCC cell lines HUH-7 and Hep-3B . HCC cells were infected 
with MV-Edm at MOl of 0.05 and 0.5. Serial analysis for cytotoxicity was performed every 24h . 
Fig. b) shows crystal vi~ let staining of i nfe~te~ .cells 96h after infection with recombinant MV-
Edm. Fig. c) shows the time course of cell Viability of HCC cells after infection with recombinant 
MV-Edm as analyzed by CeliTiter 96 AQueous nonradioactive cell proliferation assay kit (n=8). 
( • = Neg. contr., 0 = MOl 0.05, 0 = MOl 0.5). 
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the two cell lines were observed in the total susceptibility and kinetics of cell killing. In 
Hep-3B cells reduction of viability was observed within the first 24h. 72h after 
infection, viability of Hep-3B cells was reduced to 14.9% at MOl 0.5 and to 54% at 
MOl 0.05. In HUH-7 cells, the cytotoxic effect of MV-Edm started 48h after infection 
at MOl 0.5. 120h after infection of HUH-7 cells with MV-eGFP cell vialility had 
decreased to 41 % at MOl 0.5 and 77.2% at MOl 0.05. 
3.4. ~teasles virus induces apoptosis in Hee 
Measles virus infection of HCC cell lines results in syncytia formation followed by cell 
death. The mechanism of syncytia-induced cell death can either be apoptosis or a 
bioenergetic form of cell death with necrosis. The mechanism of measles vims induced 
cell death in HCC cell lines has never been evaluated. Aim of the following studies was 
the evaluation of MV-Edm induced cell death following syncytia formation. 
3.4.l. Optical analysis by TUNEL and DAPI-stain 
Human HCC cell lines HUH-7 and Hep3B were infected with MV-eGFP at a MOl of 
0.05. Cells were evaluated every 24h for apoptosis by DAPI- and TUNEL-staining for a 
total time period of 96h. The results of these experiments are shown in Fig. 37. 24h 
after infection first morphologic signs of apoptosis were noted by TUNEL as well as by 
DAPI-stain. Maximum number of cells undergoing apoptotic morphologic changes was 
observed 48h after infection. At later time points, the majority of cells were not viable 
anymore and apoptotic signals had decreased. 
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Figure 37: MV-Edm indu~ed apoptosis. Human HCC cell lines Hep-3B and HUH-7 were 
infected with GFP-expresslng MV-eGFP at a MOl of 0.05. 24h after infection, cells were 
analyzed for apoptosis by TUNEL-staining . Figure 37. shows fluoscence microscopic analysis of 
treated cells. Green fluorescence indicates GFP-expression . Blue fluorescencent structures are 
DAPI-stained DNA. Red fluorescence indicates TUNEL-positive cells . A) Negative control 
showing nuclear DAPI-staining and GFP-expression. B) Overlay image of GFP-expression and 
TUNEL-stain. C) TUNEL-stain of untreated cells . D) TUNEL-stain of MV-Edm treated cells . 
3.4.2. Caspase 317-activity after MV-Edm infection 
For confirmation of apoptosis induction following MV-Edm induced syncytia 
fo rmation, activity of caspase 3 and 7 was evaluated. Hep-3B cells and HUH-7 cell s 
were infec ted with MV-eGFP at a MOl of 0.05. 24h after infection, caspase activity was 
analyzed (Fig. 38). Un infected cells served as negative control. For a positive control , 
cells were treated with TRAIL (1 00 ng/ml) and actinomycin D (0.5 ~lg/ml) . For 
confirmation of caspase activitation, MV-Edm and TRAIL-actinomycin 0 were 
cotreated with the caspase inhibitor zV AD-FMK (1 00 ~M) . 
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Figure 38: Caspase 317 activity after MV-Edm infection. HUH-7 cells were treated with 
apoptosis inducers TRAIL (100 ng/ml) and actinomycin 0 (0.5 ~lg/ml) or infected with MV-Edm 
(MOl 0.05). Untreated cells were used as a negative control. Cotreatment was used for 
apoptosis-inhibition. After 24 and 48h cells were analyzed for caspase 3/7 activity . a) 24h post 
infection, b) 48h post infection. 
( l.; = neg. contr., • = MV-Edm, = MV-Edm+ZVAO, • = TRAIL +actinomycin 0 , 
Q = TRAIL +actinomycin D+ZVAD) 
24h after treatment, caspase 3/7 activity in the negati e control wa 3920.3 ± 119.5 
RLU. In comparison, activity in MV-Edm infected cells was 6641 . 1 ± 386.6 RLU. 
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Activity of the positive control was 7147.6 ± 483.0 RLU. Treatment with caspase 
inhibitor resulted in decrease of caspase 3/7 activity in MV-Edm treated cells to 6276.8 
± 451.8 RLU and in the positive control to 956.0 ± 57.6 RLU. 48h after treatment, 
caspase 3/7 activity in the negative control group was 3855.4 ± 62.3 RLU. Activity in 
MV-Edm infected cells had increased to 23565.6 ± 559.6 RLU. Activity decreased to 
12783.6 ± 574.9 RLU with caspase inhibitor cotreatment. TRAIL-actinomycn D 
treatment caused an increase in caspase 3/7 activity to 7443.1 ± 238.3 RLU which 
decreased to 3943.9 ± 18.2 RLU with caspase inhibitor cotreatment. 
In summary, MV-Edm infection increased caspase 3/7 activities 1.7-fold compared to 
untreated cells 24h after infection. This induction increased to 6.I-times 48h after 
infection. In comparison, treatment with apoptosis inducers TRAIL-actinomycin D 
resulted in a 1.8- and 1.9-fold increase at the same time points. 
3.4.3. Summary 
The results of these studies demonstrate that MV-Edm induced syncytia formation is 
followed by apoptosis in human HCC cell lines. The potency of this activation exceeds 
the stimulus achieved by strong apoptosis inducers such as TRAIL and actinomycin D. 
3.5. Transgene expression in M:V-Edm infected human Hee cell lines 
In order to monitor virus spread and location of infected cells we evaluated recombinant 
measles viruses expressing CEA and hNIS. Fig. 34 shows schematic diagrams of the 
full-length constructs of MV-CEA and MV-NIS 107.304. 
2 X 105 HUH-7 and Hep-3B cells were infected with MV-CEA at a MOl of 0.05 and 
0.5. Supernatant was collected every 24h for a total time period of 72 hours and 
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analyzed for CEA concentration (Fig. 39a). CEA was detected within the first 24h after 
infection in both cell lines and continuously increased over the following 48h. In detail, 
24h after infection CEA concentration in Hep-38 cell supernatant was 7.05 ng/ml at 
MOl 0.5 and 0.42 ng/mt at MOl 0.05. At 72 hours after infection, CEA concentrations 
had increased to 693.3 ng/ml at MOl 0.5 and 44.03 at MOl 0.05. In supernatant of MV-
CEA infected HUH-7 cells CEA concentrations were 8.5 ng/ml at MOl 0.5 and 0.8 
ng/ml 24h at MOl 0.05 24h after infection, and increased to 6951.7 ng/ml at MOl 0.5 
and 691 ng/ml 72h after infection. 
HUH-7 and Hep-38 cells were infected with MV -NIS at MOl 0.01, 0.1 and 1.0. 24, 48 
and 72h after infection, cells were incubated with Ix106 mCi 1251 for 1 h at 37°C 
followed by analysis of isotope uptake. In Hep-38 cells, infection with MV-NIS 
resulted in a MOl-dependent uptake of 1251 with a maximum uptake of 1617 cpm at a 
MOl of 1.0 at 24h post infection (Fig. 39b). At later time points, vims infection had 
eradicated the cell layer to an extent that overall uptake was reduced. In HUH-7 cells, 
maximum uptake with 1296.7 cpm was observed 48h after infection at MOl 0.01. In the 
following 48h activity decreased at MOl 0.1 and 1.0, but increased at MOl 0.01. 
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Figure 39: Transgene expression in human HCC cell lines after infection with MV-CEA 
and MV-NIS. Hep-38 and HUH-7 cells were infected with MV-CEA or MV-NIS at different MOls 
and analyzed for transgene expression. Fig. a) shows the time course of CEA-concentration in 
the supernatant of MV-CEA infected Hep-38 and HUH-7 cells . Data points are mean values 
with standard deviations (n=6). Data of negative controls are shown as black bars, Mal 0.05 
infected cells as w.hite bars and Mal 0.5 i~fected .cells .as 1~lay bars. Fig . b) shows isotope 
activity in MV-NIS Infected HCC cells after incubation with I. Shown are mean values with 
standard deviations (n=3). In order to show NIS-mediated 1251_uptake controls co-treated with 
KCI04 were used. 
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3.6. Intratumorall\1V-Edm therapy in human HCC-xenografts 
In order to evaluate the potential of recombinant MV-Edm for therapy of HCC, MV-
CEA was tested in ill vivo using a subcutaneous human HCC xenograft mouse model. 
Hep-38 cells and HUH-7 cells (5x106 cells/mouse) were implanted in the right flank of 
nude and SCID mice. When maximum tumor diameters measured approximately 0.5 
em, each mouse was treated with a total offive doses of MV-CEA (lxl07 TCID50) or an 
equivalent dose of UV -inactivated MV -CEA by intratumoral injection for 10 days. 
In mice bearing Hep-38 tumor xenografts, median survival of MV-CEA treated mice 
was 58 days, and median survival of mice of UV -inactivated MV -CEA treated mice 
was 33 days. This is a significant increase of median survival of MV-CEA treated mice 
of factor 1.75 compared to the control group (p=0.0015) (Fig. 40b). All mice of the 
control group had to be euthanized by day 48 according to IACUC protocol criteria. In 
the MV -CEA treated group, complete tumor regression was observed in one third of 
treated mice. In mice bearing HUH-7 tumor xenografts, median survival of MV-CEA 
treated mice was 34 days, and for mice treated with UV-inactivated MV-CEA median 
survival was 19 days. This is also significant increase of median survival of MV-CEA 
treated mice of factor 1.79 compared to the control group (p=0.004) (Fig. 40b). In both 
HCC cell line xenografts, the response first became apparent at day 10, the last day of 
therapy, and increased over time (Fig. 40a). 
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Figure 40: Tumor-suppression and survival after intratumoral MV-CEA therapy of HCC-
xenografts. Mice bearing s.c. HCC-xenografts (HUH-7, Hep-38) were injected intratumorally 
with 2x106 TCIDso of MV-CEA every other day for a total of 5 injections (= 1 x1 07 total 
TCIDso/mouse). The groups consisted of 9 mice/group. Treatment groups received active MV-
CEA the negative control mice UV-inactivated MV-CEA. In Fig . a) development of tumor 
volu~e after initiation of MV-CEA therapy is shown. The datapoints are medians with standard 
error. Tumor volume of MV-CEA treated mice is shown as solid line , tumor volume of UV-
inactivated MV-CEA treated mice is shown as dashed line. The graph ends at the time point at 
which the first mouse had to be euthanized. In Fig. b) survival curves are shown for treated 
mice (solid line) and negative control mice (dashed line). 
At the end of the studie , tumors were excised and analyzed hi stologically. Measle 
vims therapy resulted in extensive syncytia formation as shown in fi gure 41. 
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Figure 41 : Syncytia formation after intratumoral MV-Edm therapy. Mice bearing 
subcutaneous Hep-38 tumor xenografts were treated with a single intratumoral dose of MV-
CEA at a TCID50 of 2x1 06 per animal. Three days after therapy tumors were harvested and HE-
stained followed by histologic analysis . Figure 41 shows extensive syncytia formation . 
3.7. Non-invasive il1 vivo monitoring after MV-CEA therapy of HC 
In order to evaluate the potential of recombinant measles virus for non-invasive ill vivo 
monitoring, MV-CEA was tested in a subcutaneous human HCC xenograft mouse 
model. Hep-3B cells and HUH-7 cells (5x 1 06 cells/mouse) were implanted in the right 
flank of nude and SCID mice. When maximum tumor diameters measured 
approximately 0.5 em, each mouse was treated with a total of five doses of MV-CEA 
(lx107 TC1D5o) or an equivalent dose of UV-inactivated MV-CEA for 10 days by 
intratumoral injection. 
CEA was detected in MV-CEA treated but not in UV-inactivated MV-CEA treated 
mice. In both, Hep-3B and HUH-7 HCC-xenograft models serum E concentrations 
could be detected as early as 5 days after initiation of therapy and increa ed over time. 
In Hep-38 enografts model , CEA concentrations reached a maximum of 312.3 ng/ml 
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at day 35. In HUH-7 xenografts a maximum of 10360 ng/ml was reached at day 12. 
Following these maximum CEA concentrations, the mean CEA-Ievels started to 
decrease. 
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Figure 42: Serum CEA concentrations after intratumoral MV-CEA therapy of HCC-
xenografts . Mice bearing s.c. HCC-xenografts (HUH-7, Hep-38) were injected intratumorally 
with 2x106 TCIDso of MV-CEA every other day for a total of 5 injections (= 1 x1 07 total 
TCIDso/mouse). The groups consisted of 9 mice/group . Treatment groups received active MV-
CEA, the negative control mice UV-inactivated MV-CEA. The graphs represent the course of 
serum CEA concentration in HCC xenograft bearing mice after MV-CEA therapy . 
3.8. Non-invasive il1 vivo imaging after MV-N1S therapy of HCC 
HUH-7 cells were implanted subcutaneously in SC1D and nude mice as described 
above. Once tumors were 0.5 cm in diameter, mice were injected intravenously via the 
tail ein with a single dose of 2x 1 06 TCID50 of MY -NIS or an equivalent dose of UY-
inacti ated MV-NIS. 7 and 14 days after MY-NI treatment, mice were injected 
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Neg. MV-NIS 
Figure 43: Increased 1231_uptake in HCC-tumors after intravenous MV-NIS therapy. Fig a): 
Mice bearing subcutaneous HUH-7 tumor xenografts received a single i.v. injection of 2x106 
TCIDso of MV-NIS. 7d and 14 dafter MV-NIS treatment 0.5 mCi 12 I was injected 
intraperitoneally. 1h after application of the isotope, animals were analyzed by whole body 
gamma-camera imaging. Tumors , located at the right flank of the mice, show increased activity 
at the tumor site indicating 123 1 uptake. This uptake is not observed in the negative control 
mouse . Other organs showing activity are thyroid , stomach and bladder. 
intraperitoneally with 1131 (500 !lCi/mouse) and analyzed one hour later for isotope 
uptake using whole body gamma-camera imaging. As shown in Fig. 43 , in MV-NI 
treated animals we ob erved a strong signal of the HCC tumors indicating high 
intratumoral uptake of 1231; dosimetric analys is quantified intratumoral isotope 
accumulation as 7.7% of whole body activity. In contrast, UV-inactivated MV-N IS 
treated mice did not concentrate 1231 intratumorally. Viral gene expre sion and viral 
replication are tightly coupled. Serial iodide uptake tudies can be expected to reflect 
IS expression and serve as a surrogate of MV-N IS replication 304 . Therefore, we 
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repeated the experiment as described above and performed serial imaging analysis 3, 7, 
10 and 14 days after a single dose treatment with MV-NIS. The serial imaging analysis 
showed that iodide uptake changed over time with a maximum uptake between day 7 
and 10. Interestingly, in Hep-38 xenografts only minimal iodide uptake was observed at 
day 3 (data not shown). 
3.9. Intravenous l\1V-Edm therapy of human HCC-xenografts 
The next aim was to evaluate the tumor suppressive potential of recombinant MV-Edm 
after intravenous therapy. Hep-38 and HUH-7 tumor xenografts were implanted as 
described above. Therapy was initiated once tumors reached 0.5 cm in diameter. 
Therapy regimen consisted of 5 doses of 2xl06 TCIDso MV-NIS every other day; 
injection was performed intravenously via the tail vein. Mice of the control group were 
treated with equivalent doses of UV-inactivated MV-NIS. In the Hep-38 xenograft 
model, median survival of control mice was 15 days compared to 41 days in the 
treatment group (Fig. 44). This is a significant increase of median survival of factor 2.7 
(p<O.OOO I). At day 22 all of the mice of the control group had to be sacrificed. In the 
MV -NIS treated group, we observed 10% complete regression. In the HUH-7 tumor 
model, median survival in the control group was 8 days. In the treated group, median 
survival was 12 days. Intravenous MV-NIS treatment resulted in increase of median 
survival of factor 1.5 in HUH-7 xenografts (p=O.OO 18). 
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Figure 44: Tumorsuppression In HCC-tumors after intravenous MV-NIS therapy. Mice 
bearing s.c. HCC-xenografts (HUH-7, Hep-3B) were injected intravenously with 2x106 TCIDso of 
MV-NIS every other day for a total of 5 injections (= 1x107 total TCIDsolmouse). The groups 
consisted of 10 mice/group. Treatment groups received active MV-NIS, the negative control 
mice UV-inactivated MV-NIS. Survival curves are shown for treated mice (solid line) and 
negative control mice (dashed line). 
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IV. Discussion 
1. Nonviral gene delivery systems 
In this thesis, a variety of published non-viral strategies were evaluated. The most 
efficient of these approaches were chosen for further analysis, and global collaborations 
with worldwide-leading laboratories specialized in non-viral gene delivery systems 
established. Independently, synthesis of these carriers was established and their efficacy 
evaluated in vivo. The main findings of these studies are: 1. direct, intratumoral DNA 
injection is the only physical in vivo transfection method achieving significant 
intratumoral transgene expression levels, but is limited for cancer gene therapy by its 
low biodistribution, 2. pegylated, PEl-based polypi exes as well as stabilized plasmid 
lipid particles achieve specific and high levels of intratumoral trans gene expression 
after systemic administration but are limited by their low intratumoral biodistribution. 
The first study within this thesis evaluated trans gene expression after intravenous 
injection of unconjugated plasmid DNA. Transgene expression levels were very low 
with luciferase activity between 0-500 RLU/g tissue. Highest expression levels were 
observed in lung tissue. These results confirm previous observations. Kawabata et al. 
had shown that the degradation of plasmid DNA exposed in vitro to whole blood results 
in a DNA half-life of 10 min and even faster degradation rates were observed after 
intravenous injection of plasmid DNA 319. These results prompted further 
biodistribution studies showing that large amounts of DNA were taken up by hepatic 
endothelial and Kupffer-cells followed by its degradation 449,450, The early, relatively 
high pulmonary trans gene expression is also consistent with other reports showing 
relatively high accumulation of intravenously administered DNA in the lungs, and the 
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observation that DNA uptake in lungs results in transient gene expression, while hepatic 
uptake results only in its degradation. 319. Hence, the results of this thesis are consistent 
with these observations. However, overall expression levels are extremely low and are 
hardly above background activity. 
Plasmid DNA exposed in vitro to whole murine blood has a half-life of 10 min and in 
vivo of less than 5 min 319. 60% of intravenously administered plasmid DNA 
accumulates in the liver within the first minute following administration 450. Hence, it 
was hypothesized in this thesis that circumvention of liver and lung circulation should 
decrease hepatic uptake as well as pulmonary filtration of administered DNA resulting 
in higher systemic plasmid DNA concentration and thereby higher gene delivery to 
tumor-tissue. The route of administration was shown to influence biodistribution; while 
intravenous injection of recombinant adenoviral vectors resulted mainly in hepatic 
transduction, injection into the left cardiac ventricle achieved transduction mostly in 
cardiac, thymus, intercostal muscles and diaphragm 451. Results of this thesis show that 
arterial injection via left cardiac ventricle achieves 2 to 46.5-times higher transgene 
expression levels than intravenous plasmid DNA injection. The highest transgene 
expression was observed in cardiac lysates. This observation is most likely explained by 
an accidental direct myocardial injection on the injection route. Myocardial plasmid 
injection has been shown to result in trans gene expression 452. However, intratumoral 
transgene expression was only doubled compared to intravenous administration and 
overall expression levels were very low. The low tumor transduction efficiency is likely 
due to persistence of remaining biologic barriers such as serum nuclease-mediated 
DNA degradation, inefficient extravasation, impaired transport through the extracellular 
marix, extracellular nuclease-mediated degradation, inefficient cellular uptake, cytosolic 
transport, cytosolic nuclease degradation and inefficient nuclear transport. 
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Hydrodynamic gene transfer was fIrst described by Liu et al. and Zhang et al. and is 
mostly used for gene delivery to the liver 352, 353. Liu et al. observed in their study 
transgene expression in all organs; expression levels were dependent on injection rate 
and volume 352. This observation was explained by reverse blood flow. Based upon this 
observation, it was hypothesized in this thesis that the reverse flow could also result in 
hydrostatic pressure-mediated reverse flow in efferent tumor vessels. The results of this 
thesis show that the highest transgene expression levels after hydrodynamic gene 
transfer are in the liver as well as in organs directly linked to the inferior vena cava. 
However, neither in tumor nor in brain tissue was trans gene expression detected. The 
differences in transgene expression are most likely anatomically explained. Organs such 
as liver, spleen, kidney and heart as well as their blood supply are directly connected to 
the inferior vena cava. In contrast, blood supply of a subcutaneous tumor is not directly 
connected but rather secondary to cutaneous blood supply. It is likely that the 
hydrostatic pressure is not high enough to result in a reverse blood flow in cutaneous 
vessels and especially not in tumor capillaries. It could be hypothesized that in an 
orthotopic HCC model, hydrodnamic gene transfer might be more efficient. However, 
Tada et al. have previously shown in an orthotopic HCC model in rats, that 
hydrodynamic gene transfer via the tail vein achieved only 0.16% gene transduction 
effIciency in tumor tissue but 5% in non-malignant hepatic tissue. Hydrodynamic gene 
transfer via the portal vein did not result in any trans gene expression, neither in tumor 
nor non-malignant tissue. The only route through which intra tumoral trans gene 
expression was achieved, was by hydrodynamic transfer via the hepatic artery and 
concurrent transient occlusion of portal vein and inferior vena cava; however, gene 
transfer was not specifIc to tumor tissue with transduction efficiencies of 7% in 
malignant and non-malignant hepatic tissue 453. 
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The feasibility of intratumoral injection of unconjugated plasmid DNA has been shown 
in several studies 454-456. The results of this thesis confirm its feasibility in HCC. 
Intratumoral treatment of subcutaneous HCC tumors with unconjugated plasmid DNA 
achieved the highest intra tumoral trans gene expression levels of the physical gene 
transfer methods evaluated in this thesis. Expression in other organs was minimal and 
hardly above background. The highest expression was observed 8h after treatment 
followed by a steady decline in luciferase activity. This decline was expected as a non-
replicating expression plasmid was used; however, even after 48h, luciferase activity 
was still significantly above the levels observed with the other physical gene transfer 
methods. 
In summary, physical gene transfer systems for unconjugated plasmid DNA are 
suboptimal for gene therapy of HCC. They achieve no to very low transduction 
efficiencies. The only significant transgene expression was achieved by direct 
intratumoral injection. This method could be used for cases where patients have single 
intrahepatic tumors but no signs of extrahepatic or multilocular intrahepatic spread. 
Failure of other physical methods confirms previous studies and is most likely 
explained by the above-discussed biologic barriers. An alternative method described in 
the literature but not evaluated in this thesis, would be selective catheterization of the 
hepatic artery as it has been used for gene therapy of other cancers 457. The main blood 
supply of the liver is provided by the portal vein, while HCC tumors are mainly 
supplied by the hepatic artery. However, evaluation of this approach were shown to be 
only effective if DNA was complexed to PEl and co-administered with an embolizing 
agent or if efferent vessels were occluded and DNA was administered under high 
. . h h' 453 458 A h " f . hydrostatIc pressure III t e epatIc artery . . s t e maJonty 0 HCC patIents have 
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multilocular and/or large tumors at the time of diagnosis, none of these physical 
approaches appears to have therapeutic potential for cytoreductive cancer gene therapy, 
Failure of the above discussed physical methods as gene therapy tools for HCC 
prompted evaluation of different conjugated DNA gene transfer methods, Based upon 
transfection efficiencies reported in the literature, one targeted and one non-targeted 
liposomal system as well as one targeted PEl-based systems were tested, The first 
system established and evaluated for this thesis was the LipT gene transfer system 389, 
435, This system describes a transferrin-receptor targeted, cationic liposomal system 
using cationic DOTAP and the neutral, fusogenic lipid DOPE, LipT complexes were 
described to achieve 20-30% transfection efficiencies in a subcutaneous human head 
and neck cancer xenograft model in mice after treatment with a single dose systemically 
administered by tail vein injection 389, For studies in the context of this thesis, LipT 
complexes were evaluated in the subcutaneous N2A murine neuroblastoma xenograft 
model. No transgene expression was observed after systemic treatment with LipT 
complexes. Potential explanations for the discrepancy between the results of this thesis 
and the published data include the use of a different tumor model or unidentified 
technical difficulties in LipT synthesis. The N2A murine neuroblastoma model is a 
frequently used model for evaluation of non-viral gene delivery models. Transferrin-
ligand has been used successfully for targeting this tumor model 459, Differences could 
also be explained by anatomical differences such as desmoplasticity, extent or structure 
of tumor vessels. However, the N2A model has successfully been used for a variety of 
different non-viral gene transfer models including the ones evaluated in this thesis, 
showing its general amenability to transfection. The components of the LipT 
complexes, such as DOT AP and DOPE, are commonly used lipids in liposomal 
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formulations and have successfully been used in lipoplex mediated in vivo gene transfer 
460. The use of transferrin-ligand for targeting is highly efficient in vivo and has been 
shown in vitro in N2A cells to result in 100-fold increased transfection efficiency 101. 
Tf-LipT Lipoplexes were reported to have a diameter of 63.8 ± 6.3 nm and a ~-potential 
of +2.3 ± 1.9 m V, physicochemical characteristics qualifying them for efficient 
transfection 460,461. LipT complex preparation was carefully performed according to the 
originally described protocol, which is essential for achievement of the desired 
nanostructure; modifications in this protocol have been shown to result in abolishment 
of LipT nanostructure and transfection potential 101. Although, the synthesis of defective 
lipoplex particles secondary to unidentified problems in preparation or due to missing 
information in the published methodology cannot be excluded with absolute certainty, 
the data of this thesis do not confirm the published results in regard ofthe LipT-lipoplex 
efficiency. 
Transferrin-targeted, PEI-based polyplexes were evaluated in vivo in a subcutaneous 
murine neuroblastome xenograft model chosen for comparability with the original 
published results. Systemic administration of these complexes resulted in intra tumoral 
trans gene expression levels in approximately the same range as observed after 
intratumoral injection. Polyplexes also caused transgene expression in other organs but 
luciferase activity was still 30-250 times lower in these organs than in tumor tissue. The 
results of this thesis confirm the previously published results. Kircheis et al. measured 
under the same experimental conditions intratumoral transgene expression level in the 
same logarithmic range as observed in this thesis. Similarly, maximum extratumoral 
trans gene expression was observed in lung and spleen with expression levels in the 
same logarithmic range as in this thesis. Expression kinetic was similar between the 
thesis results and the original published results with maximum expression 24-48h after 
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treatment followed by a decline in trans gene expression 393. Interestingly, Kircheis et a1. 
also evaluated expression kinetics after repetitive vector administration showing 
prolonged though continuously decreasing transgene expression levels after two daily 
vector administrations. 
Hence, this system appears to be highly promising as a systemic non-viral gene delivery 
system for tumor therapy. However, two disadvantages limit its use. First, its 
unspecificity despite the use of targeting ligands requires additional targeting strategies 
in order to avoid significant complications from therapeutic transgene expression in 
non-tumoral tissue. The second and main limiting factor is the intratumoral 
biodistribution pattern. Kircheis et a1. evaluated intratumoral DNA biodistribution as 
well as intratumoral transgene expression 393. Their results showed a heterogenous gene 
expression pattern with focal areas of strong trans gene expression and broad areas 
without any visible expression. Transfected cells accumulated mostly around lacunar 
structures thought to be immature vessels indicating that the polyplexes do not migrate 
efficiently through the tumor tissue. In HCC, the thickness and impermeability of tumor 
vasculature increases with tumor size 462. This impermeability could result in significant 
decrease of extravasation and thereby in a decreased number of transduced cells. The 
authors also noted that not all of the transduced cells were of tumor origin reducing the 
number of transduced tumor cells even further. 
Stabilized plasmid lipid particles (SPLP) are a liposome-based gene transfer system 437. 
They contain the cationic lipid DODAC and the fusogenic lipid DOPE, and are 
stabilized in aqueous medium by coating with polyethylenglycol (PEG). They are 
synthezied by the detergent dialysis method. Resulting particles are -70 nm in diameter, 
consist of a unilamellar, lipid double layer membrane entrapping one plasmid copy 
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number per SPLP particle; SPLP protect DNA from serum nuclease degradation 437,463. 
Within this thesis, synthesis of SPLP was successfully achieved with encapsidation 
efficiencies of 80-90% of input DNA and a total yield of 36% of input DNA after 
completion of subsequent isolation and purification steps. These yields are consistent 
with the maximum yields achieved by the original authors describing the method (Dr. I. 
MacLachlan, personal communication). The initial in vivo studies of this thesis focused 
on SPLP biodistribution. Moderate amounts of SPLP were found intratumorally and 
appeared to be perivascular located. This is consistent with previous studies reporting 
intratumoral accumulation of3% of input SPLP and 1.5% of the total input DNA within 
24h 438. Uptake in other organs was similar to published data, with the exception of high 
renal SPLP accumulation, which had not been examined in the original reports 432, 438. 
The known SPLP half-life of 7.2 + 1.6h combined with the observation of their high 
renal accumulation after approximately 3 half-lifes indicate a renal excretion 
mechanism of SPLP. Transgene expression studies were highly interesting and 
confirmed published data. In comparison to other conjugated non-viral gene transfer 
systems evaluated in the course of this thesis, systemic SPLP treatment achieved the 
highest intratumoral transgene expression levels. At the same time, trans gene 
expression in other organs was significantly lower than with the other methods. A 
striking finding was the increasing pattern of trans gene expression over time despite the 
use of a non-replicating plasmid. These data speak for continuous, new SPLP-mediated 
transfection of intratumoral cells, as expression patterns of non-replicating vectors 
would rather be expected to decline over time. The same observation was made by Tam 
et at. and is possible explained by PEG-ceramide mediated prolonged systemic 
circulation times with 7.2 ± 1.6h circulation half-life. The prolonged half-life, increased 
vasculature and higher cell proliferation rates might explain the preferential 
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intratumoral transgene expresslOn 432. Unfortunately, intratumoral biodistribution 
studies revealed similar problems as observed with the above-discussed PEl-polypI exes. 
The intratumoral biodistribution analysis demonstrated that the transfected cell 
population was very heterogeneously and sparcely distributed. Transfected cells 
appeared to be in groups and intracellular transgene expression was strong. Hence, the 
same criticism as for PEl-polypI exes applies to SPLP. 
In summary, none of the analyzed non-viral gene transfer systems achieved high 
transfection efficiencies as discussed above. Although, two of the three tested systemic 
non-viral systems achieved intratumoral transfection, their intratumoral biodistribution 
was sparce and very heterogenous with very few transfected tumor cells. It is likely, that 
with increasing size of HCC nodules the low transduction efficiency will further 
decrease due to decreasing permeability of the tumor vessels 462. Unfortunately, the 
initial hypothesis that replicating, high trans gene expressing vector systems might 
compensate for low transfection efficiencies is unlikely to be confirmed as single cell 
trans gene expression was high but total tumor trans gene expression was low due to the 
limited number of transfected cells. In case of a cytoreductive gene therapy -even with 
the use of a transgene with a strong bystander effect- only few cells would be 
eliminated at a fast rate. Bystander transfection of initially untransfected cells is highly 
unlikely as vectors disassemble for successful trans gene expression and unspecific 
DNA-uptake of surrounding tumor cells after tumor lysis is very inefficient due to the 
above-described biologic barriers. Hence, current non-viral vector systems are severely 
limited due to their low transduction efficiencies. Future developments should focus on 
high intratumoral biodistribution. However, it needs to be kept in mind that 
transduction-focused modifications can also cause increased toxicity and 
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immunogenicity. For example, it was shown that charge ratio providing optimal 
transfection efficiencies of PEI-polyplexes and cationic lipoplexes can also be very 
close to the severly toxic ratio causing complications such as hepatic necrosis and death 
464-466. Immunogenicity of synthetic gene delivery has been described and been 
attributed to bacterial CpG-motifs 467,468. 
In conclusion, nonviral gene transfer strategies have severe limitations making viral 
vectors at the current time the more appealing and promising vector systems for genetic 
approaches of human diseases. 
2. Parvoviral replicon vectors 
This is the first study to demonstrate the feasibility of parvovirus-based replicon vectors 
as a novel, efficient and tumor selective expression system. Data of this thesis show: 1) 
genetically modified and optimized MVM-replicons are efficiently excised, replicated 
and expressed; 2) MVM-based replicons achieve continuously increasing high-level 
transgene expression levels compared to other expression systems; 3) MVM-based 
replicon vectors retain parvoviral tumorselectivity; 4) MVM-replicons tolerate 
expansion of the parvoviral genome of up to 355% but replication and expression 
decrease with increasing genome size, and 5.) recombinant MVM-based replicons lost 
the parvoviral cytotoxicity. 
Autonomously replicating parvoviruses are highly qualified as virotherapeutic agents 
for malignancies due to their oncoselectivity, oncosuppression and human 
apathogenicity. However, their use is limited by their immunogenicity, genomic size 
restriction and limitations in achievable vector yields 469. Their use as non-viral 
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replicating vector systems has never been evaluated. The problem of most plasmid 
DNA-based expression systems used for non-viral gene delivery is their lack of 
sustained transgene expression due to DNA degradation, cell mitosis and gene silencing 
470. There are several strategies to achieve sustained gene expression including the use 
of constitutive human or tissue-specific promoters or stable chromosomal integration 
h f h · 471-475 H h . I b throug use 0 transposons or page mtegrase . owever, t ese strategIes a so ear 
risks such as insertional mutagenesis and are therefore not desirable for transient gene 
transfer strategies as required for malignancies. Episomally retained, self-replicating 
vector systems -referred to as replicons- are a reasonable alternative for this indication 
470. There are a variety of different replicon vectors systems currently in use; most of 
these are based on DNA or negative and positive strand RNA viruses 476-478. Most of 
these systems are limited for their use for cancer gene therapy due to non-selectivity, 
low efficiencies or host range restrictions. Hence, the development of parvoviral 
replicons for tumor-selective gene therapy is a potentially novel and promising tool. 
Several parvovirus MVM-based replicons were generated throughout this study. In 
order to maximize genomic excision and replication, and as a result trans gene 
expression, the left palindromic end was modified by insertion of a NS I-nicking site. 
Kestler et al. had found that a NS I-nicking site was deleted in the original MVMp-clone 
described by Merchlinsky et al. 133. The missing NS I-nicking site is essential for 
efficient parvoviral genome excision. Reconstitution of this site achieved a significant 
increase in parvoviral replication and viral titers. The data of this thesis confirm these 
findings; restoration of the left parvoviral palindrome resulted in increased replication. 
The effect of this modification on trans gene expression after parvoviral DNA 
transfection had not been evaluated in previous studies. The data presented as part of 
this thesis indicate also a significant increase in trans gene expression levels through 
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reconstitution of the NS 1 nicking site. The increase in expression levels is possibly 
related to increased numbers of MVM-DNA copy numbes secondary to increased 
replication rates. A positive correlation between vector copy number and transgene 
expression levels has also been observed in other systems 479. Hence, improved excision 
results in more efficient replication and thereby higher number of parvoviral DNA copy 
numbers, which translates into higher trans gene expression levels. 
Parvoviral replicon vectors achieved high trans gene expression levels in susceptible 
cells. The maximum achieved expression was 2-3-fold higher than with expression 
systems using an enhanced CMV-promoter. These high expression levels observed after 
MVM-replicon transfection are the consequence of two factors. First, transgene were 
cloned in a position in which their expression is controlled by the P38 promotor 218. 
Transactivation of P38 through NS 1 causes an enhanced transgene expression. The 
second factor is indicated by the expression profile. Transgene expression increased 
over time likely due to sustained intracellular parvoviral DNA replication. In contrast, 
non-replicating systems have their maximum protein expression within the first 24h 
after transfection followed by a sharp decrease due to input DNA elimination as 
outlined above. The EBV-based replicating vector system is one of the most commonly 
used replicating expression systems. However, plasmids containing the oriP and EBNA-
1 sequences are maintained at low copy numbers DNA episomes and replicate only 
once per cell cycle in eukaryotic cells 480. In conclusion from parvoviral replication 
data, MVM-based replicons replicate at a higher rate. This conclusion is further 
supported by the transgene expression data indicating a continuous increase in 
transgene expression. In contrast, EBV-replicon mediated transgene expression only 
stabilized after its initial increase 24h after transfection. 
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Parvoviruses are also known for their tumor suppressive potential 469. It was 
hypothesized in this thesis that parvoviral cytotoxicity is an additional advantage of 
parvoviral replicon vectors. Parvovirus MVM has been shown to elicit cytotoxic effects 
predominantly mediated by its non-structural protein NS I 161,445. NS I-protein has been 
shown to induce cytoskeletal changes and to interfere with intracellular signaling 
pathways resulting in cytopathic effects and cell death 446,447. However, NS2 protein 
also contributed to parvoviral cytotoxicity eliciting an enhancing effect 162. Earlier 
studies using stably transfected cell clones expressing parvoviral NS proteins under the 
control of inducible promoters showed cytopathic effects in colony assays following 
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parvoviral replicon vectors should maintain their cytotoxic potential as long as NS I and 
NS2 coding regions are not interrupted. Unexpectedly, it was found that none of the 
parvoviral replicon vectors elicited a cytotoxic effect. These results cannot be explained 
by resistance of the cell lines used for evaluation as they are known to be susceptible to 
parvoviral cytotoxicity and are commonly used for titration of parvoviral virus stocks. 
NS I and NS2 coding regions were kept intact through the choice of the XbaI and 
Hindlll restriction sites as an insertion site for transgenes excluding a cloning-mediated 
defect in their expression. Previously, it was shown that mutations in the NS 1 coding 
region causing alterations of protein kinase C (PKC)-phosphorylation sites, significantly 
reduce parvoviral cytotoxicity 482, 483. However, MVM-plasmids used for the 
cytotoxicity studies in this thesis were analyzed carefully by DNA sequencing and 
found to be negative for these mutations. Most recently, recombinant MVM viral 
vectors were compared to wildtype MVM 484. Interestingly, the authors of this study 
found similar results as the ones described in this thesis. Cytoxicity of recombinant 
MVM viruses in which capsid coding regions were replaced by interleukin-2 coding 
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DNA had almost completely lost their cytotoxic potential compared to wildtype MYM 
even if used at a 10-fold higher multiplicity of infection 484. It was hypothesized that 
NS 1 is not the only mediator of parvoviral cytoxicity but that factors mediated by the 
capsid or at least contained in the deleted regions are required for parvoviral 
cytotoxicity. The results of this study confirm these observations and provide further 
evidence for additional factors required for parvoviral cytotoxicity warranting further 
studies. However, the attenuated parvoviral cytotoxicity could also be advantageous for 
tumor-directed therapy. Wodarz et al. analyzed mathematical models of optimal 
virotherapeutic strategies and concluded that a fast killing vector will result in a 
disadvantageous change of infected to uninfected proliferating cell ratio of a tumor cell 
population with the final outcome of tumor growth 314. The absent cytotoxicity in 
parvoviral vectors would allow sustained therapeutic transgene expression and thereby 
enhancement of its effect even on untransfected cells if therapeutic genes with 
bystander effects are used. 
Genetically unmodified autonomously replicating parvoviruses are not able to achieve 
1 ' 239 249 Th fi 'd'fi'" d' d comp ete tumorsuppressl0n ' . ere ore, genetic mo 1 1cation IS reqUlre m or er 
to enhance their tumor suppressive potential. However, the choices of therapeutic 
transgenes for these viruses are very limited due to genomic size restrictions 144. Kestler 
et at. as well as Brandenburger et al. have described an optimal genomic size between 
90 and 106% for parvovirus MVM. Outside these limitations, viral titers decrease 
significantly due to inefficient viral packaging 133, 251. In this thesis, the parvoviral 
genome was increased to 355% of its wildtype size. Despite the significant increase in 
genome size, recombinant MVM-replicons were replicated and transgenes expressed. 
However, the increase in genome size did result in markedly decreased replication rates 
as well as an up to 30-fold decreae in transgene expression, These data indicate, that the 
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use of the parvoviral MVM-genome as a replicon does not allow unlimited genome 
expansIon. 
Autonomously replicating parvoviruses such as MVM and HI are known for their 
tumor-selectivity. Several factors contribute to their oncotropism. The parvoviral P4-
promoter is one of the major contributers to their selectivity 144. Oncogenic 
transformation has been shown to result in enhanced P4-promoter activity 191, 192. In 
addition, cellular transcription factors ATF and E2F -mediated P4-promoter induction is 
S-phase dependent 176. However, the P4-promoter dependence alone is not sufficient to 
guarantee oncoselectivity as the isolated P4-promoter elicits activity even in 
144 
untransformed cells . 
The second mechanism contributing to parvoviral oncoselectivity is the strict S-phase 
dependency of parvoviral genome conversion from single- to duplex DNA which 
requires cellular factors such as cyclin A and CDK2 kinase activity 174. Therefore, it 
was a concern that the use of parvoviral replicons as double-stranded DNA vectors 
could interfere with these mechanisms and result in loss of oncoselectivity. However, 
the data presented in this thesis clearly demonstrate that this is not the case. Optical as 
well as highly sensitive enzymatic analysis confirmed that transfection of 
untransformed cells with parvoviral replicon vectors does not result in transgene 
expression. In contrast, high and increasing trans gene expression was observed in their 
transformed counterparts. These results prove the sustained tumor-selectivity of 
parvoviral replicons. 
In summary, this thesis has demonstrated the feasibility of parvoviral replicon as a 
novel, tumor-selective gene expression system. It provides tumor-selective, high-level 
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transgene expression. However, the hypothesis that replicons allow unlimited genome 
size increase could not be confrrmed nor did they retain their cytotoxic potential. 
3. Viral gene therapy using recombinant measles virus 
This thesis is the first study to show the tumor suppressive potential of recombinant 
MV-Edm as a viral cancer agent for the therapy of HCC. The data show that: 1) CD46 
is overexpressed in HCC in comparison to non-malignant hepatic tissue; 2) MV-Edm 
successfully infects human HCC cells resulting in trans gene expression, syncytia 
formation and tumor cell killing; 3) recombinant MV-Edm has a strong 
tumorsuppressive effect on human HCC xenografts after intratumoral and intravenous 
therapy; 4} recombinant MV-Edm expressing either CEA or hNIS allow non-invasive 
monitoring of viral expression kinetics and localization of infected tumor cells. 
MV-Edm is a RNA virus which is characterized by its oncolytic potential and its 
I .. 107 202 304 313 0 f th ~ 'b" 1'" tumorse ectlvlty , , , . ne 0 e lactors contn utmg to Its tumorse ectlvlty IS 
CD46-receptor density 284. The pathogenic wildtype of measles virus, which is not 
selectively oncolytic, uses primarily the SLAM receptor 274,485. The main receptor used 
by the vaccine strain MV-Edm is CD46 275. Virus entry increases with increasing 
CD46-receptor density; if CD46 receptor density exceeds a "threshold" density, 
syncytium formation and cell killing are induced 284. The data show that CD46 is 
strongly expressed in human HCC cell lines compared to primary human hepatocytes. 
Unfortunately, culturing of primary human hepatocytes for more than 48h resulted in 
upregulation of CD46-receptor expression and cell fusion after MV -Edm infection (data 
not shown). Since long-term culturing of human HCC cell lines might also have 
resulted in upregulation of CD46-receptor expression in these cell lines, 
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immunohistochemical analysis of human hepatic tissue samples of HCC patients was 
performed. The results of these studies confirmed overexpression of CD46 in HCC 
tumor tissue compared to non-malignant hepatic tissue. These data are in concordance 
with earlier studies by Kinugasa et al. 486. In their studies CD46 expression was 
compared in normal human hepatic tissue samples, HCC, cirrhosis and chronic 
hepatitis. Their results showed relative CD46-densities of 0.11 + 0.1 in normal hepatic 
tissue, 0.63 + 0.23 in HCC, 0.21 + 0.07 in cirrhosis and 0.25 + 0.1 in chronic hepatitis. 
These data clearly show that CD46-expression is 6-times higher in HCC than in normal 
hepatic tissue, 3-times higher in HCC than in cirrhotic liver tissue, and 2.52 higher in 
HCC than in chronic hepatitis without overlap of CD46-density. Therefore, it can be 
concluded that HCC fulfills the requirements for viral uptake and selective cell fusion 
and killing. 
Additional factors contributing to MV-Edm tumor selectivity are likely, Virally infected 
cells respond with inhibition of viral protein synthesis through IFN-a/f3, double-stranded 
RNA-dependent protein kinase, 2',5'-0Iigoadenylate synthetase and Mx-proteins 4R7-4!!9, 
In contrast to non-malignant cells, tumor cells are often defective in IFN-a/f3 and RNA-
dependent protein kinase pathways 284. 300, This impairment in cellular defense is 
thought to be one of the mechanisms underlying the tumor selectivity of other RNA 
viruses used in experimental cancer therapy 490-493, It might also be one of the 
mechanisms contributing to MV-Edm tumor selectivity in addition to other yet 
unknown mechanisms. 
Tumor selectivity in the setting of HCC is an important safety concern as 60-80% of 
HCC patients have reduced liver function due to liver cirrhosis 3, Based upon the 
observation that CD46 expression is increased in cirrhosis, though still 3-times lower 
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than in HCC, clinical Phase I toxicity studies are necessary 3,486, Nevertheless, MV-
Edm therapy of HCC is not expected to cause damage to surrounding tumor-free 
hepatic tissue for the following reasons: 
a) liver toxicity was not observed In CD46-positive mIce and monkeys treated 
systemically with MV-Edm 494; 
b) intraperitoneal treatment of Ifnar™-CD46Ge transgenic mice with MV-GFP did not 
result in significant transgene expression, despite the presence of MV-Edm RNA in 
I, ' 495 Iver tIssue ; 
c) the attenuated Edmonston vaccine strain has successfully been used for vaccination 
with an excellent safety profile; 
d) reports of wildtype measles VIruS induced hepatic damage are restricted to an 
extremely rare number of single case reports, are negligible in severity or fail to show 
, ' f 1 ' 496,497 mtrahepatIc presence 0 meas es VIruS ; 
e) post-transplant measles vaccination in liver transplantation patients did not result in 
significant complications and was considered safe 498,499, 
In addition, protection of non-malignant cells from the MV-Edm induced cytotoxicity is 
likely through the following mechanisms: 
a) measles virus has the ability to block the intracellular antiviral state by inhibition of 
IFN-a/p-pathways and inhibition of phosphorylation of STATI and STAT2; this 
suppressive mechanism is mediated by measles virus V and C protein 295-297, However, 
recombinant MV -Edm used in this thesis have a mutation in the V protein resulting in 
loss of IFN-antagonist activity 299, Therefore, normal cells will be able to efficiently 
block viral replication; 
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b) Patients as well as health care personnel will be protected by anti-MY antibodies due 
to widely used MV vaccination. 
MV -Edm resulted in a strong CPE in vitro and in vivo. Two different human HCC cell 
lines were used. Both HCC cell lines were susceptible to the cytotoxic effect of MV-
Edm but differed in the kinetics of cell death. Hep-3B cells were eliminated very 
efficiently and quickly while the cytotoxic effect of MV-Edm on HUH-7 cells was 
observed at a later time point. The in vivo data of this thesis show that intratumoral MV-
Edm therapy results in significant prolongation of survival, almost doubling median 
survival times of mice bearing human HCC xenografts and causing complete tumor 
regression in up to one third of treated animals. Intravenous MV-NIS almost tripled 
median survival in mice bearing human HCC xenografts and resulted in 10% complete 
tumor regression in Hep-3B xenografts. Intratumoral MV-Edm therapy has been shown 
to result in limited intratumoral spread of MV-Edm 255. Longer median survival after 
intravenous therapy compared to intratumoral therapy might be explained by better 
intratumoral MV-Edm distribution after intravenous delivery. Interestingly, the HCC 
cell lines showed different susceptibilities towards the cytotoxic effect MV-Edm. This 
difference in susceptibility between different HCC cell lines most likely resembles the 
situation in primary human tumors which consist of a heterogeneous tumor cell 
population 500. Both cell lines express comparable level of CD46 but they differ in other 
aspects, e.g. their p53 status 501,502. Syncytia formation results in cell death either by 
apoptosis or a bioenergetic form of cell death with necrosis 303, 305. The data of this 
thesis indicate apoptosis as the mechanism of cell death in HCC cells after MV-Edm 
induced syncytia formation. Differences in components of these pathways or other not 
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yet identified factors in the process of measles induced cytotoxicity could explain the 
different susceptibility. 
The less susceptible HUH-7 tumors showed higher transgene expression levels in vitro 
as well as in vivo than the more susceptible Hep-3B tumors. This observation might be 
explained by the delay of cell death in HUH-7 cells; that is, the increased time interval 
until cell death results in an overall increase in viral replication and expression. A 
similar observation was made in an ovarian cancer model and was explained by an 
intratumoral dynamic equilibrium between formation of new tumor cells and the death 
of infected tumor cells 3 \3. The optimal rate of cell killing depends on the growth rate of 
infected tumor cells relative to uninfected tumor cells 314. In the case of Hep-3B tumors, 
the equilibrium is shifted toward the cell killing of infected cells resulting in efficient 
and rapid destruction of infected tumor tissue. In HUH-7 tumors, the virus would be 
maintained and viral proteins be expressed until cell death occurs. Infected tumor cells 
fuse with surrounding uninfected tumor cells resulting in a strong bystander effect 503. 
Syncytia formation is CD46 dependent resulting in fusion of tumor cells but not their 
normal counterparts 284. Delayed cell death would therefore allow recruitment of more 
uninfected tumor cells in syncytia. In addition, the increased trans gene expression levels 
in less susceptible cells can be expected to allow further enhancement of the therapeutic 
effect by the use of therapeutic transgenes, as e.g. hNIS in combination with 131 I 304,431. 
131 I is a beta-particle emitting isotope with an average tissue-path length of 0.4 mm, 
thereby causing a bystander effect. HCC is susceptible toward the therapeutic effect of 
131 1 504,505. It is a future aim to explore the possibility of further enhancement of the 
therapeutic effect of MV-Edm by combined radiovirotherapy using MV-NIS and 1311. 
Another factor influencing the therapeutic outcome of MV-Edm therapy will be the 
immune response. CTL response and humoral antibodies will influence dynamics of 
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virus persistance, infection and cell death 314. It is likely, that virally infected tumor 
cells will be recognized by the host's immune system and be eliminated, and thereby 
contributing to the therapeutic effect. 
A general concern in systemic viral therapy is the potential decreased efficacy due to 
the presence of antibodies. HCC offers the possibility of local treatments. The majority 
of HCC patients do not have extrahepatic metastasis and the liver is easily accessible 
using ultrasound- or CT -guidance 506. HCC tumor nodules can easily be localized and 
injected with a therapeutic agent. In the setting of multilocular HCC, the liver offers the 
opportunity of intrahepatic delivery by hepatic artery infusion. In either case, the 
presence of anti-MY antibodies is not expected to result in significant decrease of 
efficacy. Grote et at. showed in a mouse model, in which mice received passive transfer 
of anti-MY antibodies, that intratumoral MV-Edm therapy of human lymphoma 
xenografts resulted in effective tumor regression without compromise through the 
presence of anti-MY antibodies 255. This observation was in accordance with results 
from studies involving intratumoral therapy with reovirus in immune competent C3H 
mice and a clinical phase II study with a genetically modified adenovirus in patients 
with advanced head and neck cancer. In both studies, effective tumor-regression was 
achieved despite the presence of antibodies 492, 507. Also, in the case of hepatic artery 
infusion as the route of administration, it has been shown that repeated infusion of 
replicating results in sufficient viral delivery to elicit therapeutic effects 508. 
A major drawback of many cancer agents is the lack of convenient methods of 
monitoring the agent after application to the patient. This thesis shows that MV-CEA 
and MV-NIS allow non-invasive tracking of viral gene expression in HCC as well as 
localization of infected tumor tissue. The in vivo studies show trans gene expression up 
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to 58 days after MV-CEA therapy and stable iodine uptake up to 14 days after MV-NIS 
therapy, which was the endpoint of the study. It has been shown for MV-CEA that the 
expression profile of the marker gene correlates with viral gene expression and the 
serum concentration of the marker polypeptide reflects the number of viable cells 106. 
Expression of viral proteins lasts for the duration of viability of the infected cell. Once 
the cell has reached the state of cell death, viral gene expression continues through 
infection of new cells with progeny virus. Only 15% of HCC patients express CEA. 
Therefore, MV-CEA would be well suited for the majority of these patients allowing 
non-invasive monitoring of viral expression kinetics by serum CEA analysis. MV-NIS 
combined with 1231 will allow localization of infected HCC cells by non-invasive 
imaging techniques. Analysis of these data will help to determine pharmacokinetics and 
pharmacodynamics of measles therapy in HCC; these informations are essential for 
optimization of therapy protocols for optimal safety and efficacy. 
In conclusion, this thesis has shown that trackable MV-Edm is a very potent novel 
therapeutic agent for HCC. It has an excellent safety profile and offers the possibility of 
controlling viral expression kinetics and localization of infected cells by non-invasive 
methods. The potential of monitoring measles therapy will allow modification of 
protocols for enhanced safety and efficacy. The accessibility of the liver and the relative 
low rate of extrahepatic HCC metastasis qualify HCC as an ideal target. Therefore, 
recombinant MV-Edm should further be explored as a therapeutic agent for HCC. 
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AAMR 
AASLD 
AAV 
ALDH 
ARP 
ATP 
BCLC 
bFGF 
bp 
CAR 
CnD 
CEA 
Cer 
CLIP 
cpm 
CPE 
CPV 
CTCL 
CTL 
d 
DAPI 
DHFR 
DIG 
DMEM 
DMSO 
DODAC 
DOPE 
DOTAP 
DPD 
dRF 
EBV 
EDTA 
EGFR 
ELISA 
F 
FPV 
g 
Galv-FMG 
GBM 
GFP 
GM-CSF 
GST 
H 
h 
HEPES 
Age-adjusted incidence rate 
Age-adjusted mortality rate 
American Association of the Study of Liver Disease 
Adeno-associated virus 
Aldehyde dehydrogenase 
Autonomously replicating parvovirus 
Adenosine triphosphate 
Barcelona Clinic Liver Cancer 
Basic fibroblast growth factor 
Base pairs 
Chimaeric antigen receptor 
Cytidine deaminase 
Carcinoembryonic antigen 
Ceramide 
Cancer of the Liver Italian Program 
Counts per minute 
Cytopathic effect 
Canine parvovirus 
Cutaneous T -cell lymphoma 
Cytotoxic T lymphocyte 
Day 
4,6-Diamidino-2-phenylidone 
Dihydrofolate reductase 
Digoxigenin 
Dulbecco's modified Eagle medium 
Dimethyl sulfoxide 
Dileoyldimethylammonium chloride 
Dioleoyl-L-a-phosphatidylethanolamine 
1,2 Dioleoyl 3-trimethyl ammonium propane 
Dihydropyrimidine dehydrogenase 
Dimeric replicative form 
Epstein-Barr virus 
Ethylenediaminetetraacetic acid 
Epidermal growth factor receptor 
Enzyme-linked immunosorbent assay 
Fusion protein 
Feline parvovirus 
gram 
Gibbon ape leukemia virus-fusogenic membrane glycoprotein 
Glioblastoma multi forme 
Green fluorescent protein 
Granulocyte macrophage colony-stimulating factor 
Glutathione-S-transferase 
Hemagglutinine protein 
hour 
N-2-hydroxyethylpiperazine-N -ethanesulfonic acid 
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HBSS 
HBV 
HCC 
HCV 
HLA 
HSC 
IACUC 
IL-2 
INF 
IR 
Kb 
kD 
L 
LMV 
LUV 
M 
MDR 
MEM 
MGMT 
mm 
Mal 
mRf 
MV-Edm 
MVM 
MW 
N 
NIS 
NSll2 
ORf 
P 
PBS 
PCR 
PDGF-~ 
PEG 
PEl 
PEl 
p.l. 
PKC 
PLL 
p.t. 
QELS 
RLU 
RNA 
RPM 
RT 
RT-PCR 
SCID 
SDS 
SHARP 
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Hank's balanced salt solution 
Hepatitis B virus 
Hepatocellular carcinoma 
Hepatitis C virus 
Human leukocyte antigen 
Hematopoietic stem cell 
Institutional animal care and use committee 
Interleukin-2 
Interferon 
Inverted repeat 
Kilobase 
Kilo Dalton 
Polymerase 
Large multilamellar vesicle 
Large unilamellar vesicle 
Matrix protein 
Multidrug resistance gene 
Minimum essential media 
0 6 -methylguanine-DNA methyltransferase 
Minutes 
Multiplicity of infection 
Monomer relicative form 
Edmonston strain of Measles virus 
Minute virus of mice 
Molecular weight 
Nucleoprotein 
Sodium iodide symporter 
Nonstructural proteins 112 
Open reading frame 
Phosphoprotein 
Phosphate buffered saline 
Polymerase chain reaction 
Platelet-derived endothelial growth factor-~ 
Polyethylene glycol 
Poly( ethylenimine) 
Percutaneous ethanol injection 
Post injection 
Protein kinase C 
Poly(L-Lysine) 
post transfection 
Quasi elastic light light scattering 
Relative light units 
Ribonucleic acid 
Rounds per minute 
Room temperature 
Reverse transcriptase-polymerase chain reaction 
Severe combined immunodeficiency 
Sodium dodecyl sulfate 
Sorafenib HCC Assessment Randomized Protocol 
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SLAM 
SPLP 
SSC 
SUV 
T4PNK 
TAA 
TAE 
TACE 
TBS 
TCIDso 
TCR 
Tf 
TGF-(3 
TNF-a 
TRAIL 
Tris 
TUNEL 
UNOS 
VEC 
VEGFR 
VP1I2 
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Signaling lymphocyte activation molecule 
Stabilized plasmid lipid particles 
Saline-sodium citrate buffer 
Small unilamellar vesicle 
T4 polynucleotide kinase 
Tumor-associated antigen 
Tris-acetate-EDTA buffer 
Transarterial chemoembolization 
Tris-buffered saline 
50% Tissue Culture Infective Dose 
T cell receptor 
Transferrin 
Transforming growth factor-(3 
Tumor necrosis factor-a 
TNF-related apoptosis-inducing ligand 
Tris(hydroxymethyl)aminomethane 
Terminal deoxynucleotidyl transferase dUTP nick end labeling 
United Network for Organ Sharing 
Vascular endothelial cell 
Vascular endothelial growth factor receptor 
Viral proteins 112 
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